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Aty mitochondrial membrane potential
ACAD9 acyl-CoA dehydrogenase 9
ACP acyl carrier protein
ADP adenosine diphosphate
AIF apoptosis inducing factor
a-KGDH alpha-ketoglutarate dehydrogenase
ATP adenosine triphosphate
BD bipolar disorder
BN-PAGE blue native polyacrylamide gel electrophoresis
cAMP cyclic adenosine monophosphate
cDNA copy DNA
CO2 carbon dioxide
CoA coenzyme A
COX cytochrome c oxidase
CSF cerebrospinal fluid
cyt c cytochrome c
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
dNTP deoxyribonucleoside triphosphate
ECL enhanced chemiluminescence
FAD+ flavin adenine dinucleotide (oxidized form)
f a d h 2 flavin adenine dinucleotide (reduced form)
FeS iron-sulfur
FILA fatal infantile lactic acidosis
FMN flavin mononucleotide
FRDA Friedreich's ataxia
GDP guanosine diphosphate
GFP green fluorescent protein
GRIM-19 gene associated with retinoid-interferon induced mortality-19
GTP guanosine triphosphate
H+ proton
H2O2 hydrogen peroxide
HPLC high pressure liquid chromatography
HSP hereditary spastic paraparesis
Hq Harlequin
IGA in-gel activity
IgG immunoglobulin G
HEK human embryonic kidney
kDa kilo Dalton
LDAO lauryldimethylamine oxide (N,N-dimethyl-dodecylamine N-oxide)
LHON Leber hereditary optic neuropathy
LS Leigh syndrome
MEGs mitochondrial energy generating systems
MELAS mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
MERRF myoclonic epilepsy associated with ragged-red fibres
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MRI magnetic resonance imaging
mtDNA mitochondrial DNA
NAD+ nicotinamide adenine dinucleotide (oxidized form)
NADH nicotinamide adenine dinucleotide (reduced form)
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ND NADH dehydrogenase subunit
nDNA nuclear DNA
NDUFA- NADH dehydrogenase ubiquinone a-subcomplex protein
NDUFAB- NADH dehydrogenase ubiquinone a/p-subcomplex protein
NDUFAF- NADH dehydrogenase ubiquinone assembly protein
NDUFB- NADH dehydrogenase ubiquinone (3-subcomplex protein
NDUFC- NADH dehydrogenase ubiquinone subcomplex unknown protein
NDUFS- NADH dehydrogenase ubiquinone iron-sulfur protein
NDUFV- NADH dehydrogenase ubiquinone flavoprotein
O2 molecular oxygen
O2- superoxide
OMIM online mendelian inheritance in man
OXPHOS oxidative phosphorylation
PBS phosphate buffered saline
PCR polymerase chain reaction
PD Parkinson's disease
PDHc pyruvate dehydrogenase complex
Pi inorganic phosphate
PKA protein kinase A
RNA ribonucleic acid
ROS reactive oxygen species
rRNA ribosomal RNA
RT-PCR reverse transcriptase-polymerase chain reaction
SDHA succinate dehydrogenase complex subunit A, flavoprotein
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SE standard error
STR short tandem repeat
Ta annealing temperature
TAP tandem affinity purification
TCA tricarboxylic acid
Tim translocator of the inner mitochondrial membrane
TK2 thymidine kinase 2
TMRM tetramethyl rhodamine methyl ester
tRNA transfer RNA
Q ubiquinone
QH2 ubiquinol
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Chapter 1
Mitochondria: general features
Mitochondria are double-membraned or­
ganelles present in almost all eukaryotic cells. 
Mitochondria are considered as the energy 
plants of the cell, since the primary function 
of mitochondria is the production of ATP 
[Koopman 2010]. In addition to this function, 
they are also involved in a range of other bio­
chemical processes like apoptotic cell death, 
control of cytosolic calcium concentration, 
cellular proliferation, regulation of the cellular 
redox state, production of endogenous reac­
tive oxygen species (ROS), heme and steroid 
synthesis, heat production, and iron-sulphur 
cluster biogenesis [McBride 2006]. 
Mitochondria have some unique features 
compared to other organelles. First, their 
structure is unusual, since mitochondria are 
composed of a double membrane system. 
The outer and the inner membranes divide 
the mitochondrion into the intermembrane 
space and the matrix. Furthermore, the mito­
chondrial inner membrane is highly folded 
into cristae. Second, the number of mito­
chondria in a cell varies widely, depending on 
the energy demand of the tissue. Third, each 
mitochondrion has its own DNA. The human 
mitochondrial DNA (mtDNA) is a 16,569 base 
pair circular double-stranded molecule built 
up of the complementary H and L strands 
(figure 1.1). It is maternally inherited and en­
codes for 22 tRNAs, 2 rRNAs, and 13 subunits 
of respiratory chain enzymes. Only the D- 
loop is a non-coding region, containing the 
promoters for L- and H-strand transcription. 
Since mtDNA has no introns, and the fact that 
mtDNA mutates ten times more frequently 
than nuclear DNA (nDNA), mtDNA is frequent 
associated with disease.
Mitochondrial genetics differs from nuclear 
genetics in several points. mtDNA is mater­
nally inherited, which is important for genet­
ic counseling. Each mitochondrion contains 
2-10 mtDNA copies, making them polyploid. 
Furthermore, each cell contains thousands of 
mtDNA molecules. All these copies could be 
identical (homoplasmy), or mutations in the 
mtDNA may arise leading to the co-existence 
of wild-type and mutant mtDNA (hetero- 
plasmy). The threshold effect is the minimum 
percentage of mutant mtDNA that leads to
the manifestation of a mitochondrial disor­
der. Finally, the degree of heteroplasmy may 
change during cell division (mitotic segrega­
tion). As a consequence, the phenotype of 
that particular tissue could change. Despite 
the importance of mtDNA, mitochondria de­
pend on the nDNA for the synthesis and im­
portation of proteins. Furthermore, mtDNA 
requires nDNA-encoded factors for its repli­
cation, transcription, and translation.
Cellular production of ATP
The energy that every cell of our body needs, 
is produced in the form of ATP by a number 
of distinct cellular processes. The main path­
ways are glycolysis, the citric acid cycle, and 
oxidative phosphorylation (OXPHOS). The 
glycolysis takes part in the cytosol of the cell, 
while the other processes occur within the 
mitochondrion (figure 1.2).
Glycolysis is a metabolic pathway that con-
Figure 1.1
Schematic overview of the human mtDNA. The two 
strands of the mtDNA (heavy and light) have their 
own origin of replication, OH and OL, respectively. 
The mtDNA encodes for 22 tRNAs, 2 rRNAs, and 13 
subunits of complexes I, III, IV, and V of the OXPHOS 
system which are depicted with different colours.
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verts glucose into pyruvate, accompanied by 
the formation of ATP. The process is catalyzed 
by ten cytosolic enzymes, and consists of two 
phases. In the preparatory phase, ATP is used 
to convert glucose to fructose 1,6-bisphos- 
phate. In the payoff phase, each of the two 
molecules of glyceraldehydes 3-phosphate 
derived from glucose undergoes oxidation. 
The energy of this oxidation reaction is con­
served in the formation of NADH and an acyl 
phosphate bond of 1,3-bisphosphoglycer- 
ate. Substrate-level phosphorylation and 
rearrangement of atoms finally results in the 
formation of pyruvate. The overall equation 
for glycolysis is:
glucose + 2NAD+ + 2ADP + 2Pi -> 2 pyruvate 
+ 2NADH + 2H+ + 2ATP + 2H2O.
There is a net gain of two ATP per glucose 
molecule.
Pyruvate, the end product of the glycolysis, is 
transported from the cytoplasm into the ma­
trix of the mitochondrion and undergoes de­
hydrogenation and decarboxylation by the 
pyruvate dehydrogenase complex (PDHc), to 
yield acetyl-CoA and CO2 . The PDHc is a large
Figure 1.2
Schematic overview of the cellular ATP production. 
During the glycolysis, which takes part in the cytosol 
of the cell, glucose is converted into pyruvate. The 
pyruvate is transported to the mitochondrion where 
it is converted into Acetyl-CoA. Another pathway, 
fi-oxidation, breaks down fatty acids to also produce 
Acetyl-CoA. This Acetyl-CoA can enter the TCA cycle, 
and finally the oxidative phosphorylation system, 
embedded in the inner mitochondrial membrane, 
will produce ATP.
complex, consisting of three enzymes, and 
is located in the mitochondrial matrix. PDHc 
couples the glycolysis to the citric acid cycle. 
The conversion catalysed by the PDHc is:
pyruvate + CoA + NAD+ -> acetyl-CoA + CO2 
+NADH+H+
Another metabolic pathway for energy ho­
meostasis in organs such as the heart, liver, 
and skeletal muscle is the beta-oxidation. 
In this pathway long-chain free fatty acids 
attach to carnitine and enter the mitochon­
drial matrix and undergo degradation. This 
is necessary because these fatty acids can­
not freely enter the mitochondria. They are 
broken down to form acetyl-CoA, which can 
enter the citric acid cycle.
Acetyl-CoA enters the citric acid cycle (also 
known as the Krebs or tricarboxylic acid 
(TCA) cycle), which is located in the mito­
chondria of eukaryotic cells. Citrate synthase 
catalyzes the transfer of the acetyl group of 
acetyl-CoA to oxaloacetate, which results in 
the formation of citrate. Aconitase catalyzes 
the formation of isocitrate from citrate. Next, 
isocitrate is oxidized to a-ketoglutarate by 
isotrate dehydrogenase, which yields CO2 . 
The a-ketoglutarate is converted to succinyl- 
CoA and CO2 . This succinyl-CoA reacts with 
GDP and Pi to form succinate and GTP. Sub­
sequently, succinate is oxidized to fumarate 
by succinate dehydrogenase. Fumarate is hy­
drated to malate, which is oxidized to regene­
rate oxaloacetate, available for another turn 
of the citric acid cycle. During the citric acid 
cycle 2 acetyl-CoA yields 6 NADH, 2 FADH2 
and 2 GTP molecules. The overall equation for 
the TCA cycle is:
Acetyl-CoA + 3NAD+ + GDP + Pi + FAD + 2 H2O 
-> CoA + 3NADH + FADH2 + GTP + 2 CO2 + H2O 
+ 3H+.
The OXPHOS system is the final biochemical 
pathway in ATP production. It is located in 
the mitochondrial inner membrane and con­
sist of four enzyme complexes (complex I-IV) 
of the electron transport chain, ATP synthase 
(complex V) and two mobile electron carriers 
(ubiquinone and cytochrome c). NADH and 
FADH2, produced in the citric acid cycle, are
15
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the substrates for the OXPHOS system. The 
respiratory chain transfers electrons from 
NADH (at complex I) and FADH2 (at complex 
II) to the final acceptor molecular oxygen (by 
complex IV). Energy released by this elec­
tron transport is used to translocate protons 
across the mitochondrial inner membrane at 
complexes I, III, and IV. This results in a proton 
gradient, which can be used by complex V to 
produce ATP from ADP and Pi.
The OXPHOS system is under bigenomic con­
trol. The subunits of complexes I, III, IV and
V are encoded by either the mtDNA or the 
nDNA. Only complex II is entirely encoded by 
the nDNA (figure 1.3).
Human complex I deficiency
Disturbances in the OXPHOS system cause 
mitochondrial disorders with an incidence 
of 1 in approximately 5000 births [Smeitink 
2006; Valsecchi 2010]. Complex I is the most 
frequently encountered deficiency: about 
23% of all patients with childhood respira­
tory chain deficiency [Loeffen 2000]. Mito­
chondrial disorders may affect one or more 
tissues or organs, especially the ones with 
high energy demands, like brain, heart and 
skeletal muscle. Therefore, OXPHOS disor­
ders have a wide clinical variety [Distelmaier 
2009a]. This is also due to the dual genetic 
control of the OXPHOS system, which means 
that a mutation in the mtDNA or in nuclear 
encoded genes may cause complex I defi­
ciency [Janssen 2006b; Rotig 2010]. Because 
of the heterogeneous clinical presentation of 
complex I deficiency, there is no clear geno- 
type-phenotype relation. This means that dif­
ferent mutations could have a similar clinical 
phenotype as a consequence, and the same 
mutation gives different clinical features in 
another patient. For complex I deficiency, 
the underlying genetic cause is only known 
in approximately 50% of the cases [Thorburn 
2004; also own experience, data not shown].
Aim of thesis and outline
The goal of this thesis is to identify new ge­
netic defects involved in the pathogenesis of 
complex I deficiencies and to elucidate the cell 
biological consequences. Candidate genes 
encoding both nDNA and mtDNA subunits of 
complex I, and encoding (putative) assembly 
factors of complex I, were screened for the 
presence of disease-causing mutations in a 
cohort of 34 patients with isolated complex 
I deficiency expressed in cultured fibroblasts
Figure 1.3
Representation of the oxidative phosphorylation system. The OXPHOS system is the final biochemical pathway in 
ATP production. It consists of four enzyme complexes (complex I-IV) of the electron transport chain, ATP synthase 
(complex V) and two electron carriers (ubiquinone and cytochrome c). Complexes I-IV transport electrons from 
NADH and FADH2 to the final acceptor molecular oxygen. Energy released by this transport is used to translocate 
protons across the mitochondrial inner membrane, resulting in a proton gradient, which can be used by complex 
V to produce ATP from ADP and P.. The subunits of all complexes, except for complex II, are encoded by the mito­
chondrial DNA as well as the nuclear DNA. Complex II is entirely encoded by the nuclear DNA. Figure adapted and 
modified from http://www.genome.jp/kegg
16
General introduction
and when measured in muscle tissue.
The biochemical and genetic aspects of com­
plex I deficiencies are reviewed in chapter
2. Also the criteria for selecting the group of 
patients which has been used for screening 
candidate genes, is given in that chapter. 
Disease-causing mutations were observed in 
several novel subunits of complex I. Chapter 
3 describes three patients with a complex I 
deficiency caused by mutations in the gene 
encoding subunit NDUFS1. Chapter 4 con­
tains the first report describing a mutation in 
the NDUFA2 gene and chapter 5 describes a 
novel mutation in the NDUFA10 gene. Besides 
mutations in complex I subunits, mutations 
in assembly factors may also cause complex 
I deficiency. Chapter 6 describes a patient 
with a mutation in assembly factor NDUFAF2, 
and chapter 7 contains a report about muta­
tions in NDUFAF3 in patients with complex I 
deficiencies. As far as possible, cell biological 
consequences have been investigated for all 
mutations described in these chapters. Chap­
ter 8, the general discussion, will summarize 
the findings and give directions for future 
research.
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Introduction
The oxidative phosphorylation (OXPHOS) sys­
tem is the final pathway in the mitochondrial 
energy generating system (MEGs) of the cell 
and is carried out in the inner mitochondrial 
membrane. The system consists of five en­
zyme complexes (I-V), together with two elec­
tron carriers, ubiquinone (Q) and cytochrome 
c (cyt c). Energy generated by the transfer of 
electrons from complex to complex is used to 
generate a proton gradient across the inner 
mitochondrial membrane. Complex IV trans­
fers electrons to the final electron acceptor, 
molecular oxygen. Complex V utilizes the 
proton gradient as a driving force to produce 
ATP [Shoubridge 2001]. Here, we focus on 
complex I. We describe the role of complex I in 
the oxidative phosphorylation in addition to 
the localization and function of the different 
complex I subunits. We give a brief overview 
of the assembly process and the biochemical 
studies which can be performed when a pa­
tient is suspected of a mitochondrial disorder. 
Furthermore, the molecular base for complex 
I deficiency is described and the findings in 
a research cohort of patients with complex I 
deficiency are reported.
Complex I, or NADH:ubiquinone oxidoreduc- 
tase (E.C. I.6.5.3.), is the first and largest of the 
respiratory chain complexes. It catalyzes the 
oxidation of NADH in the mitochondrial ma­
trix and is involved in transferring of the elec­
trons to ubiquinone in the inner mitochon­
drial membrane. Part of the energy released 
by this electron transport is used to remove 
protons from the matrix into the intermem­
brane space. Complex I is composed of seven 
subunits encoded by the mitochondrial DNA 
(mtDNA) and 38 nuclear-encoded subunits 
which are assembled into a large complex of 
~1 MDa [Carroll 2006]. Fourteen of these 45 
subunits are essential for the catalytic func­
tion and are conserved in prokaryotes and 
eukaryotes [Brandt 2006]. These core sub­
units are encoded by the nuclear NDUFS1, 
NDUFS2, NDUFS3, NDUFS7, NDUFS8, NDUFV1 
and NDUFV2 genes and the mitochondrial 
ND1-6 and ND4L genes. The function of the 
remaining 31 accessory subunits is largely 
not exactly known yet.
Electron microscopy of complex I reveals
a L-shaped complex consisting of a hydro­
phobic membrane part located in the inner 
mitochondrial membrane and a hydrophilic 
peripheral arm of similar size protruding into 
the mitochondrial matrix [Hofhaus 1991; 
Friedrich 2004]. Furthermore, complex I can 
be divided into three modules. The dehydro­
genase module is responsible for the oxida­
tion of NADH, containing at least the NDUFS1, 
NDUFV1 and NDUFV2 subunits. The hydroge- 
nase module, consisting of at least NDUFS2, 
NDUFS3, NDUFS7 and NDUFS8, transfers 
the electrons to ubiquinone. The third is the 
proton translocation module, comprising the 
subunits ND1-6, and ND4L [Brandt 2006].
The localization of the individual subunits has 
been elucidated by analyzing complex I and 
its subcomplexes (figure 2.1A). Treatment of 
the purified bovine complex I with the chao- 
tropic agent N,N-dimethyl-dodecylamine 
N-oxide (LDAO) dissociates the enzyme into 
four subcomplexes: Ia, Ip, Iy, and IA [Carroll 
2003; Sazanov 2000]. Subcomplex IA repre­
sents the extrinsic globular domain of the 
intact complex. Subcomplex Ia contains sub­
complex IA and part of the membrane arm. 
Subcomplex Ip forms the main part of the 
membrane arm, and subcomplex Iy contains 
the subunits which are not found in the sub­
complexes Ia and Ip. The intact complex and 
the mentioned subcomplexes have been fur­
ther analyzed. The subunits have been sepa­
rated by three independent methods (one­
dimensional SDS-PAGE, two-dimensional 
isoelectric focusing/SDS-PAGE, and reverse 
phase high pressure liquid chromatography 
(HPLC)) and subsequent analysis of the sub­
units was performed by tryptic peptide mass 
fingerprinting and tandem mass spectrome­
try. The findings are summarized in table 2.1. 
Complex I forms together with 
succinate:ubiquinone oxidoreductase, or com­
plex II, the entry points of the OXPHOS sys­
tem. It binds and oxidizes NADH to NAD+, 
and transfers two electrons to ubiquinone. The 
transfer of these two electrons is coupled to the 
translocation of four protons across the mem­
brane [Brandt 2006; Friedrich 2004; Wikstrom 
1984]. The overall reaction for complex I is:
NADH + H+ + Q + 4H+matrix -> NAD+ + QH2
+ 4H intermembrane space
20
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Complex I contains a flavin mononucleotide 
(FMN) (NDUFV1 subunit) which accepts the 
electrons from NADH. The electrons are trans­
ported through redox centres represented by 
eight iron-sulfur (FeS) clusters: N1a is located
in NDUFV2. N1b, N4, and N5 are located in 
NDUFS1. NDUFS7 contains N2, and N3 is lo­
cated in NDUFV1. Finally, NDUFS8 contains 
N6a and N6b. The electrons are accepted by 
ubiquinone, which subsequently is reduced
a
I a-A.
\ y
NDUFVV 51 kDa 
NDUFV2 ’ 24 kDa 
NDUFV3 10 kDa 
NDUFS1* 75 kDa 
NDUFS2’ 49 kDa 
NDUFS3 • 30 kDa 
NDUFS4 ' 18kDa 
NDUFS6' 13kDa 
NDUFS7* PSST  
NDUFS8 * TYKY 
NDUFA2- 88 
NDUFAS B13 
NDUFA7 B14.Sa 
NDUFA12 B17.2 
NDUFA13 B it.6
NDUFS5 15 kDa 
NDUFA V  ktWFE 
NDUFA3 89 
NDUFA6 B14 
NDUFAS PGIV 
NDUFA9 39 kDa 
NDUFA 10 ' 42 kDa 
NDUFA11* B14.7 
ND6 ‘ ND6 
NDUFC1 KFYI 
ND1• ND1 
ND2 ’ ND2 
N D3’ ND3 
ND4L' ND4L
MNLL NDUFB1 
AGGG NDUFB2 
B12 NDUFB3 
SGDH NDUFBS 
B17 NDUFB6
IP
v\WW
B18 NDUFB7
A SH NDUFB8
B22 NDUFB9
PDSW NDUFB10
ESSS NDUFB11
B14.SÒ NDUFC2
ND4 ND4’
NO 5 A/05 '
A
NDUFS2,
NDUFS3
' O
NDUFS7,
NDUFS8
ND2
I
Entry of mtDNA- 
encoded subunits
NDUFA13
NDUFA2. NDUFA12. 
NDUFS1, NDUFS4, 
NDUFV1. NDUFV2
NDUFA 1. NDUFA6. 
NDUFA9, NDUFB6
Complex I
B
Assembly factors:
<------------------X ----------------------------------------------------------------------------- >
C20orf7, Ind1 NDUFAF3. NDUFAF4
<-------------------- »
NDUFAF2, C8orf38, Ind1
<---------------- >
NDUFAF1, Ecsit, ACAD9
Figure 2.1
Complex I
(A) Distribution of complex I subunits. The human nomenclature is shown in dark blue, the bovine nomencla­
ture is shown in purple. Mutations have been described in the subunits depicted with a (*). Figure adapted from 
Janssen et al. [Janssen 2006b].
(B) Schematic assembly model of complex I. The assembly of complex I is a stepwise process, in which smaller 
modules are formed before they are being combined at different stages. Several assembly factors associate with 
assembly intermediates and make a proper assembly possible.
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Table 2.1
Mitochondrial and nuclear encoded subunits, and (putative) assembly factors for human complex I.
Homo sapiens Bos taurus Human Fraction Protein
nomenclature nomenclature chromosome
ND1 ND1 mtDNA encoded IY Core
ND2 ND2 mtDNA encoded IY
ND3 ND3 mtDNA encoded IY
ND4 ND4 mtDNA encoded Iß
ND4L ND4L mtDNA encoded IY
ND5 ND5 mtDNA encoded Iß
ND6 ND6 mtDNA encoded Ia
NDUFS1 75 kDa 2q33-q34 IÂ
NDUFS2 49 kDa 1q23 IA
NDUFS3 30 kDa 11p11.11 IA
NDUFS7 PSST 19p13.3 IA
NDUFS8 TYKY 11q13 IA
NDUFV1 51 kDa 11q13 IA
NDUFV2 24 kDa 18p11.31-p11.2 IA
NDUFS4 AQDQ 5q11.1 IA Accessory
NDUFS5 15 kDa 1p34.2-p33 Ia
NDUFS6 13 kDa 5p15.33 IA
NDUFA1 MWFE Xq24 Ia
NDUFA2 B8 5q31 IA
NDUFA3 B9 19q13.42 Ia
NDUFA4 MLRQ 7p21.3 nd
NDUFA5 B13 7q32 IA
NDUFA6 B14 22q13.2-q13.31 Ia
NDUFA7 B14.5a 19p13.2 IA
NDUFA8 PGIV 9q33.2-q34.11 Ia
NDUFA9 39 kDa 12p13.3 Ia
NDUFA10 42 kDa 2q37.3 Ia, loosely
NDUFA11 B14.7 19p13.3 Ia
NDUFA12 B17.2 12q22 IA
NDUFA13 B16.6 19p13.2 IA
NDUFAB1 SDAP 16p12.2 Ia + Iß
NDUFB1 MNLL 14q32.12 Iß
NDUFB2 AGGG 7q34 Iß
NDUFB3 B12 2q31.3 Iß
NDUFB4 B15 3q13.33 Ia + Iß
22
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NDUFB5 SGDH 3q26.33 IP
NDUFB6 B17 9p21.1 IP
NDUFB7 B18 19p13.12-p13.11 IP
NDUFB8 ASHI 10q23.2-q23.33 IP
NDUFB9 B22 8q13.3 IP
NDUFB10 PDSW 16p13.3 IP
NDUFB11 ESSS Xp11.23 IP
NDUFC1 KFYI 4q28.2-q31.1 Iy
NDUFC2 B14.5b 11q14.1 IP
NDUFV3 10 kDa 21q22.3 IA
NDUFAF1 15q11.2-q21.3 Assembly
NDUFAF2 5q12.1
NDUFAF3 3p21.31
NDUFAF4 6q16.1
Ecsit 19p13.2
C20orf7 20p12.1
C8orf38 8q22.1
ACAD9 3q21.3
NUBPL 14q12
FOXRED1 11q24.2
C2orf56/PRO1853 2p22.2 Putative
DHDPSL/C10orf65 10q24.2 assembly
OXCT2 1p34
OXCT1 5p13.1
IVD 15q14-q15
DCI 16p13.3
MCCC2 5q12-q13
GPAM 10q25.2
C7orf10 7p14
AMACR 5p13
PHYH 10p13
LYRM5 12p12.1
LACTB 15q22.1
Disease-causing mutations have been described in the genes encoding the complex I assembly factors and/or 
cell biological studies have shown the involvement of these proteins in the assembly of complex I. On the con­
trary, the role of the putative assembly factors needs to be established.
to ubiquinol (QH2). Complex I of Thermus 
thermophilus contains an extra FeS cluster, 
N7, which is absent in mammalian complex
I. Studying the anatomic structure of the pe­
ripheral arm in Thermus thermophilus with 
the use of x-ray crystallography predicts a 
pathway for complex I electron transport 
from FMN to ubiquinone. It follows the route:
23
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FMN-N3-N1b-N4-N5-N6a-N6b-N2-Q [Brandt 
2006; Hinchliffe 2005; Sazanov 2006; Sazanov
2007]. The FeS cluster N1a does probably not 
participate in the electron transfer, since it 
cannot pass the electrons to another cluster. 
It may play a role as an antioxidant. It accepts 
electrons from FMN and thereby prevents 
excessive generation of reactive oxygen spe­
cies (ROS) [Sazanov 2006].
As mentioned above, the redox reactions 
take place in the peripheral arm. On the 
contrary, the proton pumping machinery is 
located in the membrane arm. Different me­
chanisms for proton translocation have been 
described. First, a direct coupling mechanism 
for electron transfer and proton translocation 
has been proposed [Brandt 1997]. Second, 
the hypothesis of an active proton pumping 
mechanism, powered by long range con­
formational changes which are initiated by 
the oxidation of NADH has been described 
by the group of Brandt [Brandt 2003]. The 
conformational changes are initiated by the 
oxidation of NADH. Third, a combination of 
both mechanisms has also been proposed 
[Friedrich 2001], and also a conformational 
driven gated proton pumping mechanism 
[Ohnishi 2005]. Recently, Efremov and col­
leagues propose the newest model for pro­
ton translocation [Efremov 2010]. According 
to this model, NADH donates two electrons 
to the chain of FeS clusters which are passed 
on to quinone. Electron transfer is coupled to 
conformational changes in the hydrophilic 
domain, which are transmitted. Finally, this 
results in changing the conformation of ion- 
izable residue inside respective proton chan­
nels and in the translocation of three protons. 
The fourth proton is translocated at the inter­
face of the two main domains.
Function subunits of complex I
The fourteen core subunits belong to the 
minimal constitution of complex I and are im­
portant for catalysis of electron transfer from 
NADH to ubiquinone and for proton translo­
cation. The seven nuclear encoded subunits 
contain the redox centres and are involved in 
the electron transport. The mtDNA encoded 
subunits are located in the membrane arm. It
has been suggested that the subunits ND2, 
ND4 and ND5 originate from one common 
ancestor and play a role in the proton trans­
location machinery, since they seem to be 
related to subunits of K+ or Na+/K+ antiport­
ers [Friedrich 2001]. Furthermore, the subunit 
ND1 has a quinine-binding site, and is pro­
posed to be involved in ubiquinone binding. 
At present, the exact function of (most of) 
the 31 accessory subunits is largely not 
known. They may play a role in protection 
against oxidative damage, preventing ROS 
generation, binding of the complex to the 
membrane, and stabilization of the complex 
[Hirst 2003; Janssen 2006b]. In addition, some 
accessory subunits participate in the assem­
bly of the complex, and/or regulation of the 
functional activity by cellular transduction 
signals [Janssen 2006b; Scacco 2003; Schef- 
fler 2004; Papa 2008; Yadava 2008]. For some 
subunits there is experimental support for 
their function within complex I. The NDUFS4 
subunit can be phosphorylated by a mito­
chondrial cAMP-dependent protein kinase, 
which promotes the import/maturation in 
mitochondria of this nuclear encoded pro­
tein [De Rasmo 2008; Papa 2010]. However, 
another study did not support protein kinase 
A (PKA)-dependent phosphorylation of this 
subunit [Chen 2004]. The activity of complex 
I can depend on pre-existing, possibly func­
tionally damaged, NDUFS4 subunits in the 
complex with the newly synthesized protein 
[Papa 2010; Lazarou 2007]. Another subunit 
that can be phosphorylated is NDUFA1 [Ya­
dava 2008]. This X-linked subunit is a mem­
brane protein, which is required for complex 
I assembly [Yadava 2002; Yadava 2004], and 
activity [Au 1999]. The sequence of the NDUFA9 
subunit has a nucleotide-binding motif, sug­
gesting that this subunit may bind either 
NADH or NADPH [Hirst 2003; Walker 1992; 
Fearnley 1992]. In addition, sequence com­
parisons suggest that NDUFA9 is related to 
the short-chain dehydrogenase/reductases 
[Baker 1999]. This may suggest that NDUFA9 
is involved in a biosynthetic pathway besides 
its function in energy transducing activity of 
complex I. It may form a 'biosynthetic mo­
dule' with the acyl-carrier protein (ACP) SDAP 
(NDUFAB1) [Hirst 2003]. A possible role for 
NDUFAB1 might be in mitochondrial de novo
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fatty acid synthesis, elongation, or desatura­
tion. However, more research is necessary 
to prove these suggestions. The NDUFA13 
subunit is also known as GRIM-19 (gene as­
sociated with retinoid-interferon induced 
mortality-19), and has a dual role. First, GRIM- 
19 was identified as a gene involved in apop- 
tosis, induced by interferon-p and retinoic 
acid [Angell 2000]. Second, it was found as a 
subunit of complex I and is essential for com­
plex I assembly [Fearnley 2001; Huang 2004]. 
Finally, some subunits show homology to 
other proteins, giving an indication of their 
function. NDUFA11 shows homology to Tim 
proteins (Tim17, Tim22 and Tim23), which are 
involved in protein import from the cytosol 
into the mitochondria [Janssen 2006b]. NDUF- 
A2 shows homology to mitochondrial ribo- 
somal proteins L43 and S25, and NDUFA10 
to mitochondrial thymidine kinase 2 (TK2) 
[Janssen 2006b; Gabaldon 2005]. This might 
suggest a possible connection between com­
plex I and mitochondrial translation. Howev­
er, more research is necessary to prove this.
Assembly of complex I
During complex I biogenesis all the subunits 
should be assembled together to form one 
complex. The current hypothesis is that as­
sembly of complex I is a stepwise process, in 
which assembly intermediates of the mem­
brane and peripheral arm are assembled 
before they are being combined [Ugalde 
2004; Vogel 2007a]. These intermediates are 
depicted as 1-6 in the assembly model de­
scribed by Vogel et al. [Vogel 2007a]. The as­
sembly starts with the formation of the first 
subcomplex containing at least NDUFS2 and 
NDUFS3, subsequently followed by addition 
of the subunits NDUFS7 and NDUFS8. This 
forms the hydrogenase core module and 
leads to the formation of subcomplexes 2 
and 3, which is anchored to the mitochon­
drial inner membrane. Subsequently, mtDNA 
encoded subunits are incorporated at five 
entry points, which is expanded with the 
dehydrogenase module and the addition of 
membrane fragments, resulting in the for­
mation of a fully assembled complex I [Vogel 
2007a; Lazarou 2009; Koopman 2010; Perales-
Clemente 2010].
At least ten assembly factors have been de­
scribed to be involved in the assembly of 
complex I (table 2.1). The first, NDUFAF1, or 
CIA30, has been originally isolated with a 
membrane arm intermediate from N. crassa 
[Kuffner 1998]. Another study showed a re­
duced amount and activity of complex I after 
knocking down the expression of NDUFAF1 
by RNA interference [Vogel 2005]. Dunning et 
al. described NDUFAF1 to be evolved in the 
earlier steps of assembly demonstrated in a 
patient harbouring a mutation in this gene 
[Dunning 2007]. This assembly factor does 
not associate with fully assembled complex
I, but resides within complexes of ~460kDa 
and ~830 kDa [Dunning 2007; Vogel 2007d]. 
The second, NDUFAF2 (also known as B17.2L/ 
Mimitin) is a paralogue of complex I subunit 
NDUFA12. It was identified to be present in 
an ~830-kDa subcomplex in a patient with an 
assembly defect, but not in fully assembled 
complex I, suggesting that NDUFAF2 func­
tions at a late stage of the assembly [Ogilvie
2005]. The third assembly factor is NDUFAF3, 
or also known as C3orf60. This factor co-mi- 
grates with the assembly subcomplexes 3, 4, 
and 5 and colocalizes with a fourth assembly 
factor, NDUFAF4 (or known as C6orf66) [Saa- 
da 2009]. Mutations in the genes encoding 
for these two assembly factors will cause a 
reduced complex I activity and a decreased 
amount of fully assembled complex I [Saada 
2009; Saada 2008]. NDUFAF3 and NDUFAF4 
cooperate from the early until the late stages 
of assembly of complex I. They remain associ­
ated with subcomplexes 4, 5, and 6, but are 
dissociated just before the formation of the 
holo complex I [Saada 2009].
The fifth assembly factor is Ecsit, which has 
been identified with tandem affinity puri­
fication using TAP-tagged NDUFAF1 [Vo­
gel 2007b]. Ecsit knockdown resulted in a 
severely impaired complex I assembly and 
a reduced amount of NDUFAF1. Ecsit is re­
quired for stabilization of NDUFAF1 and both 
factors are involved in the early steps of com­
plex I assembly [Vogel 2007b]. Until now, no 
mutations in Ecsit have been described in 
patients with complex I deficiencies. In con­
trast, mutations affecting the assembly in an 
early stage have been described in the sixth
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factor, C20orf7 [Sugiana 2008; Gerards 2010]. 
Furthermore, this protein also has a predicted 
methyltransferase activity, suggesting that it 
might function to methylate NDUFB3. Muta­
tions in the seventh factor, C8orf38, causing a 
disturbed assembly of complex I suggest that 
this protein is involved in complex I assembly 
[Pagliarini 2008].
Recently, mutations have been described in 
the genes encoding the eighth, ninth, and 
tenth assembly factors, ACAD9, NUBPL, and 
FOXRED1, respectively [Nouws 2010; Calvo 
2010]. Knockdown of the ACAD9 protein 
leads to a severe decrease and amount of 
complex I. Furthermore, it associates with 
complex I assembly proteins NDUFAF1 and 
Ecsit and ACAD9 mutations result in com­
plex I deficiency. NUBPL, also known as Ind1, 
is specifically required for effective assem­
bly of complex I in the yeast Yarrowia lipoly- 
tica [Bych 2008]. It has been suggested that 
NUBPL plays a specific role in the assembly of 
the FeS clusters in complex I. The complex I 
deficiency observed in a patient with NUBPL 
mutations could be rescued by expression of 
a wild-type allele of NUBPL, thereby establish­
ing a pathogenic role for NUBPL mutations 
in complex I deficiency. In a similar way, this 
study also demonstrated pathogenic muta­
tions in FOXRED1 in a patient with complex I 
deficiency. Fassone et al. also showed a mu­
tation in this gene, suggesting that FOXRED1 
could be the tenth assembly or other factor 
involved in assembly, stability and/or proper 
functioning of complex I [Fassone 2010].
All these assembly factors contribute to a 
correct assembly of complex I. A schematic 
overview of the assembly model is shown in 
figure 2.1B. For a more detailed description of 
complex I assembly also see recent reviews 
[Lazarou 2009; Vogel 2007c; McKenzie 2010].
I n different organisms, such as bacteria, some 
fungi, plants and mammals the OXPHOS 
complexes have been found to be organized 
into higher supramolecular structures, called 
supercomplexes [Stroh 2004; Schagger 2000; 
Lenaz 2010]. Using different detergents, the 
respiratory chain complexes can be differ­
entially dissected from the supercomplexes 
[Schagger 2002]. Respirasomes are the super­
complexes containing complexes I, III, and IV. 
The vast majority of complex I seems toappear
in supercomplexes [Acin-Perez 2008]. It can 
exist in a CI-CIII and in a CI-CIII-CIV supercom­
plex, with a ratio of 1:2:4. Several functions for 
the formation of these supercomplexes have 
been suggested. First, channeling of ubiqui- 
nol and cytochrome c, avoiding competition 
from other enzymes. Second, catalytic en­
hancement from reduced diffusion times of 
substrates. Third, preventing the generation 
of superoxide by sequestration of the reac­
tive intermediate ubisemiquinone [Schagger
2000]. Finally, stabilization of the respiratory 
chain complexes [Schagger 2004; Dudkina 
2010].
Besides these functional reasons, supercom­
plex formation is necessary for the assembly 
and stability of complex I. Paracoccus denitri- 
ficans mutants lacking complexes III and IV, 
showed decreased amounts of complex I, be­
cause supercomplexes containing complex 
I could not be formed [Stroh 2004]. Further­
more, analyzing the state of respirasomes in 
patients with an isolated deficiency of single 
complexes showed that the formation of 
these respirasomes is essential for the assem­
bly/stability of complex I [Schagger 2004]. 
Studying human cultured cell models har­
boring cytochrome b mutations showed also 
a reduction in the amount of complex I, when 
complex III assembly is disturbed [Acin-Perez
2008]. This was not observed, when complex 
III activity was pharmacologically inhibited. 
Other studies in mutants and patients hav­
ing a deficiency in one of the enzymes of the 
OXPHOS system have suggested that com­
plex III and IV are involved in the assembly 
and stabilization of complex I in mammals 
[McKenzie 2006; Blakely 2005; Diaz 2006]. 
Also the other way around, primary complex 
I deficiencies affecting the stability of com­
plex III, have been reported for patients with 
mutations in some complex I subunits or as­
sembly factor NDUFAF2 [Ugalde 2004; Budde 
2000; Hoefs 2010; Hoefs 2009].
Mitochondrial complex I 
deficiency in human
Disturbance of the OXPHOS system cause 
mitochondrial disorders with an incidence
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of 1 in approximately 5000 births [Smeitink 
2001b]. Of these disorders, isolated complex 
I deficiency is the most frequently diagnosed 
form accounting for almost 23% of all cases of 
childhood respiratory-chain deficiency [Loef- 
fen 2000]. The age of onset of the first symp­
toms starts mostly at birth or early childhood, 
and the clinical presentations of complex I 
deficiency shows great variability. The most 
affected tissues are usually the ones with the 
highest energy demand, like brain, heart, kid­
ney, and skeletal muscle [Pitkanen 1996]. The 
most common phenotype associated with 
isolated complex I deficiency are Leigh syn­
drome and Leigh-like disease [Rahman 1996; 
Morris 1996]. Leigh disease is a progressive 
neurodegenerative disorder, with symptoms 
like psychomotor retardation, brainstem dys­
function, muscular hypotonia, dystonia, de­
velopment delay, abnormal eye movements, 
seizures, respiratory irregularities, failure to 
thrive and elevated blood and/or cerebro­
spinal fluid (CSF) [Loeffen 2000]. This disease 
is found in infancy and childhood, although 
rare adult-onset forms have been described 
[Nagashima 1999]. Other common observed 
phenotypes associated with complex I defi­
ciency are fatal infantile lactic acidosis, cardi­
omyopathy, macrocephaly with progressive 
leukodystrophy, and unspecified encephalo- 
myopathy [Loeffen 2000]. The clinical aspects 
of isolated complex I deficiency are not the 
focus of this review.
If only the medical history and the clinical 
examination are available, it is difficult to 
establish whether a patient suffers from a 
mitochondrial disorder. Therefore more pro­
found investigations are necessary. Complex 
I deficiency will in general lead to an increase 
in blood lactate because of an accumulation 
of NADH and a lack of NAD+ in the cells. This 
increase may be moderate, just above the 
upper normal value, or severe leading to lac­
tic acidaemia. Determination of lactate and 
pyruvate concentrations in blood and CSF are 
recommended for the diagnosis of complex 
I deficiency. However, normal values do not 
rule out mitochondrial disorders [DiMauro
1999]. Furthermore, analysis of amino acid 
concentrations, like alanine, and levels of 
TCA cycle intermediates or derivates, such as 
malate, succinate, and fumarate, can be per­
formed. This may also give an indication of 
the presence of mitochondrial defect. How­
ever, biochemical enzyme measurements 
help to diagnose the patients suspected of a 
complex I deficiency.
Biochemical studies
When a patient is suspected of a mitochondri­
al disorder, the diagnosis can be confirmed by 
biochemical analysis of the OXPHOS system. 
The biochemical measurement of complex I 
is based on estimation of the mitochondrial 
rotenone-sensitive NADH:ubiquinone oxi- 
doreductase activity [Fischer 1985; Smeitink 
2001a]. This can be done in fresh and frozen 
muscle tissue, cultured skin fibroblasts, or 
other tissues like heart, brain and liver. How­
ever, fresh muscle tissue is preferred because 
freezing of the tissues partly destroys the 
mitochondrial inner membrane and the in­
tegrity of the respiratory chain will be lost. As 
a consequence, measurement of oxidation 
rates and ATP production rate from pyruvate 
or succinate cannot be performed. Further­
more, a defect present in muscle tissue is not 
always expressed in fibroblasts. Therefore, 
exclusion of a defect in fibroblasts does not 
automatically exclude a defect in muscle tis­
sue [Janssen 2003].
To get more insight in the frequency of 
complex I deficiencies in our institution, we 
looked at the measurements of the single en­
zyme activities expressed in both muscle tis­
sue and cultured fibroblasts in the year 2009. 
More investigations were performed in mus­
cle tissues compared to the fibroblasts. These 
numbers were 405 and 249, respectively. In 
muscle tissue we found 36 complex I defi­
ciencies, which is 9% of all measured muscle 
samples. In fibroblasts we found a compara­
ble amount of complex I deficiencies, 8% of 
all fibroblast cultures.
As mentioned before, OXPHOS defects ex­
pressed in muscle tissue may not always be 
expressed in fibroblasts. Therefore, when 
possible, both muscle tissue and fibroblasts 
of one patient were used to measure the OXPHOS 
deficiencies. We selected patients with a 
complex I deficiency diagnosed from 1996 
until 2008 and categorised them in five differ­
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ent groups: 1) complex I deficiency expressed 
in both muscle tissue and fibroblast; 2) com­
plex I deficiency expressed in fibroblasts, no 
measurements performed in muscle tissue; 3) 
complex I deficiency expressed in muscle tis­
sue and normal values in fibroblasts; 4) com­
plex I deficiency expressed in muscle tissue, no 
measurements performed in fibroblasts, and 
5) complex I deficiency expressed in fibroblasts 
and normal values in muscle tissue (see table 
2.2). Group 1 and 2 account for 26% and 25% of 
all found complex I deficiencies, respectively. 
Group 3 is the largest, accounting for 42%, and 
group 4 and 5 were small, only 4% and 3%, res­
pectively. Most patients were categorized in 
group 3. This means that in 42% of the patients 
the complex I deficiency could only be found 
in muscle tissue, while the values for the fibro­
blasts were within the control range. Therefore, 
we advocate that when fibroblasts are tested, it 
is important to measure the enzyme activities 
in muscle tissue as well.
Molecular basis for biochemical 
complex I deficiency
The next step in the diagnosis of a complex 
I deficiency, after establishing the enzymatic 
complex I defect in muscle tissue and/or 
cultured fibroblasts, is the screening of can­
didate genes for the presence of disease- 
causing mutations. This screening is impor­
tant for genetic counselling and for prenatal 
diagnostics. When a maternal inheritance 
pattern is suggestive in the family of the in­
dex patient, the screening should be started 
with the mtDNA. When this screening does
not reveal pathogenic mutations in affected 
tissues, screening of nuclear candidate genes 
is advocated. At present in our group, we start 
with the screening of the genes encoding for 
the structural subunits like NDUFS1, NDUFS2, 
NDUFS4, NDUFS7, NDUFS8 and NDUFV1. 
Previous studies have identified pathogenic 
mutations in these genes (see next para­
graph). If no disease-causing mutations are 
observed in these genes, also other structural 
complex I genes could be screened. Further­
more, mutations have been described in as- 
semblyfactors,causingcomplexIdeficiencies. 
Before screening of those genes the complex 
I assembly profiles can be obtained with two 
dimensional blue native/SDS gel electropho­
resis. This technique can provide information 
on the possible deficiency-causing mutations 
[Calvaruso 2008]. Finally, if the genetic defect 
has still not been elucidated, the patient was 
included into a research cohort of patients 
with complex I deficiencies, which will be used 
to identify new genetic defects. Screening of 
approximately 70 genes involved in complex 
I biogenesis is time-consuming and is often 
not performed for diagnostics in the patients 
with complex I deficiency at present. In gen­
eral genetic screen-ing occurs in only (part 
of) the genes in which pathogenic mutations 
have been described before. New techniques 
like whole exome sequencing would be very 
useful to screen all known genes involved in 
complex I biogenesis.
Primary defects
Because of the dual genetic control of the 
OXPHOS system, complex I deficiencies could 
be caused by mutations in either the mtDNA 
or the nuclear DNA (nDNA). Furthermore,
Table 2.2
Patients with a complex I deficiency (n=130) diagnosed from 1996 until2008 categorised in five 
different groups.
Group Complex I deficiency features %
Complex I deficiency in muscle tissue as well as in fibroblasts 26
2 Complex I deficiency in fibroblasts, no measurements in muscle tissue 25
3 Complex I deficiency in muscle tissue, normal in fibroblasts 42
4 Complex I deficiency in muscle tissue, no measurements in fibroblasts 3
5 Complex I deficiency in fibroblasts, normal in muscle tissue 4
28
Molecular base of biochemical complex I deficiency
different patterns of heredity are known for 
mitochondrial disorders, like maternal, au­
tosomal dominant or recessive, x-linked or 
somatic mutations. Important aspects for 
mitochondrial genetics are the maternal in­
heritance, homoplasmy and heteroplasmy, 
the threshold effect and mitotic segrega­
tion. mtDNA is inherited through the mater­
nal lineage, which is important for genetic 
counselling. Each cell contains hundreds to 
thousands of mtDNA molecules. If all mol­
ecules are identical, it is called homoplasmy. 
However, somatic mtDNA mutations may 
arise and could accumulate. This will lead 
to the coexistence of wild-type and mutant 
mtDNA, which is referred as heteroplasmy. 
The threshold for a pathogenic mtDNA mu­
tation is the minimum percentage of mutant 
mtDNA that is needed for clinical manifesta­
tion of the disorder. This threshold can differ 
between tissues. The degree of heteroplasmy 
can change during cell division, known as mi­
totic segregation. This may lead to a change 
in the phenotype of that particular tissue, 
because the pathogenic threshold could be 
crossed. Because of all these characteristics, 
the clinical presentation of mitochondrial 
disorders is heterogeneous. This means that 
especially for mtDNA mutations there is no 
clear genotype-phenotype relation. Differ­
ent mutations could have a similar clinical 
phenotype as a consequence, and vice versa. 
The same mutation gives different clinical 
features in another patient.
Several mutations in structural mtDNA en­
coded subunits of complex I and mutations 
in mitochondrial tRNA genes have been as­
sociated with isolated complex I deficiency. 
Mutations have been described in all ND 
genes (ND1-6, ND4L) [Chinnery 2001; Brown 
1992; Taylor 2001; Andreu 1999; Brown 2002; 
Santorelli 1997; Jun 1996]. Mutations in these 
genes are often reported in Leber hereditary 
optic neuropathy (LHON). This is the most 
common disease caused by mtDNA muta­
tions [Man 2003]. It is characterised by bi­
lateral sequential acute or sub-acute visual 
failure caused by degeneration of the retinal 
ganglion cells and their axons.Three common 
mutations, m.3460G>A in ND1, m.11778G>A 
in ND4, and m.14484T>C in ND6 have been 
described, with the mutations in ND1 and
ND6 being the hotspots for LHON [Chinnery 
2001; Valentino 2004]. Mutations in ND5, 
like m.13513G>A may cause mitochondrial 
encephalomyopathy with lactic acidosis 
and stroke-like episodes (MELAS) [Santorelli 
1997; Shanske 2008]. However, the hotspot 
for MELAS is m.3243A>G in the tRNA leucine 
1 gene. MELAS is characterised by mental 
retardation, psychomotor deterioration, sei­
zures, convulsion, migraine, and lactic acido­
sis. Mutations in tRNA genes have also been 
related to complex I deficiency, causing syn­
dromes, like MELAS and MERRF (myoclonic 
epilepsy associated with ragged-red fibers) 
[Kirby 1999; Arenas 1999]. In childhood, only 
5%-10% of the isolated complex I deficien­
cies could be related to mtDNA mutations, in­
dicating that the main genetic defects could 
have to be present in nuclear encoded genes 
[Triepels 2001].
On the contrary to mtDNA mutations, nDNA 
mutations are often associated with complex 
I deficiency presenting in the neonatal period, 
infancy or early childhood [Rubio-Gozalbo
2000]. Furthermore, the autosomal recessive 
pattern of heredity is the most common form 
for nDNA mutations causing complex I defi­
ciencies [Loeffen 2000]. Clinical phenotypes 
often associated with these mutations are 
Leigh syndrome, fatal infantile lactic acidosis 
(FILA), leukodystrophy with macrocephaly, 
neonatal cardiomyopathy with lactic acido­
sis, and hepatopathy with renal tubulopa- 
thy [Janssen 2006b; Loeffen 2000]. Complex 
I deficiency-causing mutations have been 
found in nuclear genes encoding complex I 
subunits and in assembly factors of this com­
plex. At present, pathogenic mutations have 
been described in thirteen of the 38 nuclear 
complex I genes. These include the seven 
genes encoding the core subunits, NDUFS1, 
NDUFS2, NDUFS3, NDUFS7, NDUFS8, NDUFV1, 
and NDUFV2 [Benit 2001; Loeffen 2001; Benit 
2004; Triepels 1999; Loeffen 1998; Schuelke 
1999; Benit 2003a]. Disease-causing muta­
tions have also been described in six ac­
cessory subunits. These genes are NDUFS4, 
NDUFS6, NDUFA1, NDUFA2, NDUFA10 and 
NDUFA11 [van den Heuvel 1998; Kirby 2004b; 
Fernandez-Moreira 2007; Hoefs 2008; Berger 
2008; Hoefs 2011].
For a proper assembly of complex I, differ­
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ent assembly factors involved in this process, 
have been identified. A mutation in one of 
these factors can also result in a complex I 
deficiency. At present, disease-causing muta­
tions have been described in nine assembly 
factors, e.g. NDUFAF1, NDUFAF2, NDUFAF3, 
NDUFAF4, C8orf38, C20orf7, ACAD9, NUBPL, 
and FOXRED1 [Dunning 2007; Ogilvie 2005; 
Saada 2009; Saada 2008; Sugiana 2008; Pagli- 
arini 2008; Nouws 2010; Calvo 2010; Fassone 
2010]. Fibroblasts of most of these patients 
showed a disturbed assembly pattern. This 
latter feature may be used for selection of pa­
tients to screen for specific genes encoding 
assembly factors. Disease-causing mutations 
have been found in many different genes, but 
there are still patients of whom the genetic 
cause has not been identified yet [Triepels
2001]. Therefore, the search for new candi­
date genes, and the screening of the genes 
for the presence of mutations has to go on.
Secondary defects
Besides its function in OXPHOS, complex 
I may also play a role in the cause of neuro­
degenerative diseases. These diseases often 
involve the death and cumulative loss of cells 
from regions of the central nervous system. 
Increased oxidative stress in combination 
with the dysfunction of the OXPHOS system, 
leading to the formation of reactive oxygen 
species (ROS), is suggested to contribute to 
the pathogenesis of the neurodegenerative 
disease. The most important is Parkinson's 
disease (PD), which is characterised by the 
loss of dopaminergic neurons in the substan­
tia nigra of the brain stem and the formation 
of Lewy bodies. Association of complex I and 
PD, has been confirmed by the identification 
of a complex I deficiency in substantia nigra 
of PD patients [Schapira 1989]. Furthermore, 
reduced activity level and amount of com­
plex I have been reported in PD patients and 
in an animal model [Mizuno 1989; Schapira 
1990; Flinn 2009]. Genetic defects, environ­
mental toxins, or a combination of both, may 
cause these complex I deficiencies. One study 
shows that the reduced complex I function in 
PD brain mitochondria is due to the oxidation 
of its catalytic subunits from internal process­
es, which correlates with complex I misas- 
sembly [Keeney 2006]. An explanation for this
may be that the high level of deleted mtDNA 
in substantia nigra neurons are important in 
the selective neuronal loss observed in PD 
[Bender 2006]. Another study shows that 
mutations in DJ-1, an integral mitochondrial 
protein, cause reduction of complex I activity 
[Hayashi 2009]. DJ-1 may bind to subunits of 
complex I, enhanced by oxidative stress. The 
findings suggest that native DJ-1 prevents PD 
via maintaining complex I activity. Pesticides 
may also increase the risk for PD, through dis­
ruption of mitochondrial function. 1-Methyl- 
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
induces PD through inhibition of complex 
I in both humans and experimental animals 
[Langston 1983; Sherer 2007]. Furthermore, 
it has been shown that inhibition of com­
plex I by rotenone reproduces many charac­
teristics of PD, like selective dopaminergic 
degeneration, increased oxidative damage, 
and a-synuclein aggregation [Betarbet 2000; 
Sherer 2003].
Friedreich's ataxia (FRDA) and Hereditary 
spastic paraparesis (HSP) are caused by mu­
tations in the mitochondrial proteins frataxin 
and paraplegin, respectively. FRDA is an auto­
somal recessive neurodegenerative disorder 
which manifests in childhood or early adult­
hood with progressive ataxia, various skeletal 
abnormalities, neuropathy, and hypertrophic 
cardiomyopathy. An expanded GAA triplet 
repeat in the first intron of the frataxin gene 
has been identified as a major cause of FRDA 
[Schapira 2002]. Severe deficiencies of com­
plexes I and III have been shown in cardiac 
and skeletal muscle from patients with FRDA 
[Bradley 2000]. Furthermore, it has been sug­
gested that mutations in ND genes could 
constitute a predisposing factor which in 
combination with environmental risk factors 
affects age of onset and disease progression 
[Heidari 2009]. Common features of HSP are 
progressive lower limb weakness, spasticity, 
and decreased vibratory sense. Paraplegin 
coassembles with a homologous protein, 
AFG3L2, and together they form a high mo­
lecular mass complex. The loss of this com­
plex causes a decreased complex I activity in 
mitochondria and an increased sensitivity to 
oxidative stress [Atorino 2003].
Mutations in complex I genes have been as­
sociated with bipolar disorder (BD). BD is a
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chronic psychiatric disease characterised 
by recurrent episodes of mania, hypoma- 
nia, mixed states, and depression. Down- 
regulation of several complex I subunits (e.g. 
NDUFS7, NDUFS8, NDUFV2) occurs in BD 
[Sun 2006; Andreazza 2010; Washizuka 2003]. 
Furthermore, a mutation in ND1 has been 
associated with BD [Munakata 2004]. These 
studies provide evidence of the involvement 
of complex I dysfunction in BD. Another study 
shows significant reduction in protein levels 
of NDUFS1 and NDUFV2 subunits in brain re­
gions of patients with Down syndrome and 
Alzheimer disease compared to controls [Kim
2001]. A study of Karry and colleagues shows 
a reduction in the expression of NDUFV1 and 
NDUFV2 in the prefrontal cortex of Schizo­
phrenia patients compared with normal con­
trol brains [Karry 2004]. A variable defect in 
complex I has also been shown in muscle of 
patients with Huntington's disease [Arenas 
1998]. Furthermore, multiple mtDNA dele­
tions were found by PCR analysis in muscle 
of the patient with the most severe complex 
I deficiency. Altogether, these studies show 
the involvement of complex I in the patho­
genesis of neurodegenerative disorders.
Cell biological consequences of 
complex I deficiency
Reactive oxygen species (ROS) are partially 
derivatives of molecular oxygen (O2). Impor­
tant sources of ROS are complex I and the 
TCA cycle enzyme a-ketoglutarate dehydro­
genase (a-KGDH) [Hirst 2008; Starkov 2004]. 
They produce ROS in the form of superoxide 
(O2 ), which can be converted into other ROS, 
like hydrogen peroxide (H2O2). Mitochondrial 
ROS were mostly associated with oxidative 
stress, which occurs when the ROS concen­
trations become too high to allow effective 
removal by detoxifying systems. However, 
mitochondrial ROS can also function as intra­
cellular signaling molecules [Koopman 2010; 
Starkov 2008; Valko 2007].
Fibroblasts from patients with an isolated 
complex I deficiency showed an increased 
NADH fluorescence and ROS production 
[Verkaart 2007a; Verkaart 2007b]. This in­
crease is inversely related to the complex I 
activity in the fibroblast cells. This inverse 
relationship was also observed in healthy fi­
broblasts treated with increasing rotenone 
concentrations. These results suggest that 
the increased cellular superoxide production 
observed in isolated complex I deficiency is 
primarily a consequence of decreased cel­
lular complex I activity and not of further 
electron leakage due to the presence of a 
mutated subunit [Verkaart 2007b]. However, 
in another study these increased ROS levels 
were not measured in patients' cells [Moran 
2010]. On the contrary, this study suggests 
that the different genetic backgrounds of 
patients with OXPHOS disorders might play a 
role in the pathophysiological manifestations 
of the mutations.
The mitochondrial membrane potential (A^) 
is an indicator of mitochondrial function and 
metabolic activity. It is directly coupled to 
proper action of the respiratory chain. Com­
plex I mutations in patient fibroblasts were 
associated with a small but significant depo­
larization of A^ [Distelmaier 2009b].
Studies in research cohort of pa­
tients with complex I deficiency
In many patients the underlying genetic 
cause of the complex I deficiency is still not 
known. Therefore in one of our projects, we 
started to screen different candidate genes in 
a cohort of patients (n=34). We selected the 
patients following the criteria: 1) the complex 
I deficiency should at least be expressed in 
cultured fibroblasts, and if measurements 
were performed also in muscle tissue; 2) the 
residual activity of complex I should be below 
90% of the lowest value of the control range; 
3) age of presentation of the disease should 
be below 10 years. Keeping these criteria in 
mind, we selected a group of 34 patients (see 
table 2.3). We included also patients with a 
complex I deficiency combined with a re­
duced activity of complex III, since previous 
studies identified disease-causing mutations 
in subunits of complex I in patients with a com­
bined deficiency of complex I and III [Budde
2000]. These combined deficiencies could
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be due to the formation of supercomplexes 
in which complex I and III occur together (CI/ 
III2) [Lazarou 2007]. Therefore, screening of 
the complex I subunits should be considered 
in patients with isolated complex I deficien­
cies, and in patients with combined complex 
I and III deficiencies. Furthermore, we also in­
cluded patients with a complex I deficiency 
combined with a deficiency in the pyruvate 
dehydrogenase complex (PDHc). In our ex­
perience, a decrease in activity of the PDHc 
is sometimes observed when the complex I 
activity is severely decreased.
To identify the underlying genetic cause of 
the complex I deficiency in the 34 patients, 
we started to screen the entire mtDNA and 
found pathogenic mutations in five patients 
(see table 2.3). One patient harboured the 
m.3697G>A (p.Gly131Ser) mutation in ND1, 
which has been described before [Kirby 
2004a]. The second mutation was found 
in ND3 (m.10191T>C, p.Ser45Pro) and has 
also been described in an earlier study [Tay­
lor 2001]. Three other patients harboured 
the previously described m.14487T>C 
(p.Met63Val) mutation in ND6 [Ugalde 2003]. 
These five patients were excluded from fur­
ther research, since these mutations could 
clarify the complex I deficiency. Next, we 
screened the nuclear encoded complex I 
subunits, and started with the genes in which 
mutations had been reported. We found mu­
tations in NDUFS1 in three unrelated patients 
[Hoefs 2010]. The first patient carried a ho­
mozygous mutation in exon 12 (c.1222C>T; 
p.Arg408Cys). The second patient was 
compound heterozygous for two muta­
tions: c.1669C>T (p.Arg557X) in exon 15 and 
c.1855G>A (p.Asp619Asn) in exon 16. And 
the third patient was compound heterozy­
gous for the mutations c.631-633delGAA 
(p.211delGlu) and c.683T>C (p.Val228Ala) in 
exon 8 of the NDUFS1 gene. In addition, we 
performed homozygosity mapping for the 
patients (n=5) with consanguineous parents. 
This resulted in homozygous regions, con­
taining different candidate genes, including 
complex I subunits. Screening of these genes 
showed a homozygous mutation in NDUFA2 
(c.208+5G>A) in one patient. Pathogenicity 
of this mutation was confirmed by transduc­
tion with a baculoviral vector containing the
wild-type NDUFA2 which restored the com­
plex I amount and activity in the patient fibro­
blasts [Hoefs 2008]. Another patient showed 
a homozygous region on chromosome 5, 
containing the NDUFAF2 gene, encoding an 
assembly factor of complex I. A disease-caus­
ing mutation (c.114C>G; p.Tyr38X) has been 
found in this gene, also established by restor­
ing the complex I defect using a baculovirus 
system [Hoefs 2009]. In total, homozygosity 
mapping revealed pathogenic mutations in 
three of the five patients originating from 
consanguineous parents. The patients in 
whom the genetic defect has been dissolved, 
were again excluded from further research. 
The remaining accessory subunits and the 
known assembly factors for complex I (NDUF- 
AF1-4, Ecsit, C20orf7, C8orf38, ACAD9, NUBPL 
and FOXRED1) were screened in the patients 
in whom the genetic defect is still not identi­
fied. This resulted in two heterozygous muta­
tions in accessory subunit NDUFA10 in one 
patient [Hoefs 2011]. The first mutation was 
located in exon 1 (c.1A>G; p.Met1?) and the 
second in exon 3 (c.425A>G; p.Gln142Arg). 
Furthermore, pathogenic mutations have 
been found in one patient compound 
heterozygous for two mutations in assembly 
factor NDUFAF3 (c.2T>C;p.Met1?/c.365G>C; 
p.Arg122Pro). Finally, two patients harboured 
mutations in a new assembly factor ACAD9 
[Saada 2009; Nouws 2010]. The first patient 
carried a homozygous substitution in exon 15 
(c.1553G>A; p.Arg518His) and the second pa­
tient was compound heterozygous for a mu­
tation in exon 2 (c.187G>T; p.Glu63X) and in 
exon 12 (c.1237G>A; p.Glu413Lys). Transduc­
tion of a baculovirus expressing ACAD9-RFP 
resulted in a restoration of complex I activity 
in fibroblasts of both patients, indicating that 
the ACAD9 mutations were disease-causing. 
Nineteen proteins to be important for the 
function of complex I, including the known 
assembly factors C8orf38, C20orf7, NDUF- 
AF3, and FOXRED1, have been described by 
Pagliarini et al. [Pagliarini 2008]. Genes en­
coding these proteins are good candidate 
genes for complex I deficiency. However, we 
did not observe disease-causing mutations 
in C2orf56, DHDPSL (also known as C10orf65), 
MCCC2, C7orf10, PHYH, LYRM5, and LACTB. 
Taken together, the entire mtDNA, all nuclear
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Table 2.3.
Research cohort of patients with complex I deficiency
Patient Tissue CI CII CIII CIV PDHc Mutation Reference
Muscle 74 124 89 16S 121
Fibroblasts 86 nm nm 1S2 nm
2 Fibroblasts 48 nm 108 104 nm
S Muscle 60 121 108 182 6S
Fibroblasts 48 16S 101 121 20S
4 Muscle 81 194 114 18S 121
Fibroblasts 7S nm 92 1S4 nm
S Fibroblasts SS nm 109 107 nm
6 Fibroblasts 82 147 116 1S1 nm
7 Fibroblasts 4S nm 1SS 112 nm
8 Muscle 87 106 112 212 10S
Fibroblasts S2 nm nm 146 20S
9 Fibroblasts SS nm 1S4 90 -17S* nm NDUFAFS [Saada 2009]
10 Muscle 68 nm nm 167 nm
Fibroblasts 81 nm 172 112 194
11 Fibroblasts S1 nm 11S 1S8 nm ACAD9 [Nouws2010]
12 Muscle 7 178 60 1S2 16S NDUFA10 [Hoefs 2011]
Fibroblasts 29 nm 112 1S0 nm
1S Fibroblasts SS nm 110 14S nm NDS
14 Muscle 20 116 98 1S8 212 NDUFA2 [Hoefs 2011]
Fibroblasts S6 24S 122 1S2 nm
1S Fibroblasts 84 nm S8 161 nm
16 Muscle 10 178 70 161 6S NDUFS1 [Hoefs 2011]
Fibroblasts 20 121 120 1S8 19S
17 Muscle 47 89 - 117* 9S 198 94
Fibroblasts 97 nm 72 164 92
18 Fibroblasts SS nm 141 104 267 ND6
19 Muscle 87 nm 1S7 1S6 146
Fibroblasts 8S 12S 108 171 nm
20 Fibroblasts S6 nm 222 11S nm ACAD9 [Nouws2010]
21 Fibroblasts 4S nm 108 126 nm ND6
22 Fibroblasts 7S 261 112 nm 116
2S Muscle 70 167 1S1 S27 S2S
Fibroblasts 66 142 122 124 246
24 Muscle nm nm nm 192 S1 ND1
2S Fibroblasts S9 nm 102 1S7 nm
SS
Chapter 2
26 Fibroblasts SS nm 126 149 nm
27 Fibroblasts SS nm 120 122 S0S
28 Fibroblasts SS nm 11S 128 nm
29 Muscie 66 nm 17S 24S 146
Fibroblasts 80 11S 120 124 nm
S0 Fibroblasts 89 10S 122 141 286
S1 Fibroblasts 64 nm 1SS 146 nm ND6
S2 Fibroblasts 2S 14S 98 127 nm NDUFAF2 [Hoefs 2011]
SS Muscie 6S nm nm 142 100 NDUFS1 [Hoefs 2011]
Fibroblasts 27 nm 120 126 nm
S4 Fibroblasts 24 149 147 140 16S NDUFS1 [Hoefs 2011]
CI-CIV, complexes I-IV; PDHc, pyruvate dehydrogenase complex; nm, not measured.
* The activity of this complex was decreased in one sample, but normal in another sample.
All enzyme activities are expressed as percentages of the lowest value of the control range. Lowered activities are 
shown in bold. If muscle tissue was available, enzyme activities were also measured in this tissue.
encoded complex I subunits, all at present 
known assembly factors for complex I, and 
some of the putative proteins involved in 
complex I functioning have been screened 
in a cohort of 34 patients. Five patients har­
boured mutations in the mtDNA (15%), and 
nine patients had mutations in complex I 
subunits or assembly factors encoded by the 
nDNA (26%). This means that for our (second) 
research group in 20 patients (59%) the un­
derlying genetic cause of the complex I defi­
ciency has not been elucidated yet (figure 2.2).
Future perspectives
Isolated complex I deficiency is one of the 
most diagnosed forms of mitochondrial dis­
orders. Because of the dual genetic control, 
mutations in either the mtDNA or nDNA can 
cause the complex I deficiency. Clinical mani­
festation of pathogenic mutations in the 
mtDNA is in general associated with a more 
onset in adulthood. In our research cohort, 
consisting of patients in whom the age of 
presentation of the disease was below ten 
years of age, only a small group harboured 
mtDNA mutations. Most patients contain 
mutations in nuclear encoded genes. Most of 
the currently known mutations are located in 
the core subunits of complex I, but mutations 
have also been reported in some accessory
subunits. Furthermore, defective complex I 
assembly factors may be disease-causing. De­
spite extensive mutational studies the molec­
ular basis of the complex I deficiency has not 
been elucidated in about S0% of the patients. 
Other candidate genes, beside the complex I 
subunits and known assembly factors should 
be screened for the presence of mutations. 
For example, these are the genes encoding 
the remaining proteins described by Pagli­
arini etal. which have not been screened yet 
[Pagliarini 2008]. Although their specific role
I I mtDNA mutations 
i i nDNA mutation 
i 1 unsolved
59%
Figure 2.2
Distribution of mutations found in a research cohort 
of complex I patients. In a group of 34 patients with 
a complex I deficiency, disease-causing mutations 
have been found in 41% of the patients. In 15% the 
mutations were located in mtDNA encoded subunits, 
and in 26% in nuclear encoded subunits or assembly 
factors of complex I. This means that for this research 
cohort in 59% of the patients the complex I deficien­
cy-causing mutations needs to be elucidated.
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in the function and biogenesis of complex 
I is not exactly known and need further in­
vestigation, these genes are good candidate 
genes to be screened in patients in whom the 
complex I deficiency is not yet dissolved. 
Identifying other factors involved in the as­
sembly of complex I could be performed by 
screening for proteins that associate with 
known assembly factors. Recently, the pro­
tein ACAD9 has been shown to interact with 
NDUFAF1 and Ecsit by Tandem Affinity Purifi­
cation [Nouws 2010]. Screening of this gene 
in our patient group revealed pathogenic 
mutations in two patients displaying exercise 
intolerance, hyperthrophic cardiomyopathy, 
lactic acidosis, and failure to thrive. The com­
plex I deficiency in patients caused by muta­
tions in the ACAD9 gene, may be improved by 
riboflavin treatment [Gerards 2011].
Besides (putative) assembly factors, other 
proteins may be involved in the functioning 
or biogenesis of complex I. Expression, tar­
geting, and mitochondrial import of nuclear- 
encoded proteins are important for a proper 
functioning of complex I. Also proteins in­
volved in transcription, translation and, post- 
translational modification may be important.
Figure 2.3
Potential complex I candidate genes. Proteins in­
volved in transcription (A), translation andpost-trans- 
lational modification (B), import (C) and processing 
(D) might be important for proper functioning of 
complex I. For the assembly of complex I, the structur­
al complex I subunits (E) and assembly factors (F) are 
needed. Furthermore proteins involved in the correct 
synthesis and assembly of the FeS clusters (G) may be 
candidate genes for complex I deficiency.
In addition, genes encoding proteins in­
volved in the correct synthesis and assembly 
of the FeS clusters may be possible candidate 
genes for complex I deficiency (figure 2.3). 
Homozygosity mapping is a technique that 
has been developed to map and identify new 
mutations and can be useful in consanguine 
families. Comparing homozygous regions in 
affected patients with healthy siblings could 
reveal candidate genes. Another strategy is 
the targeted gene enrichment chip. These 
mutation chips will contain 100-200 complex 
I candidate genes. Besides these candidate 
genes, other mitochondrial proteins could be 
important for complex I. Therefore, all known 
mitochondrial proteins could be screened 
with a microarray resequencing chip. The use 
of this next generation sequence analysis has 
been shown by Vasta and colleagues [Vasta
2009] and other new techniques to elucidate 
the genetic defect has been developed. For 
example, whole exome sequencing is a tech­
nique which could be used to identify novel 
genes involved in complex I deficiency. This 
technique will reveal a lot of genetic varia­
tions which need to be functional analysed 
for their involvement in complex I biogenesis 
and function. Finally, Calvo and colleagues 
used a different approach [Calvo 2010]. They 
made a list of candidate genes possible in­
volved in complex I deficiency and performed 
pooled DNA sequencing of a cohort of indi­
viduals consisting of patients with a complex
I deficiency who lacked a previous molecular 
diagnosis, controls with established molecu­
lar diagnosis and healthy controls. This re­
sulted in a lot of variants which were filtered 
out leading to rare variants predicted to be 
deleterious. Expression of a wild-type allele 
resulted in restoration of the complex I defect 
in fibroblasts, establishing the pathogenicity 
of new mutations.
In the near future, these powerful techniques 
will make high throughput screening possible, 
improving genetic counselling and identifying 
the genetic cause of the mitochondrial com­
plex I deficiency in patients in whom patho­
genic mutations have not been found yet.
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Abstract
Mitochondrial complex I deficiency is the 
most frequently encountered defect of the 
oxidative phosphorylation system. To iden­
tify the genetic cause of the complex I defi­
ciency, we screened the gene encoding the 
NDUFS1 subunit. We report 3 patients with 
low residual complex I activity expressed in 
cultured fibroblasts, which displayed novel 
mutations in the NDUFS1 gene. One muta­
tion introduces a premature stop codon, 3 
mutations cause a substitution of amino ac­
ids and another mutation a deletion of one 
amino acid. The fibroblasts of the patients 
display a decreased amount and activity of 
complex I. In addition, a disturbed assembly 
pattern was observed. These results suggest 
that NDUFS1 is a prime candidate to screen 
for disease-causing mutations in patients 
with a very low residual complex I activity in 
cultured fibroblasts.
Introduction
The oxidative phosphorylation (OXPHOS) 
system, embedded in the inner mitochon­
drial membrane is essential for the produc­
tion of mitochondrial ATP. It is composed of 
four enzyme complexes (complex I-IV), which 
form the electron transport chain, and ATP 
synthase (complex V) [Saraste 1999]. Com­
plex I and II transfer electrons from NADH and 
FADH2 to ubiquinone. Subsequently, com­
plex III transfers the electrons from ubiquinol 
to cytochrome c, and complex IV transfers 
them to molecular oxygen. The transport of 
the electrons is coupled to the translocation 
of protons, which results in a proton gradient. 
Finally, this gradient can be used by complex
V to produce ATP from ADP + Pi.
Disturbances in the OXPHOS system cause 
mitochondrial disorders with an incidence 
of 1 in approximately 5000 births [Smeitink 
2001b]. Isolated complex I deficiency is the 
most frequently diagnosed form account­
ing for almost 23% of all cases of childhood 
respiratory-chain deficiency. Mitochondrial 
disorders may affect one or more tissues or 
organs, especially the ones with high meta­
bolic energy rates. Therefore, mitochondrial
diseases have a wide clinical variety [Pitkanen 
1996; Loeffen 2000]. This is also due to the 
bigenomic control of the OXPHOS system. 
Mutations in either the mitochondrial DNA 
(mtDNA) or nuclear encoded genes may 
cause complex I deficiency. 
NADH:ubiquinone oxidoreductase (E.C. 
I.6.5.3.), or complex I, is the largest complex 
of the OXPHOS system, consisting of 45 sub­
units. Seven are encoded by the mtDNA and 
with These are considered as the minimal 
constitution of complex I, since the subunits 
are involved in catalysis of electron transfer 
from NADH to ubiquinone and for generation 
of the membrane potential.
One of the 'core subunits' is NDUFS1. This 
protein is the largest subunit of complex I 
and is located in the iron-sulphur fragment 
of the enzyme [Smeitink 1998]. It contains 
three iron-sulphur clusters, N1b, N4 and N5 
and plays an important role in the electron 
transfer [Finel 1998]. Mutations in this gene 
are associated with isolated complex I defi­
ciency. Benit and colleagues described five 
point mutations involving highly conserved 
amino acids (del222I, D252G, M707V, R241W, 
and R557X) and one large-scale deletion in 
this gene [Benit 2001]. Additionally, two ho­
mozygous missense mutations (L231V and 
C1564A) were reported [Martin 2005; Iuso
2006]. In this study we describe novel muta­
tions in NDUFS1 in three unrelated patients 
with complex I deficiency expressed in cul­
tured skin fibroblasts and we show that the 
assembly pattern of complex I is disturbed in 
these cells. Studies identifying new disease- 
causing mutations are necessary since mo­
lecular diagnosis is still lacking in many pa­
tients [Thorburn 2004].
Materials and Methods
Patients 
Patient 1
The patient, a girl, was born from healthy 
unrelated parents after a pregnancy compli­
cated by gestational diabetes with a modest 
intrauterine growth retardation (weight 5th 
percentile). One older sib is a healthy boy. She 
had normal development in the first months 
of life, but started at age eight months with
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abnormal crying and a regression of already 
acquired motor skills. At that age her brain 
MRI showed bilateral and symmetric leu- 
codystrophic cystic lesions. Her clinical sta­
tus worsened and she ultimately developed 
spasticity, microcephaly, mental retardation, 
and a progressive neuropathy. She died at the 
age of twelve years.
Patient 2
The patient, a boy, was the third child of con­
sanguineous parents (first cousins). One of the 
older sibs is a healthy boy, the other one was 
also affected. The index patient had problems 
with the central nervous system like leucoen- 
cephalopathy, episodic brainstem events, 
reduced spontaneous movement and he had 
an abnormal breathing pattern. His clinical 
status worsened and he had feeding prob­
lems. Furthermore he had muscle dystrophy 
and generalized hypotonia and died at the 
age of eight months.
The affected brother had a similar clinical pic­
ture. The age of onset was four months. In this 
patient the levels for lactate, pyruvate and 
alanine in both plasma and liquor indicate a 
mitochondrial disorder. He died at the age of 
seven months.
Patient 3
This female patient was born after an unre­
markable pregnancy, from non-related par­
ents. The development was normal in the first 
months. Nystagmus was detected when she 
was five months of age. When she was twelve 
months of age she walked without support, 
but from that age her development stagnated 
motorically as well as mentally. After fifteen 
months she started to lose neurological abili­
ties and there was no doubt that she suffered 
from a neurological progressive disorder. Her 
clinical situation was dominated by a failure 
to thrive, crying, eating difficulties, spasticity, 
and mental retardation. She died at the age 
of two years.
Cell culture and biochemical analysis 
Skin fibroblasts were cultured in M199 me­
dium (Life Technologies) supplemented with 
10% fetal calf serum and penicillin/strepto­
mycin in a humified atmosphere of 95% air 
and 5% CO2 at 37 °C. Measurement of the
mitochondrial respiratory-chain enzymes in 
skin fibroblasts and in muscle tissue were per­
formed according to established procedures 
[Smeitink 2001a; Janssen 2006a]. The values 
were expressed relative to the activity of cy­
tochrome c oxidase and/or citrate synthase.
Genetic analysis of the NDUFS1 gene 
Patient RNA was extracted from cultured fi­
broblasts by standard procedures. The RNA 
was reverse transcribed to cDNA by super­
script II RNase H- reverse transcriptase with 
oligo(dT) and random hexamer primers. Oli­
gonucleotide primers were designed from 
the NDUFS1 gene sequence (Genbank Acces­
sion No. NM_005006). Primer sequences are 
available upon request. Polymerase chain re­
action products were run on a 1.5% agarose 
gel and sequenced directly with the BigDye 
terminator cycle sequencing chemistry on a 
Applied Biosystems ABI PRISM 3130xl Genet­
ic Analyzer. The mutations were also checked 
on genomic DNA level. Therefore, patient 
DNA was extracted from cultured skin fibro­
blasts by standard procedures [Miller 1988]. 
The nucleotide numbering reflects cDNA 
numbering with +1 corresponding to the A 
of the ATG translation initiation codon in the 
reference sequence. The initiation codon is 
codon 1.
BN-PAGE analysis and in-gel activity assay 
Mitochondria-enriched fractions were ob­
tained by incubation with 2% (w/v) digitonin 
(Calbiochem) on ice for 10 min, followed by 
centrifugation at 10,000g and 4 °C for 10 min 
and washing with PBS, twice. Blue native­
gradient gels (5-15%) were cast as described 
previously [Calvaruso 2008] and run with 40 
Hg (or 80 |jg) of the solubilised mitochondrial 
protein. After electrophoresis, the gels were 
further processed for in-gel activity assay or 
second-dimension 10% SDS-PAGE followed 
by immunoblot analysis as described by 
Nijtmans et al. [Nijtmans 2002].
Antibodies and ECL detection 
Protein immunodetection was performed 
with primary antibodies directed against 
NDUFA9 (Invitrogen), NDUFS3 (Invitrogen), 
the CII 70 kDa subunit (SDHA; Invitrogen) and 
the CIII CORE2 subunit (UQCRC2; Invitrogen).
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Secondary antibodies used were peroxidise- 
conjugated anti-mouse IgGs (Invitrogen) and 
detection of the signal performed using ECL 
Plus (Amersham Biosciences) according to 
the manufacturer's instructions.
Results
Biochemical studies
The activities of the respiratory-chain com­
plexes were measured in skin fibroblasts of 
the three patients, in frozen muscle tissue of 
patient 1 and in fresh muscle tissue of patient
2, all displaying a marked decrease of com­
plex I (table 3.1). The fibroblast complex I en­
zymatic activities were 27%, 20%, and 24% of 
the lowest control value for the patients 1, 2 
and 3, respectively. In fresh muscle tissue of 
patient 2, the enzymatic activity of complex 
III was decreased to 70% of the lowest control 
value. However, the activity of this complex in 
skin fibroblasts was within the control range.
MRI findings
MRI pictures were available for patient 1 and
3. Patient 1: the first MRI was obtained at the 
age of nine months. In the central white mat­
ter of both cerebral hemispheres, there were 
symmetric areas of marked hyperintensity 
on T2 and hypointensity of T1. The internal 
capsule was unaffected. The corpus callosum 
had normal signal, but was somewhat atro­
phic. The peripheral U-fibres were spared and 
the basal ganglia, brainstem and cerebellum
n.m. = not measured. Deficiencies are indicated in bold. 
a mU/U COX 
b mU/mU CS 
c mU/U CS
were normal.
The second MRI was done at the age of eleven 
months. There was at this stage a marked pro­
gression of the signal changes, which now 
were extending throughout the central white 
matter in the centrum semiovale. The tempo­
ral lobes were spared. There was progressive 
atrophy of the corpus callosum. The cortical 
grey matter, the basal ganglia, the brainstem, 
and cerebellum were still unaffected.
The degree of signal change was very pro­
nounced, the MRI signal not very different 
from that of the cerebrospinal fluid. The previ­
ously shown pathology, seen in the first MRI, 
now presented as “holes" within the central 
part of the new signal changes, having even 
more CSF-like signal (consistent with rarefac­
tion). MR spectroscopy was not performed. 
Patient 3: the first MRI was performed at the 
age of five months and was normal. At the 
age of sixteen months a second MRI was 
done and following features were observed: 
extensive and confluent areas with markedly 
hyperintensity on T2 and hypointensity on T1 
in subcortical and deep white matter of the 
cerebrum. It included the entire length of the 
corpus callosum, internal capsule (anterior 
limb and genu), extended through the cere­
bral peduncles and the ventral midbrain and 
ending in the central parts of pons from both 
sides. There was a striking sparing of the sub­
cortical white matter of perirolandic gyri, as 
well as the central part of the corona radiata, 
together with the posterior limb of the inter­
nal capsule and the optic radiations. The dis­
Table 3.1
Respiratory-chain enzyme activities in skin fibroblasts, and frozen and fresh muscle tissue of the index patients.
Fibroblasts Frozen muscle Fresh muslce
Control
range
Control
range
Control
rangeComplex Pi P2 P3 Pi P2
30 22 26 110-206a 53 84-273c 7 70-250c
II n.m. 648 801 536-1027a n.m. 119 67-177c
III 1520 1522 1867 1270-2620° n.m. 1540 2200-6610c
IV 860 1075 953 680-1190b 737 520-2080c 1305 810-3120c
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tribution of signal changes was symmetrical, 
dominating in the frontal and parietal lobes, 
but also affecting the periventricular areas in 
the temporal lobes. On diffusion sequence, 
there were multifocal areas with restricted 
diffusion scattered throughout the affected 
white matter, consistent with active demyeli- 
nation.
The last (third) MRI was obtained at the age of 
seventeen months (figure 3.1). The affected 
white matter was slightly swollen, and the 
cerebellum still being normal. Furthermore, 
there was symmetrical, partial involvement 
of the nucleus caudatus. Otherwise the grey 
matter was normal.
Multi-voxel MR-spectroscopy showed de­
creased NAA peaks and multifocal lactate 
peaks, anatomically corresponding to the ar­
eas of signal change.
Moleculargenetic studies in NDUFS1 gene 
We searched for the molecular defect caus­
ing these complex I deficiencies, by screening
Figure 3.1
MRI findings of patient 3.
(A) Cerebral T2-MRI of patient 3 at the age of seventeen 
months shows marked white matter abnormalities.
(B) Multi-voxel MRS shows decreased NAA signals and 
increased lactate peaks anatomically corresponding 
to the areas of signal change (left) compared to a nor­
mal spectrum from the gray matter of the same patient 
(right).
the cDNA of the NDUFS1 gene. In patient 1 we 
found a homozygous mutation, c.1855G>A, 
which introduced a substitution of amino 
acids (p.Asp619Asn). Verifying this mutation 
on genomic DNA revealed that this mutation 
was heterozygous (figure 3.2A). This suggests 
that one of the alleles results in an unstable 
RNA transcript making it undetectable on 
cDNA level. To detect a mutation on the sec­
ond allele, the remaining exons of NDUFS1 
were screened and this resulted in another 
heterozygous mutation, c.1669C>T, which in- 
troduceda prematurestopcodon(p.Arg557X) 
(figure 3.2B). The father and brother were 
found to be heterozygous for the Arg557X 
mutation, and the mother for the Asp619Asn 
mutation. Sequence analysis of both cDNA 
and genomic DNA of patient 2 demonstrated 
the presence of a homozygous substitution 
of C to T (c.1222C>T; p.Arg408Cys) (figure 
3.2C), which was also present in the other af­
fected brother. Analysis of DNA of the third 
patient showed two heterozygous mutations 
(c.631-633delGAA; c.683T>C) (figure 3.2D 
and 3.2E). The first mutation causes a deletion 
of one amino acid (p.211delGlu), the second 
a substitution of amino acids (p.Val228Ala). 
The father was found to be heterozygous for 
c.631-633del GAA and the mother heterozy­
gous for c.683T>C. All above described muta­
tions were not present in 100 healthy controls 
or 25 other patients with isolated complex I 
deficiency in cultured skin fibroblasts. Fur­
thermore, all missense mutations and the 
deletion are present in strongly conserved 
amino acids.
Computational modeling of the amino acid 
at position 228 reveals that this residue is lo­
cated in a conserved region between two FeS 
clusters (N4 and N5) and that it is important 
for the structure around these clusters. The 
mutation p.Val228Ala changed a hydrofobe 
residue into a smaller but also hydrophobic 
residue, which results in a gap within the 
NDUFS1 subunit. Furthermore the structure 
around this residue will probably be less sta­
ble. This may have an effect on the binding 
and working of the FeS clusters and therefore 
on the transfer of the electrons. Modeling of 
the other amino acids changes was not possible. 
NDUFS1 contains several structural domains, 
as shown in figure 3.2F. All above described
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mutations are located in the NADH-quinone 
oxidoreductase chain G domain. Additional­
ly, the mutations Arg408Cys, found in patient
2 and Arg557X and Asp619Asn, found in pa­
tient 1, are also located in the molybdopterin 
oxidoreductase domain (figure 3.2F).
Effect of the mutations in NDUFS1 gene on 
complex I
To study the effect of the mutations on the 
expression and activity complex I, we per­
formed BN-PAGE analysis followed by West­
ern blotting with an anti-NDUFA9 antibody 
and in-gel activity measurement with mito­
chondria enriched fractions of cultured fibro­
blasts of the three patients. Figure 3.3 shows 
severely reduced activities of complex I in the 
fibroblasts of the three patients compared 
to the control. Furthermore, the expression 
of subunit NDUFA9 was decreased in the pa­
tients compared to the control, suggesting 
a decrease in the amount of fully assembled 
complex I. Patients 2 and 3 showed also an 
extra band, which suggest the formation of 
subcomplexes. Together, these results show 
a severely reduced amount and activity of 
complex I in the patients' fibroblasts.
To further investigate the complex I as­
sembly profile in the patient fibroblasts, we 
performed two-dimensional BN/SDS-PAGE 
analysis followed by immunoblotting with an 
antibody directed against NDUFS3. Figure 3.4 
displays less complex I and the formation of 
subcomplexes in fibroblasts of patients 1 and
3 compared to the control. Even more accu­
mulation of subcomplexes was visible in cells 
of patient 2. These results suggest that the 
mutations in NDUFS1 cause a disturbance in 
the assembly and/or stability of complex I.
Discussion
In this report we describe three patients with 
complex I deficiency expressed in cultured 
fibroblasts harboring novel mutations in 
NDUFS1. Patient 1 was compound heterozy­
gous for Arg557X and Asp619Asn. The first 
mutation has been previously reported 
in a patient compound heterozygous for 
that mutation and the Arg241Trp mutation 
[Benit 2001]. The second patient harbored a
homozygous missense mutation (Arg408- 
Cys) and the third patient was compound 
heterozygous for 211delGlu and Val228Ala. 
Several lines of evidence suggest that these
Figure 3.2
Molecular analysis o f the NDUFS1 gene.
(A-E) Electropherograms showing the wild-type se­
quence o f NDUFS1 (top panels) and the nucleotide 
changes in the complex I deficient patients (bottom 
panels). Conservation o f the altered amino acids is 
shown in Clustal W alignments.
(A) Nucleotide change c.1669 T>C, and amino acid 
change Arg557Xin patient 1.
(B) Nucleotide change c.1855 G>A, and amino acid 
change Asp619Asn in patient 1.
(C) Nucleotide change c.1222 C>T, and amino acid 
change Arg408Cys in patient2.
(D) Nucleotide change c.631-622 delGAA, and amino 
acid change 211delGlu in patient 3.
(E) Nucleotide change c.683 T>C, and amino acid 
changes Val228Ala in patient 3.
(F) Overview o f the NDUFS1 protein consisting o f 727 
amino acids, with the location o f structural domains, 
according to InterProScan. The 5 different mutations 
that are described in this paper, are indicated in blue. 
The mutations described in earlier studies are indi­
cated in black.
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mutations are the underlying cause of the 
complex I deficiencies in the patients: (1) 
the mutations cause nucleotide changes in 
conserved regions of the NDUFS1 gene; (2) 
the parents are heterozygous carriers and 
the mutations are not present in 100 healthy 
controls; (3) the patient fibroblasts show a 
decrease in amount and activity of complex I, 
measured by immunoblotting and in-gel ac­
tivity assays; and (4) the assembly of complex 
I was also disturbed.
The clinical features, especially the rapid 
progression of the disease, were similar in 
the patients. Patients 1 and 3 have a some­
what different distribution of signal changes. 
Common factors are the rapid progression 
of the disease, the central white matter dis­
tribution mostly sparing of the grey matter, 
and the degree of signal change with sharp 
demarcation. The extensive signal changes 
in the white matter with relative sparing of 
the gray matter inclusive the basal ganglia is 
different from the classical findings in Leigh 
disease (being dominant in gray matter). 
However, MRI findings in these patients are 
consistent with described cases in the litera­
ture for isolated complex I deficiency [van der 
Knaap 2005]. The lactate peaks in patient 3
are consistent with anaerobe metabolism 
and are strongly suggestive of mitochondrial 
disease.
Complex I deficiency combined with a de­
crease in activity of complex III, like the en­
zyme activities in muscle tissue of patient
2, has been described before by Budde and 
colleagues [Budde 2000]. These patients har­
bored a mutation in the NDUFS4 gene. An 
explanation for these combined deficiencies 
could be the formation of supercomplexes 
in which complex I and III occur together 
(CI/CIII2) [Lazarou 2007]. This indicates that 
screening of complex I subunits including 
NDUFS1 should be considered not only in 
isolated complex I deficient patients but also 
in patients with combined complex I and III 
deficiency.
Furthermore, it is remarkable that the activ­
ity of complex I in fibroblasts of the three 
patients was very low (<30% of the lowest 
control value). An earlier study of Loeffen et 
al. showed a mean residual activity of 49% 
of the lowest control value measured in a 
cohort of 27 patients with isolated complex 
I deficiency [Loeffen 2000]. Since therapeutic 
strategies for complex I deficiency are hardly 
available, it is important to elucidate the pos-
p i P2 P3
(CI)-IGA
(CI)-NDUFA9
(CII)-SDHA
(CIII)-CORE2
Figure 3.3
The mutations in NDUFS1 cause decreased expres­
sion and activity o f complex I. BN-PAGE analysis fol­
lowed by in-gel activity measurement demonstrates 
a reduced complex I activity in the fibroblasts o f the 
patients compared to the control. The expression 
o f subunit NDUFA9 is also severely reduced, which 
indicates a decreased amount o f whole complex I. 
Furthermore, the fibroblasts o f patient 2 and 3 show 
an extra band, which suggest the formation o f sub­
complexes. The expression o f the complexes II and III 
is not affected.
Figure 3.4
The NDUFS1 mutations cause accumulation o f sub­
complexes. Two-dimensional BN/SDS-PAGE analysis 
followed by immunoblotting with an antibody direct­
ed against NDUFS3 shows less complex I in cells o f pa­
tient 1 and 3 and the accumulation o f subcomplexes 
in the fibroblasts o f the three patients.
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sible genetic causes for prenatal diagnostics 
and genetic counseling. A good pre selection 
is important, since more than 70 candidate 
genes for complex I deficiency are known 
at present. Therefore, above mentioned low 
residual complex I activities suggest that 
screening of the NDUFS1 gene is preferred 
when patients have very low complex I activi­
ties expressed in cultured fibroblasts.
NDUFS1 is the largest subunit of complex I, 
and is suggested to be incorporated into this 
complex in stage 6 of the assembly process, as 
proposed by Vogel etal. [Vogel 2007a]. In line 
with this idea is the fact that in patient 2 and 3 
an additional band of about 800 kDa is visible 
on BN blots (figure 3.3) which is lacking in the 
control cells. Such a subcomplex also occurs in 
patients with mutations in NDUFS4, NDUFV1, 
and NDUFS6 and is believed to represent a 
complex I subassembly which lacks subunits 
NDUFV1, NDUFV2, NDUFS4, NDUFS1, and 
NDUFS6 [Lazarou 2007]. Although all patients 
show decreased amounts of fully assembled 
complex I, this decrease is more pronounced 
in patient 1 and 3. Nevertheless, the similar 
decrease in enzyme activity as measured by 
spectrophotometrically and by in-gel activity 
(figure 3.3) is comparable in all patients sug­
gesting that beside the decreased amount of 
complex I also the intrinsic enzyme activity 
of the remaining complex is also affected in 
these patients.
Identifying the underlying cause of complex I 
deficiency is important to get more insight in 
the function of this complex. New strategies 
like genomic microarray screening or exome 
sequencing of the nuclear complex I and as­
sembly genes may be possible in the near 
future. Research to identify new mutations 
causing complex I deficiency is still ongoing 
to improve genetic counseling and possibili­
ties for prenatal diagnostics.
Hanka Venselaar (Centre for Molecular and 
Biomolecular Informatics, Radboud Univer­
sity Nijmegen Medical Centre, Nijmegen, The 
Netherlands) for the computational model­
ing study.
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http://www.ncbi.nlm.nih.gov/Genbank
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http://www.ebi.ac.uk/Tools/InterProScan
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Abstract
Mitochondrial isolated complex I deficiency 
is the most frequently encountered OXPHOS 
defect. We report a patient with an isolated 
complex I deficiency expressed in skin fi­
broblasts as well as muscle tissue. Because 
the parents were consanguineous, we per­
formed homozygosity mapping to identify 
homozygous regions containing candidate 
genes such as NDUFA2 on chromosome 5. 
Screening of this gene on genomic DNA re­
vealed a mutation that interferes with correct 
splicing and results in the skipping of exon 2 . 
Exon skipping was confirmed on the mRNA 
level. The mutation in this accessory subunit 
causes reduced activity and disturbed assem­
bly of complex I. Furthermore, the mutation is 
associated with a mitochondrial depolariza­
tion. The expression and activity of complex 
I and the depolarization was (partially) res­
cued with a baculovirus system expressing 
the NDUFA2 gene.
Introduction
NADH:ubiquinone oxidoreductase, or com­
plex I, is the first and largest complex of the 
mitochondrial respiratory chain. Its function is 
to liberate and transfer electrons from NADH 
to ubiquinone and meanwhile to extract part 
of their energy to drive proton translocation 
across the inner mitochondrial membrane 
and thus to creat an electrochemical proton 
gradient that can be used for the synthesis 
of ATP. Complex I consists of 45 subunits, of 
which seven are encoded by the mitochon­
drial DNA (mtDNA). The complex is L-shaped; 
it has a membrane arm embedded in the in­
ner mitochondrial membrane and a periph­
eral arm protruding into the matrix. Complex 
I can be divided into three functional frac­
tions. The flavoprotein fraction plays a role 
in FMN and NADH binding, the iron protein 
fraction is important in reduction-oxidation 
reactions via iron-sulphur clusters, and the 
hydrophobic protein fraction is involved in 
proton translocation.
Isolated complex I deficiency (MIM 252010) 
is one of the most common defects of the 
OXPHOS system [Smeitink 2001b]. It ac­
counts for almost 23% of all cases of child­
hood respiratory-chain deficiency, and the 
heterogeneous clinical presentation includes 
Leigh or Leigh-like syndrome (MIM 256000), 
cardiomyopathy, leukodystrophy, and he- 
patopathy [Pitkanen 1996; Loeffen 2000]. Pre­
vious studies identified disease-causing mu­
tations in eleven complex I nuclear structural 
genes (NDUFS1 (MIM 157655), NDUFS2 (MIM 
602985), NDUFS3 (MIM 603846), NDUFS4 
(MIM 602694), NDUFS6 (MIM 603848), 
NDUFS7 (MIM 601825), NDUFS8 (MIM 
602141), NDUFV1 (MIM 161015), NDUFV2 
(MIM 600532), NDUFA1 (MIM 300078) and 
NDUFA11) [Loeffen 1998; Loeffen 2001; Benit 
2004; van den Heuvel 1998; Kirby 2004b; 
Triepels 1999; Schuelke 1999; Benit 2003a; 
Fernandez-Moreira 2007; Benit 2001; Berger 
2008]. Most of these genes are evolutionarily 
highly conserved and play important roles 
in the catalytic activity of complex I. Muta­
tions described in these genes account for 
only a small part of all complex I deficiencies, 
suggesting that disease-causing mutations 
should be found in other genes such as those 
encoding the accessory subunits and assem­
bly factors for complex I. The latter mutations 
have been described in the NDUFAF2 (MIM 
609653), NDUFAF1 (MIM 606934) and C6orf66 
(MIM 611776) genes [Ogilvie 2005; Dunning 
2007; Saada 2008].
While for the fourteen core subunits of com­
plex I, primary roles in electron transfer and 
proton translocation have been established, 
the exact role of the remaining 31 acces­
sory subunits is not known yet. It has been 
suggested that some are important for the 
organization of the biogenesis of complex 
I. One of the accessory subunits of complex 
I is NDUFA2, or bovine B8 . This subunit is lo­
cated in the peripheral arm of complex I, and 
analysis of the structure showed a Fe2S2 ferre- 
doxin fold similar to that found in thioredoxin 
[Brockmann 2004].
In this study we describe a patient whose 
parents were consanguineous and in whom 
isolated complex I deficiency was detected in 
both muscle tissue and fibroblasts as a result 
of a mutation in NDUFA2 (MIM 602137). Ho­
mozygosity mapping revealed that the gene 
NDUFA2 is located in a homozygous region 
on chromosome 5. Screening of this gene re­
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vealed a splice-site mutation resulting in the 
skipping of exon 2. With cell biological stud­
ies we demonstrated the pathogenicity of 
this mutation. Identifying such new disease- 
causing mutations will deliver new insights 
into human complex I deficiency.
Material and Methods
Case report
The patient, a boy, was the second child of 
consanguineous Turkish parents (first cous­
ins). His older sister was healthy. Pregnancy 
and delivery were uneventful. At the fifth day 
of life, hypertrophic cardiomyopathy was di­
agnosed. Development was retarded from 
birth, and at the age of four months, cerebral 
atrophy and hypoplasia of the corpus callo­
sum were seen on MRI. Some weeks later, at­
rophy of the N. opticus was diagnosed. At 7.5 
months, after a two day episode of vomiting 
and two weeks after a varicella infection, the 
patient suddenly developed severe acidosis, 
generalized tonic-clonic seizures and coma. 
The patient did not gain consciousness again 
and needed artificial respiration for 43 days. 
Afterwards, respiration was unstable, and the 
patient had recurrent episodes of apnea and 
bradycardia, often accompanied by seizures, 
which increased in frequency. Finally, MRI 
showed demyelinization of cortico-spinal 
tracts and subacute necrotizing encephalo- 
myelopathy as seen in Leigh syndrome. At 
eleven months, the patient died of cardiovas­
cular arrest, after further episodes of apnea 
and asystolia.
Cell culture
Skin fibroblasts were cultured in M199 me­
dium (Life Technologies) supplemented with 
10%  fetal calf serum and a combination of 
penicillin and streptomycin in a humified 
atmosphere of 95% air and 5% CO2 at 37°C. 
For live cell imaging, the fibroblasts were cul­
tured as described above but in medium 199 
with Earle's salt supplemented with 10% fetal 
calf serum and penicillin/streptomycin.
Biochemical analysis
Measurement of mitochondrial respiratory- 
chain enzymes in skin fibroblasts and in mus­
cle tissue collected at the age of eight months 
as previously described [Smeitink 2001a; 
Janssen 2003], with the exception of the fig­
ure 4.3C complex I measurements that were 
performed with a recently developed assay 
[Janssen 2007]. The values were expressed 
relative to the activity of cytochrome c oxi­
dase and/or citrate synthase. The oxidation 
rates of pyruvate in the presence of malate or 
carnitine and the production rate of ATP from 
pyruvate were measured in muscle tissue as 
described before [Janssen 2006a].
Homozygosity mapping 
Patient DNA was extracted from cultured 
fibroblasts by standard procedures [Miller 
1988] and was used for a genome scan with 
the ABI PRISM Linkage Mapping Set MD10.A. 
A total of 382 fluorescently labeled short tan­
dem repeat (STR) polymorphic markers with 
an average heterozygosity of 0.76 were used. 
The average distance of the genotyped mark­
ers was 10 cM.
Genetic analysis of the NDUFA2 gene 
Oligonucleotide primers were designed ac­
cording to public sequences (Genbank acces- 
sionnumberNM_002488).The exonspanning 
primers F1 (5'-CCTTTCCGCTTCCTGTTTTT-3') 
with R1 (5'-GGGGCTTCCCTCAACTTC-3'), 
F2 (5'-CTGGGCCTGCGTGAGATT-3') with R2 
(5'-GGGCGGTCCCTTCTCTTCT-3'), and F3 (5'- 
CCATCCAGAATCAGCCAAAA-3') with R3 (5'- 
TCCCACACCTAAGCCAAGAC-3') were applied 
in a PCR for amplification of the three exons of 
the NDUFA2 gene. The exon fragments were 
amplified in a reaction volume of 25 |l con­
taining 100 ng DNA template, 1 unit of Taq 
DNA polymerase (Invitrogen), 2.5 |l of 10x 
PCR buffer, 2.0 mM MgCl2, 50 ng of forward 
and reverse primers, 0.25 mM dNTPs, and
0.75 |l DMSO. After an initial denaturation 
step of 2 min at 94°C, PCR parameters were 35 
cycles for 45 s denaturation at 94°C, 45 s an­
nealing at Ta (annealing temperature; 53°C for 
the primers F1/R1 and F3/R3 and 60°C for the 
primers F2/R2), and 1 min extension at 72°C. 
The cycles were followed by a final exten­
sion step of 10 min at 72°C. The amplification 
products were run on a 1.5% agarose gel. The 
same oligonucleotides were used for direct 
sequencing with the BigDye terminator cycle
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sequencing chemistry on an Applied Biosys­
tems ABI PRISM 3130xl Genetic Analyzer.
The mutation was also checked on the cDNA 
level. Patient RNA was extracted from cultured 
fibroblasts by standard procedures. The RNA 
was reverse transcribed to cDNA by super­
script II RNase H- reverse transcriptase with 
oligo(dT) and random hexamer primers. The 
primers F (5'-TCGCATCCACTTATGTCAGC-3') 
and R (5'-GAGGCTTCAGGCTTTACCAC-3') 
were applied in a PCR as described above 
with a Ta of 58°C and 1.5 mM MgCl2.
SDS-PAGE and Immunoblot analysis 
Mitochondrial lysates were separated on a 
10% SDS-PAGE gel. Next, the proteins were 
transferred to PROTAN nitrocellulose mem­
brane (Schleicher & Schuell) for immunode­
tection.
BN-PAGE analysis and in-gel activity assay 
Blue native gradient gels (5%-15%) were cast 
as described previously [Nijtmans 2002] and 
run with 40 or 80 |g of solubilized mitochon­
drial protein. After electrophoresis, the gels 
were further processed for in-gel activity as­
say or second-dimension 10% SDS-PAGE fol­
lowed by immunoblot analysis as described 
by Nijtmans etal. [Nijtmans 2002].
Antibodies and ECL detection 
Protein immunodetection was performed us­
ing primary antibodies directed against EGFP 
(a gift from Dr. Frank van Kuppeveld, Nijme­
gen, The Netherlands), NDUFA9 (Invitrogen), 
the CII 70 kDa subunit (SDHA; Invitrogen), 
the CIII CORE2 subunit (UQCRC2; Invitrogen) 
and the CIV COXII subunit (COXII; Invitrogen). 
For generation of the NDUFA2-specific anti­
body, rabbits were immunized with peptide 
CDQVTRALENVLSGKA that was coupled to 
keyhole limpet hemocyanin with the Imject 
maleimide-activated mcKLH kit (Pierce). 
Secondary antibodies used peroxidase-con­
jugated anti-mouse or anti-rabbit IgGs (Invit- 
rogen). The signal was generated using ECL 
Plus (Amersham Biosciences).
Generation of recombinantbaculoviruses 
We created the COX8 leader sequence (first 
210 base pairs of COX8A, Genbank accession 
numberNM_004074)andNDUFA2open-read­
ing-frame sequence (without stop codon) 
flanked by Gateway ATTB sites (Invitrogen) by 
PCR and cloned them into pDONR201 by us­
ing Gateway BP Clonase II enzyme mix (Invit­
rogen) to generate the pEntry vectors [Vogel 
2007a]. We made the Bac-to-Bac system, nor­
mally used for protein production in insect 
cells, suitable for protein expression in mam­
malian cells by cloning the vesicular stomati­
tis virus G protein cDNA behind the P10 pro­
moter of the pFastBacDual vector. Next, we 
introduced the CMV promoter and Gateway 
destination elements (cassette that contains 
the chloramphenicol resistance gene and the 
ccdB gene flanked by attR1 and attR2 sites) 
into this vector [El Sheikh 2007]. Finally, we 
cloned the AcGFPI gene (Clontech) in frame 
behind the Gateway reading-frame cassette 
to obtain the destination vector pBac-Dest- 
GFP. The pEntry vectors were combined with 
the pBac-Dest-GFP vector in the Gateway LR 
reaction to yield the baculovirus expression 
vectors. These vectors were used to generate 
infectious recombinant baculoviruses by site- 
specific transposon-mediated insertion into a 
baculovirus genome (bacmid) propagated in 
Escherichia coli cells (Bac-to-Bac, Invitrogen). 
Isolated recombinant bacmids were used 
for transfecting Spodoptera frugiperda (Sf9) 
insect cells, and the viruses were harvested 
after three passages of amplification.
Transduction of complex I-deficient fibroblasts 
with baculoviral constructs 
Fibroblasts, grown to ~50% confluency in 
175 cm2 tissue culture flasks (NUNC), were 
transduced with the appropriate baculovirus 
in a total volume of 25 ml M199 containing 
1.75 mM sodium butyrate (Sigma-Aldrich). 
After 24 h at 37°C, the virus-containing me­
dium was discarded and replaced by normal 
growth medium containing sodium bu­
tyrate. At 3 days after transduction, cells were 
harvested for gel electrophoresis or mea- 
sureme nt of biochemical complex I activity. 
Importantly, this transduction protocol was 
developed based on a careful evaluation of 
different virus concentrations and different 
exposure times. We chose the lowest virus 
concentration, shortest incubation time, and 
lowest butyrate concentration that gave a 
considerable transduction (on visual inspec­
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tion of the GFP signal expressed in ~70% of 
the cells) without signs of drastic protein 
overexpression.
Combined fluorescence microscopy of TMRM 
and NDUFA2-GFP
For fluorescence imaging of tetramethyl rho­
damine methyl ester (TMRM) and NDUFA2- 
GFP, fibroblasts, cultured in the above me­
dium containing, in addition, 25 mM HEPES, 
were seeded on glass coverslips (diameter 
24 mm) and left for 4 h to attach. Next, cells 
were transduced with a baculovirus contain­
ing the cDNA of NDUFA2-GFP for 24 h (proto­
col as described above). After transduction, 
cells were cultured to ~70% confluence in 
the presence of 1.75 mM sodium butyrate for 
another 48 h. Immediately before imaging, 
cells were loaded with 100 nM TMRM (Invit­
rogen) for 25 min at 37°C. After loading, cells 
were washed with PBS, and coverslips were 
mounted in a temperature-controlled incu­
bation chamber attached to the stage of an 
inverted microscope (Axiovert 200 M, Carl 
Zeiss, Jena, Germany) equipped with a 63x, 
1.25 NA Plan NeoFluar objective lens. During 
image recording, cells were maintained in a 
HEPES-Tris (HT) medium (132 mM NaCl, 4.2 
mM KCl, 1 mM MgCl2, 5.5 mM D-glucose, 10 
mM HEPES, and 1 mM CaC^ [pH 7.4]) at 37° C. 
TMRM was excited at 540 nm with an acquisi­
tion and illumination time of 100 ms using a 
monochromator (Polychrome IV, TILL Photo­
nics), and fluorescence light was directed by 
a 560DRLP dichroic mirror (Omega Optical) 
through a 565ALP emission filter (Omega) 
onto a CoolSNAP HQ monochrome CCD cam­
era (Roper Scientific Photometrics). NDUFA2- 
GFP was excited at 470 nm, and fluorescence 
light was directed by a 505DRLPXR dichroic 
mirror (Omega) through the 565ALP emis­
sion filter. Importantly, with these settings 
no bleed-through of the GFP signal into the 
TMRM image, and vice versa, was observed 
(for details see also reference [Distelmaier 
2008]). All hardware was controlled with 
Metafluor 6.0 software (Molecular Devices 
Corporation).
Quantitative data analysis 
After immunoblotting, the signals were quan­
tified with Image Pro Plus 5.1 (Media Cyber­
netics). The optical density of the bands was 
determined and corrected for background. 
Image analysis after the combined fluores­
cence microscopy ofTMRM and NDUFA2-GFP 
was performed as described previously [Dis­
telmaier 2008; Komen 2007]. In brief, com­
puter-assisted processing of the acquired 
TMRM images produced a mitochondria- 
specific mask. Superimposing this mask on 
the original image to allowed quantification 
of the average TMRM fluorescence pixel in­
tensity exclusively in the cell's mitochondrial 
structures. We inspected sequences of TMRM 
and GFP fluorescence in parallel to select 
for GFP-positive and -negative cells. Image 
analysis was performed with Image Pro Plus 
5.1. The average value obtained with the cor­
responding control cell line (C1) was set at 
100%, to which all other values were related. 
Numerical results were visualized with Origin 
Pro 7.5 (Originlabs), and values from multiple 
experiments were expressed as means ± SE 
(standard error). Statistical significance (Bon- 
ferroni corrected) was assessed with a Stu­
dent's t-test.
Results
Biochemical and molecular genetic studies in 
the index patient
The muscle tissue of the index patient clearly 
displayed a defect in the mitochondrial en­
ergy-generating capacity (table 4.1). Further 
investigation of the activities of the enzymes 
of the respiratory-chain complex resulted 
in an isolated complex I deficiency, both in 
muscle tissue and cultured fibroblasts. The 
fibroblast and muscle complex I enzymatic 
activities were 36% and 20% of the lowest 
control value, respectively (table 4.2). We 
screened the entire mtDNA and excluded the 
presence of disease-causing mutations. We 
performed homozygosity mapping to define 
regions with candidate genes and found six 
homozygous regions containing structural 
subunits of complex I. These subunits were 
NDUFS5, NDUFS4, NDUFA2, NDUFA4, NDUFB6 
and NDUFS3. The size of the locus on chromo­
some 5 between the markers D5S2115 and 
D5S2011 was 6.46 Mb and contained NDUFA2 
and probably around 90 other genes. NDUFS4
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and NDUFA2 are both located on chromosome 
5. Screening of the NDUFS4 gene did not re­
veal a pathogenic mutation. Amplification of 
the three NDUFA2 exons with exon-spanning 
primers and sequence analysis of genomic 
DNA of the patient demonstrated the pres­
ence of a homozygous G-to-A substitution 
(c.208+5G>A) after exon 2 (figure 4.1A). The 
mother was found to be heterozygous for the 
mutation, and the mutation was not found in 
107 Turkish controls or 25 patients with isolat­
ed complex I deficiency who did not harbor a 
mutation in the mtDNA. Leigh syndrome was 
diagnosed in five of these patients. We used 
three different splice-prediction websites to 
investigate the possible effect of the muta­
tion on splicing of the NDUFA2 gene in more 
detail. The programs predicted that the mu­
tation would result in a less efficient splice 
site, impairing splicing of exon 2. PCR analysis 
of the mRNA and subsequently sequencing 
of the mutant fragment showed that exon 2 
was almost completely missing (figures 4.1B 
and 4.1C). A small amount of wild type prod­
uct was present, probably because the splice 
site could still be used, but less efficiently. The 
mutation induced alternative splicing and
thereby introduced a frame-shift resulting in 
a truncated protein.
Complementation of the complex I deficiency 
by a baculovirus system expressing NDUFA2 
protein
To study the effect of the mutation on the 
expression of complex I, we performed SDS- 
PAGE analysis followed by immunoblotting 
with a mitochondria-enriched fraction from 
cultured patient fibroblasts. Figure 4.2A 
shows a marked decrease in protein level 
of NDUFA2 in the patient compared to the 
control. The immunoblot did not present the 
band derived from the mRNA lacking exon 2, 
probably because the mutant protein is not 
stable and will be degraded. Immunodetec­
tion with an antibody against NDUFA9 also 
displays a decrease of this subunit, which 
suggests a decrease in the amount of com­
plex I. No increase in CII-SDHA was observed. 
These results are in agreement with the bio­
chemical data. Next, we performed BN-PAGE 
analysis and in-gel activity measurement or 
immunoblotting to study the effect of the 
mutation on the activity and amount of fully 
assembled complex I. The in-gel activity (CI-
Table 4.1
Pyruvate oxidation rates and ATP production rate from pyruvate
Oxidation of: Patient Control range
[1-l4c]pyruvate + malate 0.91a 3.61-7.48 a
[1-l4c]pyruvate + carnitine 2.19 a 2.84-8.24 a
ATP+CrP- production from pyruvate 8b 42-81b
a nmol CO2/h r •mU citrate synthase 
b nmol ATP/hr •mU citrate synthase
Table 4.2
Respiratory-chain enzyme activities in skin fibroblasts and muscle tissue o f the index patient
Muscle tissue Skin fibroblasts
Complex Patient Control range Patient Control range
14 a 70-251a 0.04 b 0.11-0.26 b
II 78 a 67-177 a 0.17 b 0.07-0.18 b
III 2459 a 2200-6610 a 1.55 b 1.27-2.62 b
IV 1281 a 810-3120 a 0.90 c 0.68-1.19 c
a mU/U citrate synthase 
b mU/mU cytochrome c oxidase 
c mU/mU citrate syntase
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IGA) assay showed a lower activity of complex 
I in the patient fibroblasts compared to those 
of the control (figure 4.2B). Incubation with 
an antibody directed against NDUFA9 result­
ed in an extra band when patient fibroblasts 
were used, which suggests the formation of 
catalytically inactive subcomplexes. Further­
more, incubation with an antibody against 
NDUFA2 demonstrated less NDUFA2, which 
was only present in the holo complex I and 
not in the subcomplexes, than in the control. 
To test whether the assembly of complex I is 
disturbed, we performed two-dimensional
BN/SDS-PAGE analysis followed by immu- 
noblotting with antibodies directed against 
NDUFS3, NDUFB6 , and NDUFA2 (figure 4.2C).
Figure 4.1
Genetic analysis o f the mutation in NDUFA2.
(A) Electropherograms showing the normal sequence 
o f NDUFA2 (top) and the nucleotide change in fibro­
blasts o f the patient (middle) and the mother o f the 
patient (bottom). Asterisks represent the nucleotide 
substitution.
(B) PCR analysis o f the mRNA showed a product of 
approximately250 base pairs with control RNA, while 
the PCR with patient RNA resulted in a fragment of 
about 150 base pairs. Notably, a small amount o f wild 
type product was still present.
(C) Sequence analysis o f the PCR fragments o f (B) 
showed a normal exon boundary between exon 1 
and 2 in the control (top) and skipping o f exon 2 in the 
patient (bottom).
Abbreviations are as follows: w t= wild-type, P = index 
patient, M = mother o f patient, C = control, and NC = 
negative control.
Figure 4.2
The mutation in NDUFA2 results in a lower expression 
and activity o f complex I and in an accumulation of 
subcomplexes in the patient fibroblasts.
(A) SDS-PAGE analysis and immunoblotting with an 
antibody directed against NDUFA2 shows that the 
expression o f NDUFA2 is decreased in the patient fi­
broblasts. The expression o f subunit NDUFA9 is also 
reduced, which suggests a reduction in the expression 
o f complex I.
(B) BN-PAGE analysis followed by an in-gel activity 
assay shows decreased complex I activity in the pa­
tient with a mutation in NDUFA2 versus the control. 
Immunoblotting and incubation with an antibody 
directed against NDUFA9 shows a lower expression of 
complex I and the formation o f an extra band in the 
fibroblasts o f the patient with the NDUFA2 mutation. 
The extra band suggests the formation o f a subcom­
plex. Incubation with an antibody against NDUFA2 
shows less NDUFA2, which is present in the holo com­
plex I, when patient fibroblasts were used.
(C) Immunoblots o f two-dimensional BN/SDS-PAGE 
show the accumulation o f subcomplexes in the pa­
tient with the NDUFA2 mutation versus the control. 
There is also less NDUFA2 detectable in the patient 
fibroblasts (thirdpanel).
Abbreviations are as follows: C = control, P-A2 = pa­
tient with the mutation in NDUFA2, (CI)-NDUFA2 = 
antibody directed against NDUFA2, (CI)-NDUFA9 
= antibody for NDUFA9 to detect whole complex I, 
(CII)-SDHA = antibody for SDHA to detect complex II, 
(CI)-IGA = in-gel activity o f complex I, (CI)-NDUFS3 = 
antibody directed against NDUFS3, and (CI)-NDUFB6 
= antibody directed against NDUFB6.
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Figure 4.3
The decreased expression and activity o f complex I 
caused by a mutation in NDUFA2 can be restored by 
baculoviral complementation. SDS-PAGE and BN- 
PAGE analysis with immunoblotting o f complex I-IV 
in control fibroblasts, fibroblasts from the patient 
with a mutation in NDUFA2, and fibroblasts from a 
patient with a mutation in NDUFS7 confirmed the 
pathogenicity o f the NDUFA2 mutation.
(A) SDS-PAGE analysis followed by immunoblotting 
confirms expression o f the baculovirus transduced 
constructs o f NDUFA2-GFP or with COX8-GFP (top 
panel). A BN-PAGE gel was blotted and used for im­
munodetection with an antibody directed against 
NDUFA9 to show the expression o f complex I. The un­
treated control cells and the control cells treated with 
the baculoviruses show the same expression levels. 
Expression o f complex I in the fibroblasts o f the index 
patient with a mutation in NDUFA2 is lower than in 
the control cells but can be partly rescued i f  the cells 
are treated with the baculovirus. Treating the cells o f 
the patient with a mutation in NDUFS7 with the bacu­
lovirus did not affect the expression o f complex I. In 
the third panel, detection with an antibody directed 
against GFP confirms the incorporation o f the GFP- 
tagged subunit. COX8-GFP is located in the bottom o f
The figure shows the accumulation of sub­
complexes in the patient fibroblasts, and less 
NDUFA2 was visible as well. These results in­
dicate a disturbance in the assembly and/or 
stability of complex I.
To confirm the pathogenic role of NDUFA2, 
we used a baculovirus expression system 
containing the NDUFA2 gene in frame with a 
GFP tag or COX8-GFP as a control. The viruses 
were used for the transduction of control 
fibroblasts, fibroblasts of the index patient 
with a mutation in NDUFA2, and fibroblasts of 
an unrelated patient with a mutation in the 
NDUFS7 gene (p.Val122Met) [Triepels 1999]. 
The GFP tag allowed us to distinguish be­
tween endogenous and transduced protein, 
and this tag does not interfere with the incor­
poration of NDUFA2 into complex I (data not
the gel and is not shown. In the next panels, antibod­
ies for complex II, III and IVshowed that the assembly 
of these complexes was not affected.
(B) In-gel activity assays showed that the activity of 
complex I is the same in the untreated and treated 
control cells transduced with the baculoviruses. The 
NDUFA2-mutated patient cells treated with the bacu­
lovirus containing NDUFA2-GFP have higher complex 
I activity than the untreated cells and than the cells 
treated with the baculovirus containing COX8-GFP. 
The treatment o f the fibroblasts o f the patient with a 
NDUFS7 mutation showed a slight increase in the ac­
tivity o f complex I because more protein was loaded 
in the two last lanes (see panel CII-SDHA).
(C) Measurement o f the activity o f complex I by bio­
chemical analysis showed almost no difference or a 
slight decrease between the untreatedand the control 
cells treated with the baculoviruses. The fibroblasts of 
the index patient treated with the baculovirus conta- 
ing NDUFA2-GFP demonstrated an increase in activ­
ity compared to the untreated cells and to the cells 
treated with the baculovirus containg COX8-GFP. The 
treatment o f the cells with the NDUFS7 mutation did 
not affect the activity o f complex I. Values are given as 
mean ± standard deviation.
Abbreviations are as follows: C = control, P-A2 = pa­
tient with the mutation in NDUFA2, P-S7 = patient 
with the mutation p.Val122Met in NDUFS7, Untr = un­
treated fibroblasts, A2 = fibroblasts treated with the 
baculovirus containing the NDUFA2 construct, COX8 
= fibroblasts treated with the baculovirus containing 
the COX8 construct, (CI)-NDUFA9 = antibody directed 
against NDUFA9, (CI)-GFP = antibody for the GFP-tag, 
(CII)-SDHA = antibody for SDHA to detect complex II, 
(CIII)-CORE2 = antibody for CORE2 to detect complex
III, (CIV)-COXII = antibody for COXII to detect complex
IV, and (CI)-IGA = in-gel activity o f complex I.
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Figure 4.4
Mutation in NDUFA2 in living cells is associated with 
mitochondrial depolarization, which can be restored 
by baculoviral complementation.
(A) Average TMRM fluorescence pixel intensity per 
cell (indicative o f the cell's mitochondrial membrane 
potential) o f control fibroblasts (C1, C2, C3, C4; black 
bars), o f fibroblasts o f the patient with the mutation in 
NDUFA2 (P-A2 cells; gray bar), and o f fibroblasts from 
a patient with a mutation in NDUFS7 (P-S7; gray bar). 
Values are given as mean ± standard error. The mean 
value obtained with the C1 cells was set at 100%, to 
which all other values were related. a***, significantly 
different from C1 cells (p < 0.001).
(B) Combined imaging o f TMRM and NDUFA2-GFP 
fluorescence in baculovirus-transduced C1 cells. The 
left image depicts TMRM fluorescence (red color), the 
middle image shows the GFP signal o f the same cells 
(green color), and the right image shows an overlay 
o f these two images. The yellow color demonstrates 
colocalization o f TMRM and GFP signal, indicating 
that only the left cell is transduced. Importantly, no 
bleed-through from the GFP signal into the TMRM im­
age was present, and vice versa.
shown). The untreated fibroblasts and the fi­
broblasts treated with the baculovirus were 
used for SDS-PAGE and BN-PAGE analysis. 
The SDS-PAGE demonstrated proper expres­
sion of the transduced NDUFA2-GFP fusion 
protein (figure 4.3A, first row). Next, we per­
formed BN-PAGE of the transduced cells to 
investigate the expression of complex I. Im- 
munoblot detection with an antibody direct­
ed against NDUFA9 showed almost no differ­
ence in the expression of complex I between 
the untreated control fibroblasts and the cells 
treated with the baculovirus containing the 
NDUFA2 or COX8 construct (figure 4.3A, sec­
ond row). In contrast, when fibroblasts of the 
index patient were treated with the NDUFA2 
construct, the expression of complex I was 
increased in comparison to expression un­
treated cells and cells treated with the COX8 
construct, whereas fibroblasts of the patient 
with a mutation in the NDUFS7 gene showed 
almost no difference in complex I expression 
in untreated cells versus cells treated with the 
constructs. To check whether the wild-type 
NDUFA2 subunit was indeed incorporated, 
we performed immunoblotting with the 
antibody directed against GFP (figure 4.3A, 
third row). All NDUFA2-GFP was incorporated 
in complex I in the fibroblasts of the patient 
with the NDUFA2 mutation, whereas in the 
control and the unrelated patient mono­
meric (unincorporated) NDUFA2-GFP protein 
could also be detected (data not shown). The 
band of GFP attached to COX8 was visible at 
the bottom of the gel (data not shown). In-
(C) Quantification o f the average TMRM pixel fluo­
rescence intensity in C1, P-A2, and P-S7 cells after 
transduction with a baculovirus containing the cDNA 
o f NDUFA2-GFP. After imaging, cells were selected ac­
cording to their GFP signal (GFP-negative, black bar/ 
gray bars; GFP-positive, green bars) and for each sub­
group, the average TMRM pixel intensity per cell was 
calculated. Values are given as mean ± standard er­
ror. The mean value obtained with the GFP-negative 
C1 cells was set at 100%, to which all other values 
were related. a***, significantly different from GFP- 
negative C1 cells (p < 0.01), b**, significantly different 
from GFP-negative P-A2 cells (p < 0.01). Numerals in
(A) and (C) represent the number o f individual cells 
analyzed.
Abbreviations are as follows: C1-4 = control 1-4, P-A2 
= patient with the mutation in NDUFA2, P-S7 = pa­
tient with the mutation p.Val122Met in NDUFS7.
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cubation with antibodies for complex II, III, 
and IV showed that the assembly of these 
complexes was not affected by the NDUFA2 
mutation (figure 4.3A, rows four to six). We 
performed an IGA assay to measure the activ­
ity of complex I (figure 4.3B). Transduction of 
the control fibroblasts with baculovirus did 
not affect the activity of complex I. The activ­
ity of the untreated cells of the index patient 
was lower than that of the untreated con­
trol cells, but is partially rescued in the cells 
treated with the baculovirus containing the 
construct with NDUFA2. Transduction of the 
baculovirus into the cells of the patient with a 
mutation in NDUFS7 did not affect the activity 
of complex I. To confirm these observations, 
we also measured the activity of complex I 
by biochemical analysis (figure 4.3C). In the 
controls cells, the activity of complex I did not 
detectably alter after treatment with baculo- 
viruses. However, in the fibroblasts of the pa­
tient with the NDUFA2 mutation, the activity 
of complex I was greater in the cells treated 
with the baculovirus containing NDUFA2-GFP 
than in the untreated cells and the cells treat­
ed with the baculovirus with COX8-GFP. No 
increase in activity was seen in the fibroblasts 
of the patient with the NDUFS7 mutation after 
treatment with the baculovirus containing 
NDUFA2-GFP. All the results together confirm 
that the complex I deficiency expressed in fi­
broblasts is complemented by a baculovirus 
system expressing NDUFA2.
Mutation in NDUFA2 is associated with mito­
chondrial depolarization in living cells, which 
can be restored by baculoviral complementa­
tion
The mitochondrial membrane potential (Aÿ) 
is one of the most important indicators of 
mitochondrial function and metabolic activ­
ity. It is directly coupled to proper action of 
the respiratory chain. Using a recently devel­
oped method to sensitively measure Aÿ in 
cultured human skin fibroblasts [Distelmaier 
2008; Komen 2007], we here show that the 
accumulation of TMRM in the mitochondrial­
matrix is significantly decreased in fibroblasts 
of the index patient compared to four healthy 
subject cell lines (figure 4.4A). In addition we 
demonstrate, that mitochondrial TMRM fluo­
rescence is also reduced in the fibroblasts of
the patient with the NDUFS7 mutation, which 
suggests that the decrease in A^ is an impor­
tant feature of complex I deficiency. Although 
this reduction appears relatively small it is 
important to note that treatment of healthy 
fibroblasts with 100 nM rotenone, which 
caused a marked reduction in complex I ac­
tivity [Koopman 2005], decreased the TMRM 
signal by ~10% [Komen 2007].
Next, we investigated whether baculoviral 
transduction of the patient fibroblasts with 
the NDUFA2-GFP construct could normal­
ize the observed depolarization of A^. Here, 
we used the advantage of combined mea­
surement of TMRM and GFP fluorescence, 
enabling us to assess A^ in non-transduced 
(GFP-negative) and transduced (GFP-posi- 
tive) cells present on the same coverslip (fig­
ure 4.4B). The left image shows that TMRM is 
virtually exclusively present in the mitochon­
dria (red color), whereas the middle image 
shows that NDUFA2-GFP fluorescence is most 
intense in these organelles, but also clearly 
visible in the nucleus and cytosol. This image 
furthermore shows that the right cell does 
not detectably express NDUFA2-GFP, and 
that there was virtually no bleed-through of 
TMRM fluorescence during recording of the 
GFP image. Importantly, we carefully verified 
that there was also no bleed-through of GFP 
fluorescence in the TMRM image (for further 
details see reference [Distelmaier 2008]).
As shown in figure 4.4C, successful transduc­
tion of healthy fibroblasts (C1, GFP-positive 
cells) did not alter the TMRM signal (no sig­
nificant difference between GFP-negative 
and GFP-positive cells). On the other hand, 
the TMRM signal was fully normalized in GFP- 
positive cells of the index patient, whereas 
the signal was still significantly decreased in 
their GFP-negative counterparts. Important­
ly, no significant changes could be observed 
for the NDUFS7 patient, demonstrating that 
the effect of the NDUFA2 transduction is spe­
cific for the cells of the index patient. Taken 
together, these results convincingly demon­
strate that the mutation in the NDUFA2 gene 
is responsible for the observed depolariza­
tion of A^ in these patient fibroblasts.
Of note, our GFP measurements revealed 
that not all cells were transduced, which may 
explain why biochemical complex I activity
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measurements and blue native-gel electro­
phoresis followed by either immunoblotting 
or in-gel activity measurement did not show 
full recovery of complex I amount and activity 
in the patient fibroblasts.
Discussion
To our knowledge, this is the first report de­
scribing a mutation in the NDUFA2 gene in a 
patient with an isolated complex I deficiency 
expressed in skin fibroblasts and muscle tis­
sue. A mutation in the splice donor site after 
exon two resulted in skipping of that exon 
and, subsequently, in a truncated protein of 
48 instead of 99 amino acids. Several lines 
of evidence suggest that this mutation is 
the underlying cause of the complex I defi­
ciency and, therefore, of the disease in the 
patient: (1) the mutation involved a nucle­
otide change in a conserved region of the 
5' splice site, which is important for correct 
splicing [Cartegni 2002]; (2) the mother was 
heterozygous for the mutation and the mu­
tation was not present in 107 controls of the 
same ethnic background; (3) the functional 
consequence of the mutation, skipping of 
exon two, was confirmed at the cDNA level; 
(4) patient fibroblasts showed a decrease in 
complex I amount and activity as revealed 
by immunoblotting and biochemical and in­
gel activity measurements; (5) the assembly 
of complex I was disturbed in these cells; (6 ) 
the mitochondrial membrane potential, as 
determined in intact cells, was depolarized 
in intact patient fibroblasts; and most impor­
tantly, (7) transduction with a baculoviral vec­
tor containing the wild-type NDUFA2 gene 
specifically restored both complex I amount 
and activity and mitochondrial membrane 
potential in these patient fibroblasts. 
Fourteen of the complex I subunits are highly 
conserved across species, from mammals to 
bacteria [Carroll 2003; Murray 2003]. It is as­
sumed that the orthologs of the bacterial 
subunits form the minimal functional com­
plex of higher organisms [Fearnley 1992]. 
These subunits are essential for the catalysis 
of electron transfer from NADH to ubiqui­
none and for the generation of the proton 
gradient. Several mutations have been de­
scribed in these subunits, causing complex 
I deficiency. However, the core subunits are 
not only locations of disease-causing muta­
tions. Mutations have also been described in 
genes encoding NDUFS4, NDUFS6 , NDUFA1, 
and NDUFA11 which belong, together with 
NDUFA2, to the accessory subunits.
Not much is known yet about the role of com­
plex I accessory subunits, but the presence of 
a disease-causing mutation in NDUFA2 sup­
ports the notion that at least some of them 
are crucial for proper complex I function. With 
94% identity among mammals, NDUFA2 is 
one of the most conserved accessory sub­
units [Hirst 2003]. The structure of its bovine 
ortholog, B8 , shows a four-stranded mixed 
P sheet with three a helices packed against 
one side. Its overall structure is very similar to 
that of thioredoxins, which has led to the idea 
that this subunit might link cellular redox 
state and complex I assembly and/or activity 
[Brockmann 2004]. The data presented in this 
study show that proper assembly of enzy­
matic active complex I is indeed impaired in 
fibroblasts of the index patient. Our data fur­
thermore show a parallel decrease in amount 
and activity of the fully assembled complex, 
suggesting that the mutation primarily de­
creases the expression of the fully assembled 
complex rather than its intrinsic activity. In 
addition to its structure, homology to other 
proteins might also give an indication for the 
function of this accessory subunit. Gabaldon 
et al. described a paralogous relationship of 
NDUFA2 with the mitochondrial ribosomal 
proteins L43 and S25 [Gabaldon 2005], which 
might suggest a possible connection be­
tween complex I and mitochondrial transla­
tion.
To asses the cellular consequence of the re­
duction in complex I amount and activity in 
the fibroblasts of the index patient, we per­
formed live-cell imaging of the mitochon­
drial membrane potential (Aÿ). Aÿ is a key 
indicator of mitochondrial function and cell 
viability and is maintained by the complexes 
I to IV of the mitochondrial respiratory chain. 
The mutation in NDUFA2 caused a small but 
significant depolarization of Aÿ in the patient 
cells; such a depolarization might influence 
the function of the mitochondria. We also 
observed that Aÿ was significantly depolar­
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ized in a patient cell line with a mutation in 
NDUFS7, indicating that this depolarization 
might be a hallmark of complex I deficiency. 
Importantly, mitochondrial depolarization 
was restored upon baculoviral complemen­
tation of fibroblasts from the index patient, 
whereas the NDUFS7 cell line did not show 
any improvement upon this treatment. This 
demonstrates that mitochondrial depolar­
ization was indeed a specific consequence of 
the NDUFA2 mutation in the fibroblasts of the 
index patient.
Complex I deficiency is one of the most fre­
quent defects of the OXPHOS system [Jans­
sen 2006b]. At present, the exact cause of 
the disease is still unknown in many patients 
with complex I deficiency. Therapeutic strate­
gies for the often devastating disorders due 
to complex I malfunction are hardly available, 
and it is therefore of eminent importance to 
identify possible genetic causes for prenatal 
diagnostics and genetic counseling. Here, we 
report on a patient who had isolated complex 
I deficiency and who carried a homozygous 
mutation in the nuclear gene encoding the 
accessory complex I subunit NDUFA2, and 
we demonstrate with the use of baculovi­
ral complementation technology that this 
mutation is responsible for a disturbed as­
sembly of complex I and that this disturbed 
assembly leads to a decrease in the amount 
of enzymatic active complex, and at the level 
of the intact cell, a reduction in mitochondrial 
membrane potential.
tre, Nijmegen, The Netherlands) for perfor­
mance of homozygosity mapping.
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Abstract
Mitochondrial complex I deficiency is the 
most common defect of the oxidative phos­
phorylation system. We report a patient with 
Leigh syndrome who showed a complex I de­
ficiency expressed in cultured fibroblasts and 
muscle tissue. To find the genetic cause of the 
complex I deficiency, we screened the mito­
chondrial DNA and the nuclear encoded sub­
units of complex I. We identified compound 
heterozygous mutations in the NDUFA10 
gene, encoding an accessory subunit of com­
plex I. The first mutation disrupted the start 
codon and the second mutation resulted in 
an amino acid substitution. The fibroblasts of 
the patient displayed decreased amount and 
activity, and a disturbed assembly of com­
plex I. These results indicate that NDUFA10 is 
a novel candidate gene to screen for disease- 
causing mutations in patients with complex 
I deficiency.
Introduction
NADH:ubiquinone idoreductase (E.C.1.6.5.3.), 
or complex I, is the first and largest of the five 
complexes of the oxidative phosphorylation 
(OXPHOS) system. Its function is binding and 
oxidizing NADH to free electrons, which are 
then transferred to the electron acceptor 
ubiquinone. The energy released during this 
electron transfer is used to translocate pro­
tons across the inner mitochondrial mem­
brane, generating a proton gradient, which 
can be used for the synthesis of ATP. Complex 
I consist of 45 subunits of which seven are en­
coded by the mitochondrial DNA (mtDNA). 
It is an L-shaped complex, consisting of a 
hydrophobic membrane arm embedded in 
the mitochondrial inner membrane and a 
hydrophilic peripheral arm protruding into 
the matrix. The complex can be divided into 
three functional modules. The dehydroge­
nase module is important for the oxidation of 
NADH, the hydrogenase module has a role in 
the transport of electrons to ubiquinone, and 
the proton translocation module is involved 
in proton pumping [Brandt 2006; Efremov 
2010 ].
Isolated complex I deficiency is the most
common defect of the OXPHOS system, 
accounting for approximately 23% of all 
patients with childhood respiratory chain 
deficiency [Smeitink 2001b]. It has a wide 
clinical variety, effecting one or more tissues 
or organs [Loeffen 2000]. The organs with the 
highest energy demand such as heart, brain, 
skeletal muscle tissue and, liver are the most 
affected organs. Owing to the bi-genomic 
control of the OXPHOS system, mutations 
causing complex I deficiency can be found 
in either the mtDNA or in genes encoded by 
the nuclear DNA. Previous studies identified 
disease-causing mutations in nuclear struc­
tural genes encoding for the seven core sub­
units (NDUFS1, NDUFS2, NDUFS3, NDUFS7, 
NDUFS8 , NDUFV1, and NDUFV2) and five 
accessory subunits of complex I (NDUFS4, 
NDUFS6 , NDUFA1, NDUFA2, and NDUFA11) 
[Janssen 2006b; Fernandez-Moreira 2007; 
Hoefs 2008; Berger 2008]. Furthermore, mu­
tations have been described in eight assem­
bly factors (NDUFAF1, NDUFAF2, NDUFAF3, 
NDUFAF4, C8orf38, C20orf7, ACAD9, and 
NDUBPL) of this complex and in an uncharac­
terized protein (FOXRED1) causing complex I 
deficiency [Ogilvie 2005; Dunning 2007; Saa- 
da 2008; Pagliarini 2008; Sugiana 2008; Saada 
2009; Calvo 2010; Nouws 2010].
Although pathogenic mutations have been 
described in accessory subunits, the func­
tion of these subunits is not exactly known 
yet. It has been suggested that some are im­
portant for the biogenesis of complex I. One 
of these subunits is NDUFA10. The predicted 
355 amino acid human protein is 80% identi­
cal to the 42-kDa bovine homolog. This sub­
unit is located in the hydrophobic protein 
fraction of complex I, and might therefore be 
involved in the transfer of protons. Further­
more, NDUFA10 is one of the subunits that 
undergoes post-translational modification; 
it can be phosphorylated at a single amino 
acid, serine-59 [Schulenberg 2003; Schilling 
2005].
In the present communication, we describe 
two compound heterozygous mutations in a 
patient with a complex I deficiency, expressed 
in cultured fibroblasts and muscle tissue. Cell 
biological studies were performed to show 
the functional consequences of the genetic 
variations. A new gene responsible for human
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complex I deficiency has been identified.
Subjects and Methods
Case report
The patient, a boy, was born after a normal 
pregnancy of 32 weeks with a sectio caesaria 
because of fetal distress. His birth weight was 
2715 g. He had a normal start and neonatal 
period. From early on, he showed hypotonia. 
His milestones were uneventful with regard 
to laughing, contact, grabbing things, and 
rolling over to his back, but he did not reach 
sitting position, and head control remained 
poor. At ten months of age he was referred 
for evaluation of the cause of his retarded de­
velopment and hypotonia. Tendon reflexes 
were somewhat increased. Therefore, it was 
concluded that there was a central cause of 
hypotonia together with retarded develop­
ment. His blood and cerebrospinal fluid lac­
tate were 8.6 and 4.9 mmol/l, respectively (ref­
erence value 0.5-2.2 mmol/l), with increased 
lactate to pyruvate ratios (being around 20 
on more than one occasion and the one mea­
surement in cerebrospinal fluid). His cerebral 
MRI showed symmetrical lesions in especially 
the basal ganglia and substantia nigra. On 
the basis of the high lactate concentrations 
and the increased lactate/pyruvate ratio, a 
defect of pyruvate dehydrogenase complex 
or within the OXPHOS was likely considered. 
Biochemical investigations were performed 
in muscle and fibroblasts (table 5.1). We 
started with thiamine and a ketogenic diet
administered by gastro-intestinal tube feed­
ing. Owing to analyses of blood gases, show­
ing a pH of 7.12 with 4 mmol/l of bicarbonate, 
sodium bicarbonate was given, resulting in 
normalization of pH with some respiratory 
compensation (pCO2 usually between 3.5 
and 4.0 kPa). With these strategies, growth 
showed adequate response, so that his early 
fragility disappeared. His development im­
proved with uttering noises rather than clear 
words. During later months, he displayed pe­
riods of abnormal breathing with hypo- and 
hyperventilation. At one of the occasions, he 
seemed to have a convulsion. Routine cardiac 
evaluation by ultrasound suggested some 
hypertrophic cardiomyopathy, without clear 
clinical relevance at that moment. During one 
such episode of convulsions, he experienced 
a severe cardiac respiratory arrest. X-ray of the 
thorax showed massive pleural fluid, most 
probably as a result cardiac decompensation 
by hypertrophic cardiomyopathy. Notwith­
standing treatment with mechanical ventila­
tion, with high pressures, and the use of car­
diovascular agents to stimulate contractility 
followed by resuscitation procedures were 
unsuccessful; he died at 23 months of age. 
In his last days, he also showed hypoglycae- 
mia (glucose 1.6 mmol/l), a finding not being 
observed before, possibly because of multi­
organ failure rather than isolated liver failure. 
At autopsy, besides the already known car­
diomyopathy, degenerative abnormalities 
were reported in the liver, spleen, kidneys, 
and pancreas. Apart from these findings the 
most outspoken abnormalities were seen
Table 5.1
Respiratory chain enzyme activities in skin fibroblasts and fresh muscle tissue o f the index patient.
Fibroblasts Fresh muscle
Complex Patient Control range Patient Control range
30 104-206° 5 70-250 c
II n.m. 119 67-177 c
III 1428 1270-2620 a 1490 2200-6610 c
IV 1026 684-1190 b 1067 810-3120 c
Abbreviation: NM, not measured. 
Deficiencies are indicated in bold. 
a mU/U Cytochrome c oxidase 
b mU/mU Citrate synthase 
c mU/U Citrate synthase
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in the brain: in the thalamus, the pons, and 
also in the hippocampus degradation of my- 
eline, decreased myelinization, proliferation 
of vessels, some gliosis, and some foam cell 
response was reported. Especially from the 
abnormalities found in the thalamus and the 
pons the diagnosis classical Leigh syndrome 
was concluded.
Cell culture and biochemical analysis 
Skin fibroblasts were cultured in M199 me­
dium (Life Technologies, Breda, The Neth­
erlands) supplemented with 10%  fetal calf 
serum and 1%  penicillin/streptomycin in a 
humified atmosphere of 95% air and 5% CO2 
at 37°C. Measurement of the mitochondrial 
respiratory chain enzyme activities in muscle 
tissue and skin fibroblasts were performed ac­
cording to established procedures [Smeitink 
2001a; Janssen 2006a]. The values were ex­
pressed relative to the activity of cytochrome 
c oxidase and/or citrate synthase.
Genetic analysis of the mtDNA and nuclear 
complex I genes
Patient DNA was extracted from cultured skin 
fibroblasts by standard procedures [Miller 
1988]. Oligonucleotide primers were de­
signed from the mtDNA sequence and from 
the gene sequences of all nuclear-encoded 
complex I subunits. The Genbank accession 
number of the NDUFA10 gene sequence is 
NM_004544.3. Other Genbank accession 
numbers and primer sequences are available 
upon request. The size of the amplification 
products were checked with a 1.5% agarose 
gel and the amplimers were sequenced di­
rectly with the BigDye terminator cycle se­
quencing chemistry on a Applied Biosystems 
(Nieuwerkerk a/d IJssel, The Netherlands) ABI 
PRISM 3130xl Genetic Analyzer. The nucle­
otide numbering follows cDNA numbering 
with +1 corresponding to the A of the ATG 
translation initiation codon in the reference 
sequence. The initiation codon is codon 1.
BN-PAGE analysis and in-gel activity assay 
Blue native-gradient gels (5-15%) were cast 
and run with 40 yg of digitonin-isolated 
mitochondria as described previously [Cal- 
varuso 2008; Nijtmans 2002]. After electro­
phoresis, the gels were further processed for
in-gel activity assay or two-dimensional 10%  
SDS-PAGE, followed by immunoblot analysis 
as described by Calvaruso et al. [Calvaruso 
2008].
SDS-PAGE analysis
Mitochondrial lysates were separated on a 
10% SDS-PAGE gel. Next, the proteins were 
transferred to PROTAN nitrocellulose mem­
brane (Schleicher & Schuell, Zwijndrecht, The 
Netherlands) for immunodetection.
Antibodies and ECL detection 
Western blotting was performed with pri­
mary antibodies raised against the com­
plex I subunits NDUFA9 (Invitrogen, Breda, 
The Netherlands), NDUFS3 (Invitrogen), 
NDUFA10 (Sigma-Aldrich, Zwijndrecht, The 
Netherlands), ND1 (Dr A Lombes, Paris), and 
the complex II 70 kDa subunit (SDHA; Invit­
rogen). Secondary antibodies used were per­
oxidase-conjugated anti-mouse (Invitrogen), 
anti-rabbit (Invitrogen), or anti-chicken IgGs 
(SouthernBiotech, Birmingham, AL, USA), 
and detection of the signal performed using 
ECL Plus (Amersham Biosciences, Roosen­
daal, The Netherlands) according to the man­
ufacturer's instructions.
Results
Biochemical studies
Investigation of the activities of the respira­
tory enzyme complexes in cultured fibro­
blasts and fresh muscle tissue of the index 
patient revealed a severely reduced complex 
I activity (table 5.1). The enzymatic activities 
were 29 and 7% from the lowest value of the 
control range in the fibroblasts and muscle 
tissue, respectively. Furthermore, the activity 
of complex III in muscle tissue was slightly de­
creased (68%  of the lowest control value).
Molecular genetic studies in the NDUFA10 gene 
We searched for the molecular defect caus­
ing the complex I deficiency by screening 
the entire mtDNA, followed by screening the 
genes for all 38 nuclear-encoded subunits. 
We excluded the presence of disease-causing 
mutations in the mtDNA. Sequence analysis 
of the nuclear NDUFA10 gene demonstrated
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the presence of two heterozygous substi­
tutions (figure 5.1A). The first mutation is a 
substitution from A-to-G (c.1A>G) in exon 1, 
which disrupts the start codon methionine 
(p.Met1?). The next possible start codons 
can be found at 116 and 118 nucleotides 
upstream. However, these alternative start 
codons are either not in frame or abolish the 
mitochondrial target sequence, which makes 
both unlikely to be functional. The father of 
the index patient was carrier of this mutation. 
The second mutation was found in exon 3 
(c.425A>G), causing a substitution of amino 
acids (p.Gln142Arg). This mutation affects a 
highly conserved amino acid (figure 5.1B), 
and the mutation software SIFT (J. Craig Ven­
ter Institute, Rockville, MD, USA) predicted 
this mutation to be pathogenic because it 
affects the protein function with a score of
o.oo. Substitutions with score less than 0.05 
are predicted to affect protein function.
The mother of the patient was found to be 
heterozygous for this mutation. Both muta­
tions were not present in 108 healthy controls 
or 21 other patients with isolated complex I 
deficiency expressed in cultured fibroblasts. 
From these observations, we conclude that it 
is highly likely that both mutations are patho­
genic.
Patient 
H . sapiens 
P . troglodytes
B . taurus 
M. nusculus 
D. rerio
D, melanogaster
C. elegans
Gln142Arg
RLQSW1YSS RLiH ySDALEHLLTTG 
! ÏS DALEHLLT TG 
ÜfSDALEHLLTTG 
! ÏADALEHLLS TG 
! ÏADALEHLLS TG
RLQSWLYSSRLL
RLQSWLYSSRLL
KLQAKLYASRLL
KLQSWLYASRLL
RLQAWMYLMRLL
QFQIRMÏMLRYS
AMQDRIFNCRFD
IÏSDAVEHLLÏTG 
! ÏIDALQHVLSTG 
! YLNALAHILNTG
Figure 5.1
Molecular analysis o f the NDUFA10 gene.
(A) Electropherograms showing the wild-type se­
quence o f NDUFA10 (top) and the nucleotide changes 
in fibroblasts o f the patient (bottom). Arrows repre­
sent the nucleotide substitutions, c.1A>G (left) and, 
c.425A>G (right).
(B) Conservation o f the altered amino acid 
(p.Gln142Arg) is shown in a Clustal W alignment. 
Abbreviations are as follows: Wt: wild-type; P: index 
patient
Figure 5.2
The mutations in NDUFA10 result in decreased activ­
ity and amount o f complex I.
(A) BN-PAGE analysis followed by an in-gel activity 
assay demonstrates a decreased complex I activity 
in fibroblasts o f the patient compared with control 
cells. The amount o f subunit NDUFA9 is also severely 
reduced, indicating a decreased amount o f whole 
complex I. The amount o f complex II is not affected.
(B) SDS-PAGE analysis and immunoblotting with 
an antibody directed against NDUFA10 shows that 
the amount o f NDUFA10 is decreased in patient fi­
broblasts. The amount o f NDUFA9 is also reduced, 
suggesting a reduction in amount o f complex I. The 
amount o f complex II is not affected.
Abbreviations are as follows: C: control; P-A10: pa­
tient with NDUFA10 mutations; CI, II: complexes I, II; 
IGA: in-gel activity; SDHA: succinate dehydrogenase 
complex subunit A
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Effect of the NDUFA10 mutations on the activity 
and steady-state level of complex I 
The effect of the mutations on the activity of 
complex I was examined by performing BN- 
PAGE analysis followed by western blotting 
with an anti-NDUFA9 antibody to detect com­
plex I amounts, and in-gel complex I activity 
measurements with mitochondria-enriched 
fractions of the cultured patient fibroblasts. 
Figure 5.2A shows a marked decrease of com­
plex I activity in patient fibroblasts compared 
with the control cells. Furthermore, the ex­
pression of NDUFA9, indicative of the amount 
of fully assembled complex I, was severely de­
creased. These results are in agreement with 
the spectrophotometric complex I observa­
tions in the patient fibroblasts.
Next, we performed SDS-PAGE analysis to 
study the effect of the mutations on the ex­
pression of complex I. Figure 5.2B shows a 
clear decrease in the protein level of NDUF- 
A10 in the patient compared with the control. 
The expression of the NDUFA9 subunit was 
also decreased.
Effect of the NDUFA10 mutations on the assem­
bly of complex I
To test whether the assembly of complex I is 
disturbed, we performed two-dimensional 
BN/SDS-PAGE analysis followed by immu- 
noblotting with antibodies directed against 
NDUFS3 and ND1 (figure 5.3). This figure 
shows a decreased amount of fully-assem­
bled complex I and an increased amount of 
subcomplexes in cultured fibroblasts of the 
patient compared with the control, suggest­
ing a disturbed assembly or stability of com­
plex I. Remarkably, subcomplexes 4 and 5, as 
previously described [Vogel 2007a], are accu­
mulated, indicating that subunit NDUFA10 is 
incorporated in complex I after the formation 
of subcomplex 5. This suggests that NDUFA10 
will be incorporated in a late stage of complex 
I assembly.
Discussion
This is the first report describing compound 
heterozygosity for two mutations in the 
NDUFA10 gene in a patient with complex I 
deficiency, expressed in both cultured fibro­
blasts as well as in muscle tissue. One of the 
mutations is located in the sequence encod­
ing start codon for translation and the other 
mutation introduced an amino acid substitu­
tion from glutamine to arginine. Several lines 
of evidence suggest that these compound 
heterozygous mutations are the underly­
ing cause of the complex I deficiency. First, 
the start codon disappeared and the second 
mutation affected a highly conserved amino 
acid. Second, the father was carrier of the 
first mutation and the mother of the second 
mutation. Third, both mutations were not 
present in 108 controls and 21 patients with 
isolated complex I deficiency. Fourth, the pa­
tient fibroblasts showed decreased amount 
and activity of complex I, and finally, we dem­
onstrated a disturbed assembly of complex I 
in the patient fibroblasts.
Besides the severely reduced complex I defi­
ciency, the activity of complex III in muscle tis­
sue was also somewhat reduced. This obser­
vation has been described before in several 
complex I deficiencies, and could be because 
of the fact that in the normal situation, super­
complexes can be found, in which complex­
es I and III occur together (CI1/CIII2) [Budde 
2000; Hoefs 2009; Hoefs 2010; Lazarou 2007]. 
Therefore, screening of NDUFA10 should not 
be limited to only patients with isolated com­
plex I deficiencies but also patients with a 
reduced complex I deficiency combined with 
a reduction in comolex III activity should be
mww
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Figure 5.3
The mutations in NDUFA10 result in accumulation 
o f subcomplexes o f complex I. Two-dimensional BN/ 
SDS-PAGE analysis followed by immunoblotting with 
antibodies directed against NDUFS3, to investigate 
the early steps o f the complex I assembly, and ND1 
to examine the incorporation o f the mtDNA encoded 
subunits, shows the accumulation o f mainly the sub­
complexes 4 and 5 in the index patient. The subcom­
plexes are numbered according the assembly model 
described by Vogel and colleagues [Vogel2007a]. 
Abbreviations are as follows: C: control; P-A10: pa­
tient with NDUFA10 mutations; CI: complex I
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screened for the presence of disease-causing 
mutations.
The seven mtDNA encoded subunits to­
gether with seven nuclear-encoded subunits 
form the minimal constitution of complex I, 
as these are involved in catalysis of electron 
transfer from NADH to ubiquinone and for 
the generation of the proton gradient. Most 
mutations causing complex I deficiencies 
have been described in these genes. Howev­
er, genes encoding accessory subunits, such 
as NDUFS4, NDUFS6 , NDUFA1, NDUFA2, and 
NDUFA11 may also contain pathogenic mu­
tations [van den Heuvel 1998; Kirby 2004b; 
Fernandez-Moreira 2007; Hoefs 2008; Berger 
2008]. NDUFA10 also belongs to these acces­
sory subunits.
Not much is known about the function of 
the accessory subunits, but the mutations 
observed in the NDUFA10 gene indicate that 
at least this subunit is important for proper 
functioning of complex I. NDUFA10 is one 
of the subunits that can be phosphorylated, 
which could be important for the function of 
this subunit, as phosphorylation of complex 
I subunits has been involved in regulation 
of enzymatic activity and possibly affects 
electron transfer [Schulenberg 2003; Schil­
ling 2005]. Therefore, NDUFA10 might play 
a role in the control of the activity of com­
plex I through binding of NADH [Yamaguchi 
2000; Chen 1984]. Furthermore, it has been 
described that unlike other protein compo­
nents of the membrane arm, NDUFA10 is a 
relatively hydrophilic protein and is thought 
to be generally weakly associated with com­
plex I [Finel 1992; Sazanov 2000]. The phos­
phorylation might influence the binding af­
finity of NDUFA10 and regulate the amount 
of fully-active complex. In addition, the loose 
association of the NDUFA10 subunit would 
make it more accessible to external interac­
tions with other proteins like kinases and 
phosphatases.
Complex I deficiency is one of the most fre­
quently diagnosed defects of the OXPHOS 
system. At present, the diagnosis is often only 
based on biochemical measurements of the 
single enzyme activities of the OXPHOS sys­
tem, as the genetic cause is still unknown in 
many patients. Therefore, improved methods 
like genomic microarray screening or exome
sequencing of the nuclear genes encoding 
subunits and assembly factors of complex 
I may be useful tools in the near future. Our 
finding of mutations in accessory subunit 
NDUFA10 emphasises that disease-causing 
mutations are not restricted to a certain set 
of subunits and genetic screening should in­
volve all subunits. Identifying new mutations 
causing complex I deficiency is important to 
improve genetic counselling and to get more 
insight in the function of complex I.
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Abstract
Mitochondrial complex I deficiency is the 
most common defect of the OXPHOS sys­
tem. We report a patient from consanguin­
eous parents with a complex I deficiency 
expressed in skin fibroblasts. Homozygosity 
mapping revealed several homozygous re­
gions with candidate genes, including the 
gene encoding an assembly factor for com­
plex I, NDUFAF2. Screening of this gene on 
genomic DNA revealed a homozygous stop- 
codon resulting in a truncation of the protein 
at position 38. The mutation causes a severely 
reduced activity and a disturbed assembly of 
complex I. A baculovirus containing the GFP- 
tagged wild-type NDUFAF2 gene was used 
to prove the functional consequences of 
the mutation. The expression and activity of 
complex I was almost completely rescued by 
complementation of the patient fibroblasts 
with the baculovirus. Therefore, the homozy­
gous substitution in NDUFAF2 is the disease- 
causing mutation, which results in a complex 
I deficiency in the fibroblasts of the patient.
Introduction
The oxidative phosphorylation (OXPHOS) 
system, located in the inner mitochondrial 
membrane, is responsible for the production 
of ATP. It consists of four enzyme complexes 
(complex I-IV) of the electron transport chain 
and ATP synthase (complex V). Electrons are 
transferred from substrates NADH and FADH2 
to the final electron acceptor molecular oxy­
gen by complex I-IV. Energy released by this 
transport results in translocation of protons 
across the inner mitochondrial membrane. 
Complex V uses this proton gradient to pro­
duce ATP from ADP and Pi [Smeitink 2001b]. 
Mitochondrial disorders are a heterogeneous 
group of multisystemic diseases mostly 
caused by the dysfunction of one or more 
complexes of the OXPHOS system. Complex 
I deficiency (MIM# 252010) is one of the most 
common disorders of the OXPHOS system 
displaying a clinical variety including Leigh or 
Leigh-like syndrome (MIM# 256000), cardio­
myopathy, leukodystrophy, and hepatopa- 
thy [Pitkanen 1996; Loeffen 2000]. Complex
I consists of 45 subunits that are encoded by 
the mitochondrial DNA (mtDNA) (N = 7), and 
the nuclear genome [Carroll 2006]. Due to the 
size of complex I, the assembly of this protein 
complex is a complicated process. The sub­
units are not incorporated one by one, but 
assembly intermediates consisting of sev­
eral subunits are combined during assembly 
[Ugalde 2004]. Different molecular chaper­
ones are involved in assembling the subunits 
into the holocomplex. One of these assembly 
factors is NDUFAF2 (MIM# 609653), which is 
a paralogue of complex I subunit NDUFA12 
[Gabaldon 2005]. Previously, this factor was 
identified as a mitochondrial protein of un­
known function in a screen for transcriptional 
targets of c-myc [Tsuneoka2005]. Knockdown 
of this protein showed growth inhibition of 
some tumor lines. In the assembly of com­
plex I, NDUFAF2 is present in a subcomplex of 
about 830 kDa and was found associated to 
the complex I subunits ND1 (MIM# 516000), 
NDUFS2 (MIM# 602985), NDUFS3 (MIM# 
603846), NDUFS4 (MIM# 602694), NDUFV1 
(MIM# 161015), NDUFV2 (MIM# 600532), and 
NDUFA13 (MIM# 609435) [Ogilvie 2005]. This 
suggests that NDUFAF2 is required in a late 
stage of complex I assembly.
Earlier studies described mutations in NDUF- 
AF2 causing a complex I enzyme deficiency. 
Ogilvie and colleagues identified a mutation 
in exon two resulting in a premature stop 
codon in a patient with progressive enceph­
alopathy [Ogilvie 2005]. A missense mutation 
resulting in a substitution of the first methi­
onine by leucine has been found in two pa­
tients with a progressive neurological disease 
[Barghuti 2008].
Disease-causing mutations have also been 
described in four other assembly factors: 
NDUFAF1 (MIM# 606934), C6 orf66  (MIM# 
611776), C8orf38 (MIM# 612392), and C20orf7 
(MIM# 612360) [Dunning 2007; Saada 2008; 
Pagliarini 2008; Sugiana 2008] and in twelve 
nuclear encoded subunits of complex I (re­
viewed in [Janssen 2006b] [Fernandez-Mor- 
eira 2007; Hoefs 2008; Berger 2008]. However, 
molecular diagnosis is still lacking for 50% of 
the patients [Thorburn 2004]. Therefore, stud­
ies identifying new mutations are necessary. 
In this study, we describe a patient from con­
sanguineous parents with a new mutation in
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the gene for assembly factor NDUFAF2, and 
cell biological studies are performed to dis­
play the functional consequences of the ob­
served genetic variation.
Materials and Methods
Case report
The patient, a girl, was the first child of healthy 
consanguineous parents (mothers of the 
grandmothers having the same father). Preg­
nancy and delivery were uneventful and the 
patient was born at term with a birthweight 
of 3040 gram, normal length and head cir­
cumference. She presented at three months 
of age with nystagmus. At seven months of 
age the patient was admitted because of 
vomiting, renal tubular acidosis, feeding dif­
ficulties and poor weight gain. It was obvi­
ous that she also had a neurological disease 
with nystagmus, generalized hypotonia and 
developmental retardation, mainly affecting 
the motor skills. Laboratory investigations 
revealed elevated blood lactate concentra­
tions ranging between 3-5 mmol/L (ref. <2.3 
mmol/L). Elevated levels of fumarate and
Figure 6.1
Magnetic Resonance Imaging o f the brain was per­
formed at nine months o f age. Axial T2-weighted im­
ages show hyper intense lesions in the thalami and in 
regions o f the brainstem.
malate were present in the urine. Magnetic 
resonance imaging (MRI) of the brain and 
spinal cord showed symmetrical, bilateral, 
high signalling abnormalities in thalamus, 
cerebral peduncles, brainstem and spinal 
cord (figure 6.1). Clinical symptoms and MRI 
findings were consistent with Leigh syn­
drome (LS). Later, the girl developed dyski- 
netic movements and a respiratory alkalosis 
due to central hyperventilation, typical of LS. 
The disease gradually progressed with loss of 
skills and she died at the age of one year, due 
to respiratory failure.
Cell culture and biochemical analysis 
Skin fibroblasts were cultured in M199 me­
dium (Life Technologies) supplemented with 
10%  fetal calf serum and 1%  penicillin/strep­
tomycin in a humified atmosphere of 95% 
air and 5% CO2 at 37°C. Measurement of the 
mitochondrial respiratory-chain enzymes in 
skin fibroblasts collected at the age of nine 
months was performed as described previ­
ously [Smeitink 2001a; Janssen 2003]. The 
values were expressed relative to the activity 
of cytochrome c oxidase and/or citrate syn­
thase.
Homozygosity mapping 
Patient DNA was extracted from cultured skin 
fibroblasts by standard procedures [Miller 
1988] and was used for a genome scan with 
the ABI PRISM Linkage Mapping Set MD10.A. 
A total of 382 fluorescently labelled short tan­
dem repeat (STR) polymorphic markers with 
an average heterozygosity of 0.76 were used. 
The average distance of the genotyped mark­
ers was 10 cM.
Genetic analysis of the NDUFAF2 gene 
Intronic oligonucleotide primers were de­
signed according to public sequences (Gen­
bank accession number NM_174889.4) to 
flank the coding sequences and exon-intron 
junctions. Primer sequences are available on 
request. The exon fragments were amplified 
in a reaction volume of 25 |jl containing 100 
ng DNA template, 1 unit of Taq DNA poly­
merase (Invitrogen), 2.5 |jl of 10x PCR buffer,
2.0 mM MgCl2, 50 ng of forward and reverse 
primers, 0.25 mM dNTPs, and 0.75 |jl DMSO. 
After an initial denaturation step of 2 min at
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94°C, PCR parameters were 35 cycles for 45 
s denaturation at 94°C, 45 s annealing at Ta 
(58°C for exon 1 and 4, 53°C for exon 2 and 3), 
and 1 min extension at 72°C. The cycles were 
followed by a final extension step of 10 min 
at 72°C. The amplimers were run on a 1.5% 
agarose gel. The same oligonucleotides were 
used for direct sequencing with the BigDye 
terminator cycle sequencing chemistry on an 
Applied Biosystems ABI PRISM 3130xl Genetic 
Analyzer. The nucleotide numbering reflects 
cDNA numbering with +1 corresponding to 
the A of the ATG translation initiation codon 
in the reference sequence, according to jour­
nal guidelines (www.hgvs.org/mutnomen). 
The initiation codon is codon 1.
BN-PAGE analysis and in-gel activity assay 
Mitochondria-enriched fractions were ob­
tained by incubation with 2%  (w/v) digitonin 
(Calbiochem) on ice for 10 min, followed by 
centrifugation at 10,000 g and 4°C for 10 min 
and washing with PBS, twice. Blue native-gra­
dient gels (5%-15%) were cast as described 
previously [Nijtmans 2002] and run with 40 
or 80 |jg of the solubilised mitochondrial 
protein. After electrophoresis, the gels were 
further processed for in-gel activity assay or 
second-dimension 10% SDS-PAGE followed 
by immunoblot analysis as described by 
Nijtmans etal. [Nijtmans 2002].
SDS-PAGE analysis
Mitochondrial lysates were separated on a 
10% SDS-PAGE gel. Next, the proteins were 
transferred to PROTAN nitrocellulose mem­
brane (Schleicher & Schuell) for immunode­
tection.
Antibodies and ECL detection 
Protein immunodection was performed with 
primary monoclonal antibodies directed 
against NDUFA9 (Invitrogen), the CII 70 kDa 
subunit (SDHA; Invitrogen), and NDUFS3 
(Invitrogen), and primary polyclonal anti­
bodies directed against NDUFAF2 (a kind gift 
from Prof M. Tsuneoka, Kurume, Japan), and 
NDUFS2 (a kind gift from Prof B. Robinson, To­
ronto, Canada). Secondary antibodies used 
were peroxidase-conjugated anti-mouse or 
anti-rabbit IgGs (Invitrogen). The signal was 
generated with ECL Plus (Amersham Bio­
sciences).
Transduction of complex I-deficient fibroblasts 
with baculoviral constructs 
Baculoviral constructs containing the COX8 
leader sequence (first 210 basepairs of Gen­
bank accession number NM_004074.2) and 
the open-reading-frame sequence of NDUF- 
AF2 in front of AcGFP were created as de­
scribed previously [Hoefs 2008]. Subsequent­
ly, fibroblasts grown to ~50% confluence in 
175 cm2 tissue culture flasks (NUNC) were 
transduced with the appropriate baculovirus 
in a total volume of 25 ml M199 containing 
2.3 mM sodium butyrate (Sigma-Aldrich). Af­
ter 24 h at 37°C, the virus-containing medium 
was discarded and replaced with normal 
growth medium containing sodium butyrate. 
At three days after transduction, cells were 
harvested for gel electrophoresis. After SDS- 
PAGE analysis, the expression of the trans­
duced NDUFAF2-GFP and COX8-GFP was 
tested with a fluorescence scanner (FLA5100, 
FUJIFILM) to detect the GFP signal.
Table 6.1
OXPHOS enzyme activities in skin fibroblasts o f the index patient
Activity mU/U COX Control range Activity mU/U CS* Control range
Complex I 25 110 260 21 100 - 310
Complex II 767 536 - 1027 664 520 - 845
Complex III 1249 1270 2620 1082 1320 - 2610
Complex IV n.a. 866 680 - 1190
Complex V 410 209 935 n.d.
* The activity o f the reference enzyme was 224 mU/mg protein (control range 144 - 257 mU/mg protein). 
n.a. = not available, n.d. = not determined
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Results
Biochemical and molecular genetic studies 
Investigation of the activities of the enzyme 
complexes of the respiratory chain and of
Figure 6.2
The mutation in NDUFAF2 causes decreased expres­
sion and activity o f complex I and accumulation of 
subcomplexes in the patient fibroblasts.
(A) SDS-PAGE analysis and immunoblotting with an 
antibody directed against NDUFAF2 could not detect 
expression o f NDUFAF2 in the patient fibroblasts (first 
panel). BN-PAGE analysis followed by an in-gel activ­
ity assay demonstrates a severely reduced activity of 
complex I in the cells o f the index patient compared to 
the control (second panel). Immunoblotting with an 
antibody directed against NDUFA9 displays almost 
no expression o f this subunit, indicating a lower ex­
pression o f complex I (third panel). The expression of 
complex II is not affected (fourth panel).
(B) Immunoblots o f two-dimensional BN/SDS-PAGE 
show the accumulation o f subcomplexes 2 and 3 in 
the patient with the NDUFAF2 mutation. The sub­
complexes are numbered according to the model of 
complex I assembly proposed by Vogel et al. [Vogel 
2007a]. Other assembly intermediates, probably cor­
responding to 4 and 5, were also increased in the cells 
o f the patient compared to control cells. 
Abbreviations are as follows: C =  control, P-AF2 =  
patient with the mutation in NDUFAF2, NDUFAF2 =  
antibody directed against NDUFAF2, (CI)-IGA = in-gel 
activity o f complex I, (CI)-NDUFA9 = antibody direct­
ed against NDUFA9, (CII)-SDHA = antibody for SDHA 
to detect complex II, (CI)-NDUFS3 = antibody directed 
against NDUFS3, and (CI)-NDUFS2 = antibody direct­
ed against NDUFS2.
ATP synthase in cultured fibroblasts of the 
index patient displayed a marked decrease in 
complex I and a slight decrease in complex III 
to 21-23% and 82-98% of the lowest control 
value, respectively (table 6.1). We screened 
the NDUFS4 gene first since this gene is as­
sociated with a combined deficiency of 
complex I and III [Budde 2000] and excluded 
any disease-causing mutations. Because of 
consanguinity we performed homozygosity 
mapping to identify regions on the nuclear 
genome containing candidate genes and 
found two homozygous regions (>4 Mb). 
The size of the locus on chromosome 5 be­
tween the SNPs rs446155 and rs458362 was 
4.5 Mb. This locus contained the assembly 
factor NDUFAF2. Amplification of the four 
exons of this gene and sequence analysis of 
genomic DNA of the patient demonstrated 
the presence of a homozygous substitution 
of C to G (c.114C>G; p.Tyr38X). The mutation 
introduced an early stopcodon resulting in a 
truncated protein. Semi-quantitative RT-PCR 
for the NDUFAF2 transcript displayed similar 
amounts of NDUFAF2 mRNA in control and 
patients fibroblasts suggesting the patient 
NDUFAF2 transcript escapes NMD.
Effect of the NDUFAF2 mutation on complex I 
The effect of the mutation on the expression 
of NDUFAF2 and the expression and activ­
ity of complex I was examined by perform­
ing SDS-PAGE followed by Western blotting 
with an anti-NDUFAF2 antibody, BN-PAGE 
analysis followed by Western blotting with 
an anti-NDUFA9 antibody and in-gel activity 
measurement with mitochondria enriched 
fractions of cultured fibroblasts of the index 
patient. Patient cells did not express detect­
able amounts of NDUFAF2 (figure 6.2A). This 
figure furthermore shows that the activity of 
complex I in these cells was severely reduced 
compared to the control while also the pres­
ence of NDUFA9, indicative of the amount of 
fully assembled complex I, could hardly be 
demonstrated by immunodetection with an 
antibody directed against this subunit (figure 
6.2A). Together, these results demonstrate a 
severe decrease in the amount of complex I 
in the cultured skin fibroblasts of the index 
patient.
In another experiment we performed two-
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Figure 6.3
Baculoviral complementation restores the decreased 
expression and activity o f complex I caused by the 
mutation in NDUFAF2.
(A) SDS-PAGE analysis followed by a fluorescence 
scan o f the gel confirms the expression o f NDUFAF2- 
GFP and COX8-GFP (top panel). An in-gel activity as­
say shows that the activity o f complex I is the same 
in the untreated and treated control cells transduced 
with the baculoviruses (second panel). Patient fibro­
blasts transduced with the baculovirus containing 
NDUFAF2-GFP have a higher complex I activity com­
pared with untreated cells and cells transduced with 
the baculovirus containing COX8-GFP Fibroblasts o f 
the patient with a mutation in NDUFS7 show a slight, 
but not reproducible, increase in complex I activity 
upon treatment with the baculovirus with the COX8- 
GFP construct. Immunoblotting and incubation with 
an antibody directed against NDUFA9 gives almost 
similar expression levels o f NDUFA9 in the control 
fibroblasts. The expression in the untreated patient 
fibroblasts can be partly rescued by transducing the 
cells with the NDUFAF2-GFP baculovirus. The expres­
sion o f NDUFA9 is higher in the NDUFS7-mutated 
cells transduced with the COX8-GFP baculovirus. 
However, as mentioned above for the in-gel activity, 
this latter effect was not reproducible. In the last pan­
el, an antibody for complex II shows that the assembly 
o f this complex was not affected.
(B) Measurement o f the activity o f complex I by bio­
chemical analyses showed almost no difference 
between the untreated control cells and the control
dimensional BN/SDS-PAGE analysis followed 
by immunoblotting with antibodies directed 
against NDUFS3 and NDUFS2 to examine the 
assembly of complex I. Figure 6.2B demon­
strates increased amounts of subcomplexes 
in the fibroblasts of the patient compared to 
the control. Probably similar subcomplexes 
have been described by Vogel et al. depict­
ed as subcomplexes 2 and 3 [Vogel 2007a]. 
Other assembly intermediates, probably cor­
responding to the subcomplexes depicted 4 
and 5, were also increased in the cells of the 
patient. These results suggest that the muta­
tion in NDUFAF2 causes a disturbance in the 
assembly of complex I.
Complementation of the complex I deficiency 
by a baculovirus system expressing the NDUF- 
AF2 protein
To prove whether the Y38X mutation was in 
fact the disease-causing mutation, we trans­
duced control fibroblasts, fibroblasts of the 
index patient with the NDUFAF2 mutation 
and fibroblasts of an unrelated patient with a 
mutation in NDUFS7 (p.Val122Met) [Triepels
cells treated with the baculoviruses. The index patient 
fibroblasts treated with the baculovirus containing 
NDUFAF2-GFP displayed an increase in activity com­
pared to the untreated cells and the cells treated with 
the baculovirus containing COX8-GFP Treatment o f 
the cells with the NDUFS7 mutation did not affect 
complex I activity. Values are given as means ± stan­
dard deviation.
(C) Untreated control and index patient cells and con­
trol and index patients cells treated with the baculo­
virus containing NDUFAF2-GFP were used to perform 
two-dimensional BN/SDS-PAGE analysis. Immuno­
blotting with an antibody against NDUFS3 showed 
less complex I and the presence o f subcomplexes in 
the untreated index patient fibroblasts, compared 
to the control. These subcomplexes disappeared and 
the amount o f complex I was restored after treatment 
of the cells with the appropriate baculovirus. 
Abbreviations are as follows: C = control, P-AF2 = pa­
tient with the mutation in NDUFAF2, P-S7 = patient 
with a mutation in NDUFS7, Untr = untreated fibro­
blasts, AF2 = fibroblasts treated with the baculovirus 
containing the NDUFAF2 construct, COX8 = fibro­
blasts treated with the baculovirus containing the 
COX8 construct, (CI)-IGA = in-gel activity o f complex 
I, (CI)-NDUFA9 = antibody directed against NDUFA9, 
and (CII)-SDHA = antibody for SDHA to detect com­
plex II.
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1999] with a baculovirus containing either 
wild-type NDUFAF2 fused in frame with GFP 
or COX8-GFP as a control. SDS-PAGE analysis 
showed proper expression of the transduced 
NDUFAF2-GFP protein in all three cell lines 
(figure 6.3A). BN-PAGE analysis followed by 
in-gel activity measurement displayed simi­
lar activities for complex I in untreated con­
trol fibroblasts and control cells treated with 
baculoviruses containing either the NDUFAF2 
or COX8 construct, indicating that the baculo- 
viral transduction procedure did not hamper 
expression and activity of complex I (figure 
6.3A). In contrast, untreated fibroblasts of the 
index patient showed a very low complex I 
activity, which could be almost completely 
rescued by transducing the cells with the 
baculovirus containing the NDUFAF2 con­
struct, whereas fibroblasts of the patient with 
the NDUFS7 mutation showed no difference 
in untreated cells versus cells treated with 
this construct. Immunodetection with the 
NDUFA9 antibody showed a slight increase 
in the expression of complex I in control cells 
treated with the two different baculoviruses 
(figure 6.3A). However, the index patient fi­
broblasts displayed an obvious increase in 
the amount of complex I after treatment with 
the baculovirus containing the NDUFAF2-GFP 
construct compared with the untreated cells 
and cells treated with the baculovirus con­
taining COX8-GFP. Cells of the patient with a 
mutation in the NDUFS7 gene showed only 
an increase after treatment with the baculo­
virus with COX8-GFP. This increase was not 
the effect of the transduction conditions, 
since these were standard and the increase 
was not present in a second experiment (data 
not shown). To confirm these observations, 
we also measured the activity of complex I by 
biochemical analyses (figure 6.3B). The index 
patient fibroblasts showed a clear increase 
of complex I activity after transduction with 
the baculovirus containing the NDUFAF2 con­
struct. This was not observed in the control fi­
broblasts, and cells of the NDUFS7 patient. 
Furthermore, we used the untreated control 
and index patient cells and the control and in­
dex patient cells treated with the baculovirus 
containing NDUFAF2-GFP to perform two-di­
mensional BN/SDS-PAGE analysis. Figure 6.3C 
demonstrates less complex I and the pres­
ence of subcomplexes in the untreated index 
patient fibroblasts compared to the control. 
After treatment with the baculovirus, the sub­
complexes disappeared and the amount of 
complex I increased. This was not observed in 
the control fibroblasts. These results together 
show that the complex I deficiency in the pa­
tient fibroblasts could be complemented by a 
baculovirus system expressing NDUFAF2.
Discussion
In this report we describe a mutation in an 
assembly factor for complex I, NDUFAF2, in a 
patient with a complex I deficiency expressed 
in cultured fibroblasts. A mutation in the first 
exon of the NDUFAF2 gene resulted in a ho­
mozygous stop-codon, and subsequently, in 
a truncated protein of 37 instead of 169 ami­
no acids. With cell biological experiments we 
demonstrate a decrease in complex I amount 
and activity in the fibroblasts of the index pa­
tient, and a disturbed assembly of complex I. 
Most importantly, we show that transduction 
with a baculovirus containing the NDUFAF2 
gene specifically restored both the amount 
and activity of complex I. This proves that the 
mutation in NDUFAF2 is pathogenic and in 
this case the baculovirus system is an excel­
lent tool for complementation study. 
NDUFAF2 is an assembly factor which specifi­
cally associates with a large subassembly of 
830 kDa and is required until the late stages of 
assembly [Ogilvie 2005]. In addition, Lazarou 
and colleagues found that NDUFAF2 was also 
present in a high-molecular-weight complex 
that represents its association with complex III 
in the supercomplex (CI,/CIII2) [Lazarou 2007]. 
Our index patient shows a marked decrease 
in complex I activity and a slight decrease in 
complex III activity. This might be due to the 
alterations in the NDUFAF2 protein. The ho­
mozygous mutation causes absence of the 
NDUFAF2 protein and this may interfere in 
the formation of the supercomplex CI/CII^ 
leading to a combination of severely complex 
I and slightly complex III deficiency.
At present, six assembly factors (NDUFAF1, 
NDUFAF2, C6 orf66 , ECSIT, C8orf38, and 
C20orf7) are known to be involved in the bio­
genesis of complex I [Dunning 2007; Ogilvie
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2005; Saada 2008; Vogel 2007b; Pagliarini 
2008; Sugiana 2008]. Mutations have been 
described in the genes encoding these fac­
tors, except in the gene for ECSIT. However, 
these mutations explain only a small part 
of all hitherto unsolved complex I deficien­
cies, suggesting that more factors must be 
involved in the assembly of complex I. Re­
cently, Pagliarini and colleagues described 19 
proteins to be important for the function of 
complex I [Pagliarini 2008]. These candidate 
proteins need further investigation to elu­
cidate their specific role in the function and 
biogenesis of complex I. However, at present 
these genes are good candidate genes which 
should be screened to identify the genetic 
defect of mitochondrial complex I deficien­
cies in patients in whom this defect is not yet 
dissolved.
Besides above mentioned candidate genes 
for complex I also other genes may be in­
volved in the biogenesis of complex I. These 
candidate genes may encode new transcrip­
tion and translation factors for complex I, and 
genes encoding transfer RNA and ribosomal 
RNA.
Since the exact cause of the complex I de­
ficiency is still unknown in many patients, 
improved methods for diagnosing mito­
chondrial disorders are necessary. Mutations 
in the mitochondrial DNA can be identified 
using a mitochip [van Eijsden 2006] and in 
the future genomic microarray screening for 
nuclear mutations may be possible as well. 
Benit and colleagues show that genotyping 
microsatellite DNA markers at putative dis­
ease loci in consanguineous families helps to 
identify the disease-causing mutations [Benit 
2003b]. Therefore, homozygosity mapping is 
a method to preselect (new) candidate genes 
in consanguineous families. Identifying the 
genetic causes of complex I deficiency is 
important for prenatal diagnostics, genetic 
counseling and for more insight in the func­
tion of complex I.
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Abstract
Mitochondrial complex I deficiency is the 
most prevalent and least understood disor­
der of the oxidative phosphorylation system. 
The genetic cause of many cases of isolated 
complex I deficiency is unknown because of 
insufficient understanding of the complex I 
assembly process and the factors involved. 
We performed homozygosity mapping and 
gene sequencing to identify the genetic de­
fect in five complex I-deficient patients from 
three different families.All patientsharboured 
mutations in the NDUFAF3 (C3ORF60) gene, 
of which the pathogenic nature was assessed 
by NDUFAF3-GFP baculovirus complementa­
tion in fibroblasts. We found that NDUFAF3 is 
a genuine mitochondrial complex I assembly 
protein that interacts with complex I subunits. 
Furthermore, we show that NDUFAF3 tightly 
interacts with NDUFAF4 (C6 ORF66 ), a protein 
previously implicated in complex I deficiency. 
Additional gene observation analysis links 
NDUFAF3 to bacterial-membrane-insertion 
gene cluster SecF/SecD/YajC and to C8ORF38, 
also implicated in complex I deficiency. These 
data not only show that NDUFAF3 mutations 
cause complex I deficiency but also relate dif­
ferent complex I disease genes by the close 
cooperation of their encoded proteins during 
the assembly process.
Introduction
Disorders of the oxidative phosphorylation 
(OXPHOS) system have an incidence of ap­
proximately 1:5000 living births, frequently 
resulting in severe multisystem disease with 
a consequence of early childhood death 
[Smeitink 2006; Smeitink 2001b; Thorburn 
2004]. The molecular cause is improper func­
tion and/or assembly of one or more of the 
five multiprotein enzyme complexes of the 
OXPHOS system.
The most prevalent OXPHOS disorder is iso­
lated complex I deficiency (MIM 252010). So 
far, sequencing efforts have attributed about 
half of the cases to mutations in one of the 
seven mitochondrial and 38 nuclear genes 
that encode the structural components of 
complex I. Frequently, these mutations dis­
turb complex I assembly, and intricate 45- 
component puzzle [Vogel 2007c]. At present, 
we know that complex I assembly involves 
the formation of multiple assembly interme­
diates, presumably starting with several high­
ly conserved subunits (NDUFS2, NDUFS3, 
and NDUFS7) [Vogel 2007c; Antonicka 2003; 
Ugalde 2004; Lazarou 2007; Vogel 2007a; La­
zarou 2009]. This de novo assembly is most 
likely accompanied by subunit exchange to 
maintain complex I integrity [Lazarou 2007]. 
In addition, aided by recent developments 
in bioinformatics and genetics, the number 
of putative complex I assembly proteins has 
grown considerably. Five of these have been 
implicated in complex I deficiency (NDUFAF1, 
NDUFAF2, C6 ORF66 , C8ORF38, and C20ORF7) 
[Dunning 2007; Ogilvie 2005; Saada 2008; 
Pagliarini 2008; Sugiana 2008], and an addi­
tional three have been shown to be required 
for complex I assembly (Ecsit, AIF, and Ind1) 
[Vogel 2007b; Vahsen 2004; Bych 2008].
Most likely, many more non-structural pro­
teins required for proper complex I function, 
assembly, and stability await discovery. This is 
illustrated by the fact that only half of the cas­
es of isolated complex I deficiency can be ge­
netically explained [Smeitink 2006; Smeitink 
2001b; Thorburn 2004]. In a recent paper, Pag­
liarini and colleagues have used compara­
tive genomics to predict proteins involved 
in complex I biology and disease, ultimately 
verified by RNA interference for several can­
didates and the discovery of two complex 
I-deficient patients that harbor mutations in 
candidate gene C8ORF38 (MIM 612392) [Pag- 
liarini 2008]. One of the candidate genes 
picked up in this study is C3ORF60, hereafter 
referred to as NDUFAF3.
Here, we describe five complex I-deficient 
patients with mutations in the NDUFAF3 
gene, and we perform a detailed study of 
the requirement of the NDUFAF3 protein for 
complex I assembly. We show cooperation 
between NDUFAF3 and previously described 
chaperone NDUFAF4 (C6 ORF66 ) and reveal 
gene-order conservation with C8ORF38 and 
genes involved in the Sec membrane-inser­
tion machinery in bacteria. The discovery of 
cooperation between proteins encoded by 
different complex I disease genes is an im­
portant step forward in the understanding
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of the molecular basis of complex I assembly 
defects.
Subjects and Methods
Case reports
Family I consisted of consanguineous parents 
of Muslim origin and their five children. Their 
second (I-1), third (I-2), and fifth (I-3) children, 
two females and one male, were born at 34­
38 weeks of gestation, and their birth weights 
were 1490-2560 g. The three newborns pre­
sented similarly with severe lactic acidosis 
(peak level 27 mM, n < 2.2) at 1-3 days of life, 
which persisted and led their death at three 
months of age. Throughout their life, in­
creased muscle tone developed but physical 
examination was otherwise normal. Specifi­
cally, the patients followed moving objects, 
smiled socially, and had normal brain MRI, 
EEG, abdominal ultrasound, and echocardio­
gram results. Treatment with dichloroacetate, 
carnitine, thiamine, and CoQ10 did not affect 
the course of the disease.
The patient from the second family (II-1) was 
a male, the fifth child born to first cousins 
of Arab-Muslim origin. His parents and four 
older siblings were healthy. He was born at 
term and had a birth weight of 2900 g. At 
three weeks of age, he became hypoactive 
and sucked poorly. Physical examination re­
vealed macrocephaly (head circumference 
+3 SD), a weak cry, wide anterior fontanelle, 
and axial hypotonia. Generalized tonic move­
ments were intermittently seen, and fundo- 
scopy revealed bilateral pallor of the optic 
disc. Plasma lactate was 5.4 mM, and CSF 
lactate was 6 mM (n < 1.8). The EEG recording 
showed a burst suppression pattern. At three 
months of age, there was no eye contact and 
marked axial hypotonia with brisk tendon 
reflexes and a lack of sucking were observed. 
Breathing was irregular, and the patient was 
mechanically ventilated and fed via a naso­
gastric tube until his death at four months 
of age. Muscle biopsy was performed at two 
months of age.
The patient from the third family (III-1) was 
a daughter of unrelated parents of Jewish 
origin. She was admitted at three months of 
age because of myoclonic seizure disorder. A
brain MRI revealed diffuse brain leukomala- 
cia, and an abdominal ultrasound disclosed 
left hydroureter and hydronephrosis. Skin 
fibroblasts showed mitochondrial complex 
I deficiency. She had respiratory failure and 
was readmitted to the hospital two more 
times. She died at six months of age.
Enzyme measurements 
For enzymatic assays, mitochondria were 
isolated from muscle and fibroblasts as 
described [Saada 2003; Janssen 2007]. Mi­
tochondrial isolation and measurement 
of rotenone-sensitive NADH-ubiquinone 
reductase activity were performed as previ­
ously described [Saada 2003; Janssen 2007]. 
Complex I function was assessed by three 
assays: NADH-ferricyanide reductase, rote- 
none-sensitive NADH-ubiquinone reductase, 
and rotenone-sensitive NADH-cytochrome c 
reductase (complexes I and III). Activities were 
normalized to citrate synthase, a mitochon­
drial matrix enzyme [Saada 2004] (patients of 
families I and II), or to cytochrome c oxidase 
(patient III-1).
Homozygosity mapping and sequencing 
All experiments involving DNA of the pa­
tients, their relatives, healthy controls, and 
patient cells were approved by the institu­
tional review boards of the participating 
centers. Homozygosity mapping of DNA was 
performed with the Affymetrix Human Map­
ping 50K Array Xba240 for patients I-1 and
I-2 of family 1 and with the GeneChip Hu­
man Mapping 250K Nsp Array for family 2, as 
previously described [Edvardson 2007]. The 
NDUFAF3 gene was amplified from genomic 
DNA in five exons by PCR (primer sequences 
available upon request). For exon 1, all three 
alternative spliced exons were analyzed. Frag­
ments included both DNA sequences of the 
individual exons, the splice donor and splice 
acceptor sites. The amplimers thus obtained 
were subjected to DNA sequence analysis as 
described by Hoefs etal. [Hoefs 2008].
Modeling
Homology modeling was performed with the 
use of the NMR structure of Rpa2829 protein 
from Rhodopseudomonas palustris as a tem­
plate (Protein Data Bank [PDB] file 2FVT, 30%
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sequence identity). The mitochondrial target 
signal at the N terminus and the 11 C-terminal 
residues could not be modeled. A model of 
the aligned residues was built with the WHAT 
IF web server for modeling and with theWHAT 
IF and Yasara Twinset for model optimization 
and analysis [Krieger 2004]. Default param­
eters were used during the entire modeling 
and model-optimization procedures.
Complementation
We obtained the NDUFAF3 isoform A open 
reading frame (ORF) sequence (GI:41327780, 
without stop codon) flanked by Gateway 
ATTB sites (Invitrogen) by PCR and cloned this 
into pD0NR201 by using the Gateway BP Clo­
nase II enzyme mix (Invitrogen) to generate 
the pEntry vectors. GFP-tagged C0X8 leader 
was cloned as described previously [Hoefs 
2008]. These constructs were then used to 
make baculovirus and perform complemen­
tation as described previously [Hoefs 2008].
RNA interference
For transfection, HeLa cells were plated in 2 
ml of Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal calf 
serum (FCS) (without antibiotics) in 6-well 
plates with a cell density of 2.0 x 105 cells 
per well. The next day, cells were transfected 
with siRNA duplex in the presence of oligo- 
fectamine (7.5 |jl) (Invitrogen) and opti-MEM 
(Invitrogen), for a final concentration of 100 
nM siRNA in a total volume of 2.4 ml per well. 
Control was cyclophilin B (Dharmacon), NDUF- 
AF3 #1 antisense strand: 5'-AU GUAAGU- 
GAAGUCCCUCC dTdT-3', #2 antisense strand: 
5'-AGGAAGUUGAAGGUGGCAC dTdT-3'; 
NDUFAF4 #1 antisense strand: 5'- UGGAUA- 
GAGACUAAUCUGC dTdT-3', #2 antisense 
strand: 5'-AUCUUUGGAAUCAACAUAC dT- 
dT-3'. Cells were incubated at 37°C in a C02 
incubator for 48 hr, after which the cells were 
transferred to new wells. After 24 hr, these 
cells were transfected for a second time and 
incubated for 24 hr before further analysis.
Generation of inducible cell lines and cell cul­
ture
NDUFS3 (GI:4758787), NDUFAF3 
(GI:41327780), and NDUFAF4 (GI:215599255) 
ORF sequences (without stop codon) flanked
by Gateway AttB sites (Invitrogen) were 
created by PCR, in accordance with the 
manufacturer's instruction, and cloned into 
pD0NR201 with the use of Gateway BP Clo­
nase II enzyme mix (Invitrogen). Gateway 
tandem affinity purification (TAP) and green 
fluorescent protein (GFP) destination vec­
tors are available in our lab (previously de­
scribed in [Antonicka 2003]). For inducible 
NDUFS3-TAP and -GFP, NDUFAF3-TAP and 
-GFP, and NDUFAF4-TAP and -GFP vectors, the 
pD0NR201 vector containing NDUFS3, NDUF- 
AF3, and NDUFAF4 inserts was recombined 
with the TAP and GFP destination vectors via 
the Gateway LR Clonase II Enzyme Mix (Invi­
trogen). All constructs were transfected into 
Flp-In T-REx293 cells (Invitrogen) with Super- 
Fect Transfection Reagent (QIAGEN), in ac­
cordance with the manufacturer's protocols. 
HeLa and Human Embryonic Kidney (HEK) 
293 cells were cultured in DMEM (Biowhita- 
ker) supplemented with 10%  fetal calf serum 
(v/v) and 1%  penicillin and streptomycin (v/v) 
(GIBC0). The inducible cell lines were treated 
with 1 |jg/ml doxycycline (Sigma Aldrich) for 
24 hr for expression of the transgene. For the 
chloramphenicol-inhibition experiment, a 
final concentration of 50 ^g/ml of chloram­
phenicol (Sigma Aldrich) was added to the 
culture medium for 3 days. 0n the final day, 
1 |jg/ml doxycycline was added for 24 hr for 
induction of the transgenes before cell har­
vest. Patient skin fibroblasts were cultured in 
medium 199 supplemented with 10% fetal 
calf serum, bicarbonate, and antibiotics. The 
cells were cultured until confluency.
Localization studies
For confocal imaging, HEK293 cells express­
ing inducible NDUFAF3-GFP were cultured in 
a Wilco dish (Intracel, Royston, UK), washed 
with phosphate-buffered saline (PBS), and 
incubated with 1 |jM Mitotracker Red (Invi­
trogen) for 15 min and with 10 |jM Hoechst 
3342 (Invitrogen) for 30 min, both at 37°C. 
Before imaging, the culture medium was re­
placed by a colorless HEPESTris (HT) solution 
(132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 5.5 mM D-glucose, and 10 mM HEPES, 
pH 7.4) and fluorescence images were taken 
on a ZEISS LSM510 Meta confocal microscope 
(Carl Zeiss). Images were acquired at a rate
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of 10 Hz with the use of a x63 oil-immersion 
objective (N.A. 1.4; Carl Zeiss). Zoom factor 2 
and pinhole settings were selected for the at­
tainment of an optical section thickness of < 
1 um. Measurements were performed at 20°C 
in the dark. Confocal images of GFP and Mi- 
toTracker Red fluorescence were simultane­
ously collected with the use of an argon laser 
(laser power 1%) with a 488 nm dichroic mir­
ror and a 500-530 nm band-pass barrier filter 
in combination with a helium-neon (HeNe) 1 
laser (laser power 43%) with a 543 nm dichro­
ic mirror and a 560 nm long-pass filter. With 
the multitrack setting used, Hoechst fluores­
cence was subsequently imaged with the use 
of a 405 nm diode laser (laser power 10%) and 
a 420-480 band-pass barrier filter. Image pro­
cessing and analysis were performed with Im­
age Pro Plus 5.1 (Media Cybernetics, Bethes- 
da, MD, USA). For biochemical fractionation, 
HEK293 mitochondria were obtained by pot­
tering as described previously [Vogel 2005]. 
Mitochondria were sonicated on ice for 10 s at 
10% amplitude (Branson Digital Sonifier, type 
W-250D) in isotonic buffer (0.25 M sucrose, 5 
mM Tris-HCL, 0.2 mM EDTA, 1 mM PMSF, pro­
tease inhibitor mix [Amersham], pH 7.5), fol­
lowed by a 30 min spindown (10.000 g, 4°C) to 
pellet unbroken mitochondria. The superna­
tant was submitted to ultracentrifugation at
100,000 g for 1 hr. The resulting supernatant 
contains the nonmembrane proteins. The 
pellet was subsequently resuspended in car­
bonate buffer (0.1 M Na2C0 3, 1 mM PMSF, Pro­
tease Inhibitor Mix [Amersham], pH 11.5) for 
unfolding of the membrane structures and 
incubated for 30 min on ice. After a second 
round of ultracentrifugation at 100,000 g for 
1 hr, the supernatant containing peripheral 
membrane proteins was separated from the 
integral membrane fraction.
Blue-Native- and SDS-PAGE analysis and CI in­
gel activity assay
0 ne-dimensional 10%  sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and 5%-15% blue-native (BN)- 
PAGE was performed as described previously 
[Ugalde 2004; Nijtmans 2002]. Lanes were 
loaded with 40 (SDS analysis) or 80 (BN analy­
sis) ug of solubilized mitochondrial protein. 
After electrophoresis, gels were processed
further for in-gel complex I activity assay, in­
gel fluorescence detection, immunoblotting, 
or two-dimensional 10% SDS-PAGE as de­
scribed by Nijtmans et al. [Nijtmans 2002] For 
blotting, proteins were transferred to a PRO­
TAN nitrocellulose membrane (Schleicher & 
Schuell).
Antibodies and ECL detection 
Affinity-purified NDUFAF3 antibody was 
manufactured by Eurogentec with the use 
of two peptides: no. 1, APRRGHRLSPADDELY; 
no. 2, RQRGIAVEVQDTPNAC. The NDUFAF4 
antibody was kindly provided by H. Lorber- 
boum-Galski, Jerusalem, Israël. The GFP anti­
body was kindly provided by Frank van Kup­
peveld, Nijmegen, The Netherlands. Complex 
I subunit antibodies were NDUFS3 (Invitro­
gen), ND1 (a gift from Anne Lombes, Paris, 
France), NDUFS2 (a gift from Brian Robinson, 
Montreal, Canada), our NDUFA2 antibody,8 
NDUFA5, NDUFA9, and NDUFS3 (Invitrogen). 
Other antibodies used were raised against 
SDHA, Core II, COX5A, ATPase a (all Invitro­
gen), cytochrome c, and mtHSP70 (both Ab- 
cam). Secondary antibodies that were used 
are peroxidase-conjugated anti-mouse or 
anti-rabbit IgGs (Invitrogen). Signal was gen­
erated with ECL Plus (Amersham Biosciences) 
and exposed to X-ray film (Kodak).
Tandem affinity purification and FT-MS analysis 
Tandem affinity purification (TAP) was per­
formed according to the protocol for the In­
terPlay Mammalian TAP System (Stratagene). 
Proteins were eluted by incubation in 50 mM 
NH4HCO3 (pH 8.0) at 95°C for 5 min. Subse­
quent Fourier transform-mass spectrom­
etry (FT-MS) analysis was performed with a 
nano-HPLC Agilent 1100 nanoflow system 
connected to a linear quadrupole ion trap­
Fourier transform mass spectrometer (LTQ- 
FT, Thermo Electron). The eluate was applied 
to 10% SDS-PAGE for the removal of buffer 
components from the TAP procedure. Subse­
quently, the band containing the eluted pro­
teins was excised from the gel, and proteins 
were in-gel reduced with 10mM dithiotreitol 
and alkylated with 50 mM iodoacetamide 
before in-gel digestion with trypsin. Peptides 
were extracted from the gel and were puri­
fied and desalted with Stage tips [Rappsilber
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2003]. Peptide-identification experiments 
were performed with a nano-HPLC Agilent 
1100 nanoflow system connected online to 
a linear ion trap-Fourier transform (LTQ-FT) 
(Thermo Electron). Liquid chromatography 
(LC) and MS settings are further explained 
in table S7.1, available online. Peptides and 
proteins were identified with the use of the 
Mascot (Matrix Science) algorithm for search 
of a local version of the NCBInr database. 
First-ranked peptides were parsed from Mas­
cot database search html files with MSQuant 
for the generation of unique first-ranked pep­
tide lists.
Gene-order-conservation analysis 
To assess thegene-orderconservationamong 
bacteria, we used STRING [Jensen 2009] in 
the “protein mode" using as query the most 
similar bacterial protein to NDUFAF3: protein 
amb2521, from the alphaproteobacterium 
Magnetospirillum magneticum.
Results
Clinical and enzymatic data 
We identified five patients from three families 
that presented with a severe metabolic disor­
der. Shortly after birth, all affected children 
from family I presented with lactic acidemia. 
Besides the children's increased muscle tone, 
physical examination and radiological and 
electrophysiological studies were normal. 
Patient II-1 showed macrocephaly and severe 
muscle weakness and hypotonia as the most 
prominent clinical findings. Patient III-1 devel­
oped diffuse leukomalacia. Despite various
interventions and supplementation, all pa­
tients deteriorated and died at 2-6 months of 
age. Enzymatic analysis of OXPHOS function 
in fibroblast and muscle revealed a severe iso­
lated complex I deficiency in all investigated 
patients (table 7.1 and tables S7.2-S7.4).
Genetic analysis and modeling of NDUFAF3 
and the G77RandRI22Psubstitutions 
Multiple genomic stretches of successive 
homozygous SNPs, longer than 4 Mb, were 
present in the DNA of the patients from 
families 1 and 2. One of the regions shared 
in the patients of family 1 spanned 33.83 Mb 
(24.23-58.06 Mb, rs10510540-rs6445945) on 
chromosome 3. Patient II-1 of family 2 also 
had a large homozygous region on chromo­
some 3, spanning 26.6 Mb (45.98-72.59 Mb, 
rs3796376-rs11128275). The SNP haplotype 
was different for each family, excluding a 
common founder mutation. The genomic se­
quence of the four coding exons of NDUFAF3 
was determined. The three patients of family 
1 were homozygous for c.229G>C resulting in 
G77R, the parents and the second twin were 
heterozygous for the mutation, and the older 
healthy daughter was normally homozygous. 
Patient II-1 was homozygous for c.365G>C re­
sulting in R122P. His parents and two siblings 
were heterozygous for the mutation, and two 
other siblings were normally homozygous. 
Patient III-1 was compound heterozygous for 
two mutations: c.2T>C resulting in M1T and 
c.365G>C resulting in R122P. Three healthy 
children in the same family were heterozy­
gous for the c.365G>C mutation. Each of the 
described mutations was absent in at least 
210 ethnic control alleles. The M1T substitu­
Table 7.1
Complex I activities in patient fibroblast and muscle mitochondria
Patient Base change Amino acid change Fibroblast* Muscle*
Control 217 241
I-1 c.229 G>C G77R n.d. 23 (32%)
I-2 c.229 G>C G77R 16 (39%) 49 (40%)
I-3 c.229 G>C G77R n.d. n.d.
II-1 c.365 G>C R122P 5 (18%) 60 (26%)
III-1 c.2 T>C; c.365 G>C M1T; R122P 9 (33%) n.d.
* NADH:ubiquinone oxidoreducatase activity in nmol/min/mg (% control, normalized to citrate synthase).
84
Mutations in NDUFAF3 (C3ORF60) cause fatal neonatal mitochondrial disease
tion disrupts the start codon. An overview of 
the c.229G>C and c.365G>C mutations and 
evolutionary conservation of the substituted 
amino acids is shown in figures 7.1A and 7.1B, 
respectively.
A three-dimensional model of NDUFAF3 was 
made for a better understanding of the struc­
tural consequences of the mutations. A BLAST
search with the NDUFAF3 sequence against 
all proteins in the PDB resulted in a protein 
with unknown function (PDB code 2FVT) that 
shares 30% sequence identity over a stretch 
of 129 amino acids. This was used as a tem­
plate for modeling of the NDUFAF3 protein 
(figure 7.1C, positions of the mutations indi­
cated). The R122P mutation is located at the
c.229 G>C
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Figure 7.1
Genetic and molecular characterization o f the c.229G>C and c.365G>C mutations
(A) DNA samples o f (a) a patient from family 1, the c.229G>C mutation indicated by an arrow, (b) an obligate 
heterozygote from family 1, (c) a control, (d) a patient from family 2, the c.365G>C mutation indicated by an ar­
row, (e) an obligate heterozygote from family 2, and (f) a control.
(B) Conservation o f the altered amino acids is shown via clustalW alignments. Asterisks (*) indicate identical 
amino acids, colons (:) indicate conserved substitutions, and periods (.) indicate semiconserved substitutions.
(C) Model o f NDUFAF3 and the two mutations found in the patients. Middle panel: NDUFAF3 is shown in ribbon 
visualization and colored by secondary structure element (red = beta strand, blue = alpha helix, green = turn, 
cyan = coil). The positions o f the two mutations found in patients are indicated by the arrows and colored yellow. 
Side panels: the R122P and G77R mutations shown in more detail. The protein is gray. The side chains o f both the 
wild-type residue (green) and the mutant residue (red) are shown. Both mutations result in modifications at the 
same side o f the protein.
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C-terminal side of the protein and is predict­
ed to change the local structure of the loop, 
which might influence interactions or the 
stability of the protein. Gly77 is conserved be­
tween the 2FVT template and the NDUFAF3 
model and has backbone-torsion angles that 
are very unfavorable for other residue types 
(figure S7.2). The G77R mutation is therefore 
energetically unfavorable and likely to dis­
rupt the structure. The model of the NDUF- 
AF3 structure exposes a large hydrophobic 
domain of about 600 squared Angstroms 
(figure S7.3), which is commonly observed 
for protein-protein interactions [Jones 1996; 
Chakrabarti 2002]. The homology model and 
all modeling details are available online.
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Figure 7.2
Complementation o f the complex I deficiency in fibroblasts from patients I-2 and II-1
NI: not infected. Cox8: infected with GFP-tagged COX8 leader sequence. AF3: NDUFAF3-GFP infected.
(A) SDS-PAGE immunodetections o f GFP, NDUFS3, and NDUFA9.
(B) Complex I in-gel activity (CIIGA) and BN-PAGE immunodetections o f complex I (ND1), complex V (ATPase a), 
complexIII (core II), complex IV(COX5A), and complex II (SDHA).
(C) Enzymatic activities o f complexes I (assayed as NADH-ubiquinone reductase), II, and IV after normalization to 
citrate synthase activity and untreated control (source data in table S7.2).
(D) Two-dimensional BN-SDS immunodetections o f NDUFS2 and ND1 in control and patient II-1 fibroblasts, be­
fore and after complementation (Compl.).
(E and F) RNA interference-mediated knockdowns o f NDUFAF3 and NDUFAF4 in HeLa cells. N: not treated. M: 
mock transfected. #1, #2: targets 1 and 2. (E) SDS-PAGE immunodetection o f NDUFAF3, NDUFAF4, complex I sub­
units NDUFS3 and ND1, and control CII-70 kDa, after each knockdown.
(F) BN-PAGE analysis o f complex I in-gel activity (IGA) and immunodetection o f complex I subunit NDUFA9, com­
plex II-70 kDa, and complex III core II subunits.
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Requirement of NDUFAF3 for complex I assem- NDUFS3 and NDUFA9 were decreased (fig-
bly and activity
The specific complex I deficiency was con­
firmed by SDS- and BN-PAGE analysis for pa­
tient II-1 and patient I-2 fibroblasts (figures 
7.2A and 7.2B). Protein levels of subunits
ure 7.2A), and the amount and in-gel activity 
of complex I were severely impaired (figure 
7.2B, CI WB and CI IGA).
The fibroblast cell lines were complemented 
with the use of a NDUFAF3-GFP-expressing
Figure 7.3
Mitochondrial localization and high-molecular-weight associations o f NDUFAF3
(A) NDUFAF3-GFP, mitotracker, and Hoechst staining o f NDUFAF3-GFP-inducible HEK293 Flp-in cells a t different 
magnifications (a and b).
(B) SDS-PAGE immunodetection analysis after subcellular and mitochondrial fractionation o f HEK293 cells. Cyto: 
cytoplasm. Mito: mitochondria. After sonication o f purified mitochondria, the pellet (P) contains membrane 
structures and the supernatant (S) represents the soluble fraction. Carbonate extraction unfolds membrane 
structures, releasing peripherally associated proteins to the supernatant.
(C) Detection o f NDUFS3-GFP (S3-GFP) and NDUFAF3-GFP (AF3-GFP) in native protein complexes via fluorscan 
o f a 5%-15% BN-PAGE gel. Previously identified complex I intermediates are indicated as by Vogel et al [Vogel 
2007a].
(D) Two-dimensional BN- and SDS-PAGE immunodetection o f NDUFAF3 and complex I subunits NDUFS2, 
NDUFS3, and ND1.
(E) TAP identification o f binding partners o f NDUFAF3. SDS-PAGE immunodetections o f proteins after NDUFS3-, 
NDUFAF3-, and NDUFAF4-TAP purifications indicated on the left. L: lysate. E: eluate. "-": without doxycycline. "+": 
with 1 mg/ml doxycycline for 24 hr.
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baculovirus system. Figure 7.2A shows that 
the GFP-tagged COX8 leader (negative con­
trol) and NDUFAF3 proteins were present 
after infection and that the NDUFA9 protein 
level appears slightly increased after infection 
with NDUFAF3-GFP. BN analysis in figure 7.2B 
shows the restoration of complex I amount 
and activity, which could be confirmed by 
enzymatic assay (figure 7.2C and table S7.2). 
Two-dimensional BN- and SDS-PAGE immu­
nodetection (figure 7.2D) reveals no accumu­
lation of assembly intermediates for patient
II-1 as assayed for peripheral (NDUFS2)- and 
membrane (ND1)-arm subunits of complex
I. NDUFAF3-GFP baculovirus infection of 
a patient fibroblast cell line harboring the 
NDUFS7 (MIM 601825) V122M mutation [Trie- 
pels 1999] did not restore complex I amount 
and in-gel activity, further supporting the 
specificity of the NDUFAF3 complementation 
(figure S7.1).
To verify the requirement of NDUFAF3 for 
complex I assembly, we performed RNA in­
terference in HeLa cells, using two targets 
(figure 7.2E). In addition to the expected 
decrease of NDUFAF3 (figure 7.2E) and com­
plex I amount and activity (figure 7.2F) ob­
served, we observed a strong reduction of 
the NDUFAF4 protein (figure 7.2E). NDUFAF4 
(C6ORF66 ) is a previously described complex I 
assembly protein [Saada 2008]. To investigate 
a putative interdependence, we performed 
RNA interference for NDUFAF4, which also 
resulted in decrease in NDUFAF3 protein (fig­
ure 7.2E) and complex I amount and activity 
(figure 7.2F). As controls, complexes II and III 
remained unaffected by both knockdowns.
Mitochondrial localization and associations 
The human NDUFAF3 gene encodes two 
isoforms, A and B, which share a ''domain of 
unknown function" (DUF498). In addition, 
the longer A isoform harbors an in silico pre­
dicted N-terminal mitochondrial-targeting 
sequence of about 35 amino acids (Mitopro- 
tII, TargetP, and Predotar). Sequence data of 
the human NDUFAF3 variants and interspe­
cies homology of the A isoform are summa­
rized in table S7.5. To verify the predicted 
mitochondrial targeting of isoform A, we per­
formed confocal microscopy for analysis of 
GFP-tagged NDUFAF3 isoform A (figure 7.3A)
and subcellular fractionation experiments for 
analysis of the wild-type protein (figure 7.3B). 
Both analyses demonstrate that NDUFAF3 is 
predominantly (if not exclusively) localized 
to the mitochondrion. In the submitochon­
drial fractionation (figure 7.3B), NDUFAF3 
remained in the pellet after carbonate extrac­
tion. This suggests a strong interaction with 
the mitochondrial membrane, although this 
protein has no predicted transmembrane he­
lices. The localization appeared identical to 
that of the NDUFAF4 protein. As controls, in­
tegral membrane protein ND1 also remained 
in the pellet, whereas cytochrome c and com­
plex I subunit NDUFS3 did not. MtHSP70 and 
NDUFS2 display partial membrane associa­
tion.
The NDUFAF3 protein accurately comigrates 
with previously described complex I assem­
bly intermediates 3, 4, and 5 [Vogel 2007a] 
(figure 7.3C for NDUFAF3-GFP, figure 7.3D 
for endogenous NDUFAF3). In addition, 
multiple bands are observed at the approxi­
mate size of intermediate 6 (figure 7.3C). The 
same comigration is observed for NDUFAF4 
(figure 7.4C). To investigate putative interac­
tions between NDUFAF3 and NDUFAF4, we 
constructed stable HEK293 Trex Flp-in clones 
containing TAP-tagged NDUFS3-, NDUFAF3-, 
and NDUFAF4-inducible constructs. Each 
protein was purified after 24 hr of expression. 
TAP of NDUFS3, NDUFAF3, and NDUFAF4 re­
sulted in copurification of all three proteins, 
plus NDUFS2 (figure 7.3E). Subunits NDUFA9, 
ND1, and NDUFA2 were not detected in the 
eluates, suggesting that NDUFAF3 and NDUF- 
AF4 predominantly interact with complex I 
core subunits NDUFS2 and NDUFS3. To de­
tect additional proteins, we analyzed the 
eluates by mass spectrometry (table S7.6). In 
addition to the copurification observed for 
NDUFS2, NDUFS3, NDUFAF3, and NDUFAF4, 
this analysis revealed the copurification of 
NDUFA5 and NDUFS8 .
Role of NDUFAF3 in complex I assembly 
Inhibition of mitochondrial translation dis­
turbs complex I assembly because the mito­
chondrial DNA-encoded ND subunits of com­
plex I are no longer formed and incorporated. 
Such inhibition can be achieved by culturing 
cells in the presence of chloramphenicol for
88
Mutations in NDUFAF3 (C3ORF60) cause fatal neonatal mitochondrial disease
Figure 7.4.
Inhibition o f translation and proposed role o f NDUFAF3 during complex I assembly
HEK293 cells were induced for NDUFS3-, NDUFAF3-, and NDUFAF4-GFP expression with and without prior 
chloramphenicol treatment (± CAP) for 3 days.
(A) Complex I in-gel activity (CI-IGA) assay.
(B) SDS-PAGE fluorscan for GFP-tagged protein.
(C) BN-PAGE immunodetection with antibody to GFP. Previously described NDUFS3-containing intermediates 
are indicated on the left as by Vogel et al. [Vogel 2007a] M: monomer. Accumulation is indicated with arrows, 
referring to subcomplexes o f NDUFAF3 (AF3) and o f NDUFAF4 (AF4).
(D) The conserved gene cluster in alphaproteobacteria that links orthologs o f NDUFAF3 to the bacterial prepro­
tein translocase complex SecD/SecF/YajC, involved in targeting proteins to the membrane, and to CrtB, a phy- 
toene/squalene synthetase o f which the human ortholog C8ORF38 has been implicated in complex I assembly 
[Pagliarini 2008]. Green: proteins only observed in bacteria. Red: proteins observed in eukaryotes and bacteria.
(E) Tentative model for the role o f NDUFAF3 and NDUFAF4 during early complex I assembly. Subcomplex 2 is 
loosely associated to the mitochondrial inner membrane, as demonstrated by Dieteren et al. [Dieteren 2008], 
by an unknown factor (X). NDUFAF3 and NDUFAF4 are codependent, membrane localized, and present in sub­
complex 3, which contains at least subunits NDUFS2 and NDUFS3, and possibly NDUFS8 and NDUFA5. This 
complex requires mitochondrial translation for progression to higher-molecular-weight subcomplexes. Without 
mitochondrial translation, NDUFAF3 no longer associates with subcomplex3 and the complex, with NDUFAF4, 
accumulates. With mitochondrial translation, both proteins are present until subcomplex 6, close to finalization 
o f holo-complex I. It is yet unknown which factors aid membrane insertion o f mitochondrial translation products 
(indicated with Y). AF3: NDUFAF3. AF4: NDUFAF4. S3: subcomplex 3. Xand Y: unknown factors. ND: ND subunits. 
Green structure: mitochondrial ribosome.
89
Chapter 7
>24 hr, which typically results in accumulation 
of NDUFS3-containing assembly intermedi­
ates 2 and 3 (see Vogel et al. [Vogel 2007a] 
and figure 7.4C, NDUFS3-GFP + CAP). Given 
the tight relation among NDUFS3, NDUFAF3, 
and NDUFAF4, the effect of such inhibition 
on the incorporation of GFP-tagged NDUF- 
AF3 and NDUFAF4 was investigated. Upon 
inhibition, complex I in-gel activity was de­
creased (figure 7.4A), whereas the amount of 
GFP-tagged NDUFAF3 and NDUFAF4 protein 
remained similar (figure 7.4B). Nevertheless, 
inhibition resulted in disturbed incorpora­
tion of NDUFAF3 (figure 7.4C) and in accu­
mulation of NDUFAF4 in a complex similar to 
subcomplex 3 (figure 7.4C, arrow).
To obtain additional clues about the func­
tion of NDUFAF3, we performed gene-order- 
conservation analysis. Complex I has been 
lost six times in the evolution of the cur­
rently sequenced eukaryotic genomes [Bych
2008]. Profile-based homology searches 
with PSI-Blast confirm the observation that 
NDUFAF3 has also been lost from these lin­
eages [Pagliarini 2008] and is present in the 
complex I-containing lineages, supporting 
an interaction with complex I. We examined 
whether the bacterial orthologs of NDUFAF3 
show gene-order conservation in the alpha- 
proteobacterial ancestors of the mitochon­
dria, a reliable indicator of protein interac­
tion [Huynen 2000]. We detected significant 
gene-order conservation with the Squalene/ 
phytoene synthase (CrtB) ortholog (COG1562, 
C8ORF38) (figure 7.4D) that has been impli­
cated in complex I assembly in man [Pagliar- 
ini 2008], supporting the role for NDUFAF3 in 
complex I assembly. Furthermore, we detect­
ed significant gene-order conservation with 
the SecF/SecD/YajC gene cluster. The gene 
cluster of NDUFAF3 with SecD/SecF/YajC is 
conserved among 20 genera in the current 
version of STRING. In bacteria, proteins of this 
cluster are located in the inner membrane, 
where they are involved in membrane-pro­
tein insertion and interact with YidC [Nou- 
wen 2002 ], the bacterial ancestor of the mito­
chondrial membrane protein OXA1. The link 
with CrtB is a bit less conserved, occurring in 
13 genera, but still significant (likelihood of 
interaction SecD - NDUFAF3 = 0.8, likelihood 
of interaction CrtB - NDUFAF3 = 0.5).
Discussion
We describe five patients with a severe com­
plex I deficiency presenting with lactic aci­
demia soon after birth. All children died be­
fore the age of six months. The deficiencies 
were caused by three different mutations in 
the NDUFAF3 gene. We show that NDUFAF3 
is essential for human complex I assembly, in 
line with its predicted function based on cor­
related genomic occurrence with complex I 
proteins [Pagliarini 2008].
With NDUFAF3, the sixth assembly protein 
implicated in complex I deficiency [Dunning 
2007; Ogilvie 2005; Saada 2008; Pagliarini 
2008; Sugiana 2008], we show cooperation 
of multiple assembly chaperones in similar 
assembly steps of complex I. The interac­
tion among NDUFAF3, NDUFAF4, NDUFS2, 
NDUFS3, and, most likely, subunits NDUFS8 
and NDUFA5 shows that NDUFAF3 and NDUF- 
AF4 are bound to similar complex I substruc­
tures. In addition, NDUFAF3 and NDUFAF4 
colocalize in the mitochondrial innermem­
brane, comigrate in at least three previously 
described assembly intermediates, and are 
codependent, as shown by RNA interference. 
Taken altogether, these data show that NDUF- 
AF3 and NDUFAF4 cooperate from early to 
late stages of complex I assembly in associa­
tion with at least the highly conserved sub­
units NDUFS2, NDUFS3, and NDUFS8 , and 
accessory subunit NDUFA5 until step 6 in our 
assembly scheme [Vogel 2007a].
The NDUFAF3-NDUFAF4 interaction provides 
insights into the mechanism of early complex 
I assembly. The requirement of mitochondrial 
translation for NDUFAF3 to occur in high-mo- 
lecular-weight associations supports a func­
tion related to mitochondrial translation or 
steps thereafter, such as early assembly of the 
mitochondrial DNA-encoded ND subunits 
of complex I. In contrast, the same inhibition 
causes NDUFAF4 to accumulate in a small 
nuclear-DNA-encoded intermediate similar 
to that observed for NDUFS3 [Vogel 2007a]. 
One explanation for the combined results is 
that NDUFAF4, bound to NDUFAF3, recruits a 
nuclear-DNA-encoded early assembly inter­
mediate that contains at least NDUFS2 and 
NDUFS3 at the mitochondrial inner mem­
brane (figure 7.4E). Without mitochondrial
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translation, NDUFAF3 can no longer efficient­
ly associate to subcomplex 3, and an interme­
diate that consists of NDUFAF4 and at least 
NDUFS2 and NDUFS3 accumulates.
The predicted interaction of the ancestors of 
NDUFAF3 with the Sec membrane-translo­
cation machinery in alpha-proteobacteria is 
exciting, because a Sec-like translocase has 
not yet been demonstrated for the mam­
malian OXPHOS system. It supports a role for 
NDUFAF3 in coupling mitochondrial transla­
tion to membrane insertion during assembly. 
In addition, the gene-order-conservation 
analysis links NDUFAF3 to C8ORF38, another 
assembly chaperone implicated in complex I 
deficiency [Pagliarini 2008].
In conclusion, we show that mutations in 
NDUFAF3 cause complex I deficiency. Fur­
thermore, characterization of NDUFAF3 dem­
onstrates its role as a NDUFAF4-interacting 
complex I assembly protein and highlights 
a translation- dependent early assembly 
mechanism. Discovery of the involvement 
of multiple, disease-implicated chaperones 
in similar assembly stages constitutes an im­
portant step forward in the understanding 
of the molecular basis of complex I assembly 
defects.
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Chapter 8
Isolated complex I deficiency is the most fre­
quently encountered defect of the OXPHOS 
system in children with a mitochondrial dis­
order [Smeitink 2001b]. Although adults with 
a complex I deficiency have been described, 
in general the first clinical symptoms of the 
disease start soon after birth or in early child­
hood. Complex I deficiencies may affect one 
or more tissues, especially the ones with 
high-energy requirement. As a consequence, 
complex I deficiency has a wide clinical va­
riety. Clinical phenotypes include Leigh or 
Leigh-like syndrome, cardiomyopathy, en­
cephalopathy, leukodystrophy, and liver fail­
ure [Loeffen 2000; Distelmaier 2009a]. There 
is no cure for complex I deficiency in humans 
available yet. Symptomatic therapy can be 
offered, which needs a multi-disciplinary ap­
proach for each individual patient, because of 
the involvement of multiple organs, variable 
expression and chronic progressive course of 
a mitochondrial disorder [Finsterer 2010].
The diagnosis of complex I is performed 
by biochemical measurements, based on 
estimation of the mitochondrial rotenone- 
sensitive NADH:ubiquinone oxidoreductase 
activities [Fischer 1985; Smeitink 2001a; 
Janssen 2003]. These measurements are per­
formed in mitochondria-enriched fractions 
obtained from muscle tissue, skin fibroblasts, 
or other clinically relevant tissues [Roden­
burg 2010]. After establishing the complex I 
deficiency, mutational analysis is performed 
to elucidate the genetic cause. At present, for 
approximately 50% of the patients the dis­
ease-causing mutation is known [Thorburn 
2004; also own experience, data not shown]. 
Identifying the genetic cause is important for 
genetic counselling and prenatal diagnosis. 
Knowing the nuclear pathogenic mutation 
makes a specific and accurate prenatal diag­
nosis possible. Otherwise, the diagnosis de­
pends on measuring the enzyme activities of 
the OXPHOS system in native chorionic villi. 
However, this method of prenatal diagnosis 
is applicable to only a subgroup of complex 
I deficiencies [Niers 2001]. Therefore, studies 
identifying new genetic defects in patients 
with complex I deficiency are important.
To identify new disease-causing mutations 
we selected a group of 34 patients with a 
complex I deficiency expressed in cultured
fibroblasts and if measurements were per­
formed also in muscle tissue. The age of on­
set of clinical symptoms was below 10 years. 
Patients with a (severe) complex I deficiency, 
combined with a mildly reduced complex III 
deficiency were also included in the research 
group. The formation of supercomplexes in 
which complex I and III occur together (CI/ 
CIII2) may cause the combined deficiency 
[Lazarou 2007]. Furthermore, mutations have 
previously been described in genes encod­
ing subunits and an assembly factor of com­
plex I in patients with a deficiency in complex 
I combined with a reduction in the activity of 
complex III [Budde 2000; Hoefs 2010; Hoefs 
2009; Hoefs 2011].
We started to screen the entire mtDNA in 
affected tissue and found mutations in five 
patients (table 8.1 and chapter 2). One in the 
ND1 gene, one in the ND3 gene and three in 
the ND6 gene. Previous studies described 
these mutations as being pathogenic [Kirby 
2004a; Taylor 2001; Ugalde 2003]. For the 
remaining group of the patients (85%) the 
pathogenic mutation should be found in a 
nuclear encoded gene. This is in agreement 
with earlier studies, describing that most 
patients with a OXPHOS defect caused by a 
mtDNA mutation became symptomatic at an 
older age. These patients also show a greater 
variability in the clinical course and severity 
[Rubio-Gozalbo 2000; Shoffner 1996].
After screening the mtDNA we started to 
screen all 38 nuclear encoded subunits of 
complex I, starting with the ones in which 
mutations had been described before. In 
three unrelated patients we observed patho­
genic mutations in the NDUFS1 gene (chap­
ter 3). NDUFS1 belongs to the core subunits 
and is the largest subunit of complex I. The 
complex I activity in the fibroblasts of these 
three patients was very low (<30% of the low­
est control value). This low residual enzyme 
activity may be used as a pre selection, since 
more than 70 candidate genes are known at 
present, although also other gene defects 
may lead to very low activities. Therefore, 
screening of the NDUFS1 gene is preferred 
when patients' fibroblasts show a very low 
residual complex I activity.
In our study we also observed mutations in 
genes encoding complex I subunits in which
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no mutations have been described before. 
The first gene is NDUFA2, encoding one of 
the accessory subunits (chapter 4). Pathoge­
nicity of this splice-site mutation in a patient 
with Leigh disease has been confirmed by 
using a baculovirus expression system con­
taining the wild-type NDUFA2 gene. Trans­
duction with this baculoviral vector restored 
the amount and activity of complex I in the 
fibroblasts of the patient. Also the mitochon­
drial membrane potential has been restored. 
In this case the baculovirus system is an excel­
lent tool for complementation study to prove 
the pathogenic nature of the mutation. At 
present, not much is known about the role of 
accessory subunits. Finding disease-causing 
mutations in these genes indicate that at 
least some are important for proper function 
of complex I.
In another patient with Leigh disease we 
observed two compound heterozygous 
mutations in the NDUFA10 gene which also 
encodes an accessory complex I subunit 
(chapter 5). Because NDUFA10 can be phos- 
phorylated, it might be involved in the control 
of the complex I activity through binding of 
NADH [Yamaguchi 2000; Chen 2004]. In addi­
tion, it has been suggested that this subunit is
weakly associated with complex I [Finel 1992; 
Sazanov 2000]. Therefore, the phosphoryla­
tion might influence the binding affinity of 
NDUFA10 and regulate the amount of fully 
active complex. These two studies show the 
importance of screening the accessory sub­
units as well.
For the remaining group of patients, we 
screened the genes encoding assembly fac­
tors of complex I, starting with the ones in 
which mutations had been described before. 
In one patient we observed a new nonsense 
mutation in the first exon of NDUFAF2 (chap­
ter 6 ). The fibroblasts of the patient displayed 
a decrease in complex I amount and activity 
and a disturbed assembly of complex I, which 
could be restored after transduction with a 
baculovirus containing the NDUFAF2 gene. 
Also other studies described pathogenic mu­
tations in NDUFAF2, which makes this gene a 
good candidate to screen in complex I defi­
ciencies [Ogilvie 2005; Barghuti 2008; Jans­
sen 2009; Herzer 2010].
In one patient of our research cohort we 
identified two compound heterozygous mu­
tations in a gene encoding a new complex I 
assembly factor NDUFAF3 (chapter 7). This 
factor interacts with assembly protein NDUF-
Table 8.1
Observed mutations in the research cohort o f 34 patients with complex I deficiency
Disease-causing gene Mutation on DNA level Functional consequences Reference
ND1 m.3697G>A p.Gly131Ser -
NDB m.10191T>C p.Ser45Pro -
ND6 m.14487T>C p.Met63Val -
ND6 m.14487T>C p.Met63Val -
ND6 m.14487T>C p.Met63Val -
NDUFS1 c.1222C>T p.Arg408Cys [Hoefs 2G1G]
NDUFS1 c.1669C>T; c.1855G>A p.Arg557X; p.Asp619Asn [Hoefs 2G1G]
NDUFS1 c.631-633delGAA; c.683T>C p.211delGlu; p.Val228Ala [Hoefs 2G1G]
NDUFA2 c.208+5G>A unknown [Hoefs 2GG8]
NDUFA1G c.1A>G; c.425A>G p.Met1?; p.Gln142Arg [Hoefs 2G11]
NDUFAF2 c.114C>G p.Tyr38X [Hoefs 2GG9]
NDUFAFB c.2T>C; c.365G>C p.Met1?; p.Arg122Pro [Saada 2GG9]
ACAD9 c.1553G>A p.Arg518His [Nouws 2G1G]
ACAD9 c.187G>T; c.1237G>A p.Glu63X; p.Glu413Lys [Nouws 2G1G]
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AF4, and together they cooperate from early 
to late stages of complex I assembly. The 
pathogenic nature of the NDUFAF3 mutations 
has been established by NDUFAF3 baculovi­
rus complementation in fibroblasts.
Finally, we observed in two patients disease- 
causing mutations in a new complex I assem­
bly factor, ACAD9, described by Nouws et al. 
[Nouws 2010]. Previously, this protein has 
been described to be involved in fatty acid 
oxidation [He 2007]. However, Nouws et al. 
showed that ACAD9 is specifically required 
for complex I assembly. Taken altogether, we 
identified the underlying genetic defect of 
the complex I deficiencies in fourteen of the 
34 patients (accounting for 41 %). The observed 
mutations are summarized in table 8.1. 
However, after screening all complex I sub­
units and assembly factors, for 59% of our pa­
tient group the genetic defect has not been 
elucidated yet. To identify the disease-caus­
ing mutation other candidate genes should 
be screened. Pagliarini et al. described such 
candidate genes using phylogenetic profil­
ing, a technique which uses shared evolu­
tionary history to highlight functionally relat­
ed proteins [Pagliarini 2008; Pellegrini 1999]. 
Some of the genes encoding those proteins 
have already been screened, the others are 
new candidates to screen. Recently, a new 
complex I assembly factor has been discov­
ered by using the known assembly factors 
NDUFAF1 and Ecsit in coprecipitation experi­
ments [Nouws 2010]. ACAD9 copurified with 
these proteins, which has been confirmed by 
mitochondrial membrane fractionations and 
colocalization of ACAD9 with assembly inter­
mediates. This tandem affinity purification is 
an excellent method to identify new putative 
assembly factors. More proteins involved in 
the assembly are probably required, as sug­
gested by the more than 20 factors necessary 
for the assembly of the smaller complex IV. 
These novel genes encoding putative assem­
bly factors for complex I are good candidates 
to screen in the future.
Other proteins for example involved in ex­
pression, targeting, and mitochondrial im­
port of nuclear encoded proteins might 
be important for complex I function and 
therefore candidates to screen. Also genes 
encoding proteins involved in transcription,
translation, and post-translational modifica­
tion could be screened for the presence of 
disease-causing mutations responsible for 
human complex I deficiency. Finally, proteins 
involved in the correct synthesis and assem­
bly of FeS clusters and the FMN biogenesis 
might be important for proper functioning 
of complex I and thus good candidates to 
screen for complex I deficiency.
Future perspectives
Identifying new genes encoding proteins in­
volved in complex I biogenesis is challenging 
and requires new technologies, since screen­
ing genes one by one using the conven­
tional approach of polymerase chain reac­
tion followed by DNA or Sanger sequencing 
is expensive and time-consuming. With an 
already existing technique, homozygosity 
mapping, the chromosomal region carrying 
the genetic defect, may be identified. This is a 
good method for consanguineous families to 
select candidate genes responsible for com­
plex I deficiency. However, there are not so 
many consanguineous families in Northern 
Europe. Therefore, next generation sequenc­
ing methods form a better strategy. Whole 
genome sequencing could be performed, 
identifying numerous variations. An alterna­
tive for this is exome sequencing, a technique 
using targeted sequencing of all protein- 
coding regions. For both methods, extensive 
bioinformatical analysis of all genetic variants 
that were identified is necessary. Finally, this 
will reveal a couple of variations which could 
possibly be pathogenic. To confirm this, a de­
tailed functional analysis of these variations 
might be necessary. The use of next genera­
tion sequence analysis for mitochondrial dis­
orders has been shown by Vasta et al. [Vasta
2009]. Another approach, used by Calvo et al. 
is high-throughput pooled sequencing [Calvo
2010]. DNA pools from approximately 20 in­
dividuals including healthy controls, patients 
with known genetic defects and patients for 
unknown genetic cause were created. Target 
regions were selected and sequenced to high 
depth, resulting in new variants in each pool. 
Genotyping resulted in newly discovered 
variants and pathogenic mutations which
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have been described before. Using molecu­
lar approaches including cDNA rescue in fi­
broblasts confirmed the pathogenic nature 
of prioritized variants. In the future, all these 
new technologies will make a better diagno­
sis and genetic counselling for complex I defi­
ciency patients possible.
The next generation sequencing techniques 
are promising high throughput technologies 
for identifying the cause of the genetic het­
erogeneous mitochondrial complex I defi­
ciencies. With these methods, new assembly 
factors or other proteins involved in the bio­
genesis of complex I may be found. However, 
the other way around, finding new assembly 
factors which can serve as good candidate 
genes to screen in complex I deficiency is also 
important. Furthermore, identifying the role 
of the different accessory subunits may give 
more insight in the functioning of complex I. 
These subunits may have connections with 
other pathways, which may result in new can­
didate genes.
At present, no cure for mitochondrial disor­
ders is available, and only symptomatic treat­
ment can be offered. Only a few clinical trials 
investigating the effect of different supple­
ments have been performed. These studies 
with compounds like creatine in combination 
with antioxidants (a combination of vitamins 
or cofactors such as ubiquinone, riboflavin, 
lipoic acid, thiamine, and vitamin E and K) 
showed variable results. Pan-European initia­
tives with respect to patient-registries and 
the development of prognostic scores are 
executed to elucidate the effect of potential 
new treatment.
Besides the symptomatic therapy, new 
causal treatment strategies are in a prelimi­
nary experimental phase [Koene 2009]. One 
approach is prevention of disease transmis­
sion from mother to child, which may be per­
formed for both mtDNA and nDNA mutations. 
This includes oocyte donation, mutation 
analysis in amniocytes or chorionic villi, and 
preimplantation genetic diagnostics. Tachi- 
bana et al. demonstrated that the mtDNA can 
be efficiently replaced in mature oocytes of 
Macaca mulatta by spindle-chromosomal 
complex transfer from one egg to an enucle­
ated, mitochondrial replete-egg. This may 
be a method to prevent the transmission of
mtDNA mutations [Tachibana 2009].
Another strategy is gene therapy, including 
rescue of a defect by expression of an engi­
neered gene from the nucleus (allotopic or 
xenotopic expression), import of wild type 
mtDNA into the mitochondrion, and gene 
shifting, that is manipulation of the mtDNA 
heteroplasmy [Finsterer 2010; Kyriakouli 
2008]. Recently, Maas et al. showed in the 
fungal model Podospora anserina that over­
expression of the alternative NADH dehydro­
genase NDI1, a paralogue of human AIF, can 
fully restore physiological consequences of 
complex I deficiency [Maas 2010].
Patients with a mitochondrial disorder fre­
quently suffer from exercise intolerance due 
to their impaired oxidative capacity and phys­
ical deconditioning. Exercise therapy may be 
useful because this training might increase 
the maximal oxygen uptake, endurance per­
formance, walking distance, and peripheral 
muscle strength [Cejudo 2005]. Furthermore, 
metabolic manipulation may be used as new 
treatment strategy. This method uses dietary 
modification or small molecule therapy to for 
example prevent oxygen damage by scav­
enging enzymes [Koene 2009]. However, all 
described possible new treatment therapies 
are preliminary and need further investiga­
tion. Mouse models for complex I deficiency 
may be useful to test these future treatment 
strategies [Koene 2010].
In conclusion, progress in elucidating the ge­
netic defect causing mitochondrial complex 
I deficiencies is essential for a better genetic 
counselling, prenatal diagnostic possibilities 
and further development of new treatment 
strategies to cure these complex I deficien­
cies in the future. With the help of the emerg­
ing high through-put genomics technologies 
like whole exome sequencing we expect the 
discovery of numerous novel disease-caus­
ing genes for human complex I deficiency in 
due time.
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Summary
The five multi-protein assemblies of the oxi­
dative phosphorylation (OXPHOS) system, lo­
cated in the mitochondrial inner membrane, 
form the final step in the oxidative energy 
production (in the form of ATP) in the cell. 
Electrons from NADH and succinate are trans­
ported from complex to complex to the final 
acceptor molecular oxygen. Energy released 
with this transport is used to generate a pro­
ton gradient across the mitochondrial inner 
membrane, which can be used as a driving 
force by complex V to produce ATP.
Defects in the OXPHOS system belong to 
the most frequent inborn errors of metabo­
lism and lead to a group of heterogeneous 
pathologies affecting different organs and 
tissues. Of these complexes, complex I is the 
most frequently affected and disease presen­
tation of isolated complex I deficiency often 
starts at birth or early childhood with mostly 
a fatal outcome. Complex I is the largest 
complex of the OXPHOS system and biogen­
esis is under dual genetic control. Therefore, 
disease-causing mutations can be observed 
in either the mitochondrial DNA (mtDNA) 
or the nuclear DNA (nDNA) encoding struc­
tural subunits of complex I, assembly factors 
and other proteins which may be involved 
in the biogenesis of complex I. Biochemical 
and genetic aspects of complex I deficiency 
are described in chapter 2. Furthermore, the 
subunit composition and the assembly pro­
cess are described in this chapter. Besides its 
function in OXPHOS, complex I may also play 
a role in the pathogenesis of neurodegenera­
tive diseases such as Parkinson's disease, Frie­
dreich's ataxia, and Alzheimer disease. 
Besides the medical history, clinical exami­
nation, laboratory studies, and imaging, bio­
chemical analysis of the OXPHOS system and 
screening of candidate genes are necessary 
to establish whether a patient suffers from a 
mitochondrial disorder. In addition, knowing 
the disease-causing mutation makes a specif­
ic and accurate prenatal diagnosis possible. 
Otherwise, in specific cases the diagnosis de­
pends on measuring the OXPHOS activities in 
native chorionic villi. Measuring normal val­
ues for complex I activity does not necessarily 
rule out a complex I deficiency, which shows
the importance of identifying the underlying 
genetic cause of a mitochondrial disorder. 
However, for many patients the genetic de­
fect causing the mitochondrial complex I de­
ficiency has not been identified yet. Because 
of the heterogenous clinical presentation of 
complex I deficiency there is no clear geno- 
type-phenotype relation, which makes iden­
tifying the pathogenic mutation more diffi­
cult. Therefore, the goal of this thesis was to 
identify new genetic defects involved in the 
pathogenesis of complex I deficiencies and 
to study the cell biological consequences.
To identify new genetic defects, we selected a 
group of 34 patients with complex I deficien­
cy in at least cultured fibroblasts following 
the criteria described in chapter 2. We start­
ed to screen the entire mtDNA and found 
disease-causing mutations for five patients. 
One patient harboured a mutation in the ND1 
gene, another patient in the ND3 gene and 
three patients in the ND6 gene. The patients 
in whom the underlying genetic defect has 
been observed were excluded from further 
research.
Mutation detection was followed in the genes 
in which mutations have been described by 
earlier studies. This revealed pathogenic mu­
tations in the gene encoding one of the core 
subunits, NDUFS1, in three unrelated patients 
as described in chapter 3. The fibroblasts of 
these patients displayed low residual com­
plex I activity, which may be used as pre selec­
tion for screening of the NDUFS1 gene. 
Identification of the disease-causing muta­
tion in the remaining patients was followed 
by screening the genes encoding structural 
complex I subunits in which no mutations 
have been described before. This revealed 
new mutations in two accessory subunits. The 
first mutation has been identified in NDUFA2 
in one patient using homozygosity mapping 
(chapter 4). Complementation studies with a 
baculovirus system expressing the wild-type 
NDUFA2 gene demonstrated that this muta­
tion is responsible for a disturbed assembly 
of complex I. Consequently, this leads to a de­
creased amount and activity of the complex 
and a reduction in the mitochondrial mem­
brane potential.
Screening of NDUFA10 revealed two com­
pound heterozygous mutations in the sec­
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ond gene encoding an accessory subunit 
(chapter 5). These studies showed that com­
plex I deficiency-causing mutations are not 
restricted to a certain set of subunits and ge­
netic screening should involve all subunits. 
When a mutation has been observed, cell 
biological studies may be used to confirm the 
pathogenicity of the mutation. For example, 
a baculovirus system is a good tool for com­
plementation study.
Besides mutations in structural subunits, 
disease-causing mutations have also been 
described in assembly factors for complex
I. We followed our study by screening those 
genes and identified a mutation in NDUFAF2, 
as described in chapter 6 . Studies with a 
baculovirus expression system revealed res­
toration of the amount, activity, and assem­
bly of complex I, confirming the pathogenic­
ity of this mutation. Earlier studies described 
also other mutations in NDUFAF2, indicating 
that it is important to include this gene in the 
screening process.
In one patient of our research cohort we 
identified two compound heterozygous 
mutations in NDUFAF3, a gene encoding a 
new assembly factor of complex I (chapter 
7). Characterization of NDUFAF3 showed its 
role as a NDUFAF4-interacting complex I as­
sembly protein. These proteins cooperate 
from the early to late steps of the assembly 
process.
All observed mutations have been summa­
rized in table 8.1 (chapter 8 ), including new 
mutations observed in the assembly protein 
ACAD9. In this patient group, 15% harboured 
a mutation in complex I subunits encoded by 
the mtDNA. In 26% the mutation was located 
in a subunit or assembly factor encoded by 
the nDNA and for 59% of the patients the 
disease-causing mutation has not been iden­
tified yet. Therefore, new candidate genes 
should be screened for the presence of muta­
tions. Phylogenetic profiling may be used to 
identify candidate genes and with tandem 
affinity purification new (putative) complex I 
assembly factors may be identified.
In addition, new powerful techniques such 
as whole genome or exome sequencing are 
necessary to make high throughput screen­
ing possible. Whole exome sequencing is a 
technique using targeted sequencing of all
protein-coding regions. Both techniques 
will reveal numerous genetic variants for 
which extensive bioinformatical analysis is 
required. The use of targeted next generation 
sequencing for elucidating the genetic cause 
in mitochondrial disorders has been shown, 
recently. Furthermore, with high-through­
put pooled sequencing, target regions were 
sequenced to high depths in DNA pools in­
cluding controls and patients with unknown 
genetic cause. Genotyping resulted in new 
genetic variants which require cell biologi­
cal studies to prove their pathogenic role. 
Together, these techniques will improve the 
genetic counselling.
Summarizing, the studies presented in this 
thesis give us new insight in the molecular 
base of complex I deficiencies. This is impor­
tant for a better genetic counselling, prenatal 
diagnosis and future development of new 
treatment strategies to cure complex I dis­
eased patients.
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In de cellen van ons lichaam wordt energie 
geproduceerd in de vorm van ATP. De oxi- 
datieve fosforylering (OXFOS) is de laatste 
stap in de ATP productie en wordt uitge­
voerd door vijf eiwitcomplexen die zich in 
de binnenmembraan van de mitochondriën 
bevinden. Elektronen afkomstig van NADH 
en succinaat worden via de eiwitcomplexen 
naar de uiteindelijke ontvanger molecu­
lair zuurstof getransporteerd. De energie 
die hierbij vrij komt wordt gebruikt om een 
proton gradiënt te ontwikkelen. Uiteindelijk 
wordt deze gradiënt door het laatste complex 
(complex V) gebruikt om ATP te produceren. 
Defecten van het OXFOS systeem behoren 
tot de meest voorkomende aangeboren 
stofwisselingsstoornissen en leiden tot een 
groep van heterogene ziekten, waarbij ver­
schillende organen en weefsels aangedaan 
zijn. Van de vijf complexen is een defect 
van complex I het meest voorkomend. Ge­
isoleerde complex I deficiënties komen vaak 
al bij de geboorte of vroeg in de kinderjaren 
tot uiting en leiden meestal tot een voortijdig 
overlijden.
Complex I is het grootste complex van het 
OXFOS systeem en voor de biogenese zijn 
zowel het mitochondriële DNA (mtDNA) als 
het kern gecodeerde DNA (nDNA) nodig. Hier­
door kunnen pathogene mutaties gevonden 
worden in het mtDNA of in the nDNA dat 
voor de structurele bouwstenen van com­
plex I, de assemblage factoren en andere ei­
witten betrokken in biogenese van complex 
I codeert. De biochemische en genetische 
aspecten van de complex I deficiëntie zijn in 
hoofdstuk 2 beschreven. Tevens worden de 
samenstelling van de bouwstenen van com­
plex I en het assemblage proces in dit hoofd­
stuk beschreven. Complex I heeft niet alleen 
een functie in de OXFOS, maar speelt ook een 
rol in de pathologie van neurodegeneratieve 
aandoeningen zoals de ziekten van Parkin­
son en Alzheimer.
Om vast te stellen of een patiënt een mito­
chondriële afwijking heeft, zijn naast de me­
dische achtergrond en het klinische onder­
zoek ook de biochemische analyse en het 
screenen van kandidaat genen noodzake­
lijk. Een specifieke en nauwkeurige prenatale
diagnose is mogelijk als de pathogene mu­
tatie bekend is. Als de mutatie niet bekend 
is, is de diagnose afhankelijk van het bepalen 
van de OXFOS activiteiten in chorion villi. Dit 
heeft als nadeel dat de gemeten normale 
waarden voor de complex I activiteit niet 
per se een complex I deficiëntie uit slui­
ten. Daarom is het van groot belang om de 
onderliggende genetische oorzaak van een 
mitochondriële ziekte te achterhalen. Echter, 
voor veel patiënten is het genetisch defect 
dat de mitochondriële complex I deficiëntie 
veroorzaakt nog niet bekend. En doordat 
complex I deficiënties heterogene ziekten 
zijn, bestaat er geen duidelijke relatie tussen 
het genotype en het fenotype. Dit maakt het 
vinden van de pathogene mutatie moeilijker. 
Het doel van dit proefschrift was het identi­
ficeren van nieuwe genetische defecten ver­
antwoordelijk voor de complex I deficiënties 
en de cel biologische consequenties van de 
gevonden mutaties achterhalen.
Om nieuwe genetische defecten op te spo­
ren, hebben we een groep van 34 patiënten 
met een complex I deficiëntie, aangetoond 
in tenminste gekweekte fibroblasten, 
samengesteld. De gebruikte criteria om de 
groep samen te stellen staan beschreven 
in hoofdstuk 2. We zijn begonnen met het 
screenen van het hele mtDNA en vonden 
pathogene mutaties in vijf patiënten. Een 
patiënt had een mutatie in het ND1 gen, een 
andere patiënt in het ND3 gen en drie patiën­
ten in het ND6 gen. Deze patiënten werden 
uitgesloten voor verder onderzoek.
Mutatie detectie werd vervolgd in de genen 
waarin door eerdere studies mutaties zijn be- 
schreven.Indriepatiëntenwerdenpathogene 
mutaties in het NDUFS1 gen dat codeert voor 
een van de kern bouwstenen van complex I 
gevonden. Deze staan beschreven in hoofd­
stuk 3. De fibroblasten van deze patiënten 
vertoonden lage complex I rest activiteiten, 
wat als pre selectie voor het nakijken van het 
NDUFS1 gen gebruikt kan worden.
In de overige patiënten zijn de genen die 
coderen voor de structurele complex I bouw­
stenen waarin nog niet eerder mutaties zijn 
beschreven, nagekeken op de aanwezigheid 
van pathogene mutaties. Hierbij zijn nieuwe 
mutaties gevonden in twee bouwstenen die 
niet bij de kern bouwstenen behoren. Door
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gebruik te maken van “homozygosity map­
ping" kon in een patiënt een mutatie in het 
NDUFA2 gen opgespoord worden (hoofd­
stuk 4). Met behulp van een baculovirus 
systeem dat het wild-type NDUFA2 gen tot 
expressie bracht is aangetoond dat de mu­
tatie zorgt voor de verstoorde assemblage 
van complex I. Dit leidt tot een afname in de 
hoeveelheid en activiteit van het complex 
en een reductie in de mitochondriële mem­
braan potentiaal.
In een andere patiënt zijn twee heterozy­
gote mutaties in het NDUFA10 gen gevonden 
(hoofdstuk 5). Deze en de vorige studie heb­
ben aangetoond dat mutaties niet alleen in 
bepaalde bouwstenen van complex I gevon­
den worden, maar dat alle bouwstenen in de 
screening opgenomen moeten worden. Als 
er een mutatie is gevonden kunnen cel bio­
logische studies gebruikt worden om te be­
wijzen of de mutatie daadwerkelijk patho- 
geen is. Een voorbeeld hiervan is het baculo­
virus systeem.
Behalve mutaties in structurele bouwstenen 
zijn er ook mutaties in complex I assemblage 
factoren beschreven. Het screenen van deze 
genen leverde een mutatie in NDUFAF2 op, 
zoals beschreven in hoofdstuk 6 . Experi­
menten met een baculovirus expressie sys­
teem lieten een herstel in de hoeveelheid, ac­
tiviteit en de assemblage van complex I zien, 
waarmee werd aangetoond dat de mutatie 
pathogeen is. Het is belangrijk om NDUFAF2 
te screenen, omdat ook eerdere studies mu­
taties in dit gen hebben beschreven.
In een patiënt van onze onderzoeksgroep 
hebben we twee heterozygote mutaties 
gevonden in het NDUFAF3 gen, dat codeert 
voor een nieuw complex I assemblage factor 
(hoofdstuk 7). Onderzoek heeft aangetoond 
dat NDUFAF3 een interactie aangaat met 
NDUFAF4 en dat beide assemblage factoren 
samenwerken tijdens de vroege tot de late 
stappen in het assemblage proces.
Alle gevonden mutaties staan weergegeven 
in tabel 8.1 (hoofdstuk 8 ). Deze tabel bevat 
ook de mutaties gevonden in een nieuw as­
semblage factor, ACAD9. In de onderzochte 
patiëntengroep heeft 15% een mutatie in 
een bouwsteen van complex I dat door het 
mtDNA gecodeerd wordt. In 26% lag de 
mutatie in een bouwsteen of assemblage
factor dat door het nDNA gecodeerd wordt 
en in 59% is de pathogene mutatie nog niet 
gevonden. Daarom is het belangrijk om 
nieuwe kandidaat genen na te kijken op de 
aanwezigheid van mutaties. Fylogenetische 
profilering kan worden gebruikt om nieuwe 
kandidaat genen te vinden en met zuiverings­
technieken kunnen nieuwe (potentiële) as­
semblage factoren geïdentificeerd worden. 
Nieuwekrachtigetechnieken waarbijsequen- 
tie analyse van het hele genoom of van alle 
eiwit coderende regio's wordt uitgevoerd zijn 
noodzakelijk om“high throughput" screening 
mogelijk te maken. Beide technieken leveren 
talrijke genetische variaties op, waarvoor uit­
gebreide bioinformatica nodig is. Onlangs is 
het gebruik van “targeted next generation 
sequencing", een techniek waarmee de ge­
netische oorzaak van mitochondriële ziekten 
is achterhaald, beschreven. En met een an­
dere techniek, “high-throughput pooled se­
quencing", worden sequentie analyses uitge­
voerd van geselecteerde regio's in een groep 
dat DNA bevat van controle personen en van 
patiënten waarvan de genetische oorzaak 
nog niet bekend is. Genotypering levert 
nieuwe genetische veranderingen op, waar­
voor cel biologische experimenten nodig 
zijn om aan te tonen dat ze pathogeen zijn. 
Tezamen zullen deze technieken de kans op 
het vinden van een pathogene mutatie ver­
groten.
Samenvattend geven de onderzoeken be­
schreven in dit proefschrift nieuwe inzichten 
in de moleculaire achtergrond van complex 
I deficiënties. Dit is belangrijk voor het uit­
voeren van accurate (prenatale) diagnostiek 
en voor de verdere ontwikkeling van nieuwe 
behandelingsstrategieën om uiteindelijk 
deze complex I deficiënties te genezen.
105
1G6
References
107
References
References
Acin-Perez R, Fernandez-Silva P, Peleato ML, 
Perez-Martos A, and Enriquez JA. Respiratory 
active mitochondrial supercomplexes. Mol 
Cell 2008; 32: 529-539.
Andreazza AC, Shao L, Wang JF, and Young LT. 
Mitochondrial complex I activity and oxida­
tive damage to mitochondrial proteins in the 
prefrontal cortex of patients with bipolar dis­
order. Arch Gen Psychiatry 2010; 67: 360-368.
Andreu AL, Tanji K, Bruno C, Hadjigeorgiou 
GM, Sue CM, Jay C, Ohnishi T, Shanske S, Bo­
nilla E, and DiMauro S. Exercise intolerance 
due to a nonsense mutation in the mtDNA 
ND4 gene. Ann Neurol 1999; 45: 820-823.
Angell JE, Lindner DJ, Shapiro PS, Hofmann 
ER, and Kalvakolanu DV. Identification of 
GRIM-19, a novel cell death-regulatory gene 
induced by the interferon-beta and retinoic 
acid combination, using a genetic approach. 
JBiolChem 2000; 275: 33416-33426.
Antonicka H, Ogilvie I, Taivassalo T, Anitori RP, 
Haller RG, Vissing J, Kennaway NG, and Shou- 
bridge EA. Identification and characteriza­
tion of a common set of complex I assembly 
intermediates in mitochondria from patients 
with complex I deficiency. J  Biol Chem 2003; 
278: 43081-43088.
Arenas J, Campos Y, Bornstein B, Ribacoba R, 
Martin MA, Rubio JC, Santorelli FM, Zeviani M, 
DiMauro S, and Garesse R. A double mutation 
(A8296G and G8363A) in the mitochondrial 
DNA tRNA (Lys) gene associated with myo­
clonus epilepsy with ragged-red fibers. Neu­
rology 1999; 52: 377-382.
Arenas J, Campos Y, Ribacoba R, Martin MA, 
Rubio JC, Ablanedo P, and Cabello A. Com­
plex I defect in muscle from patients with 
Huntington's disease. Ann Neurol 1998; 43: 
397-400.
Atorino L, Silvestri L, Koppen M, Cassina L, 
Ballabio A, Marconi R, Langer T, and Casari 
G. Loss of m-AAA protease in mitochondria 
causes complex I deficiency and increased
sensitivity to oxidative stress in hereditary 
spastic paraplegia. J  Cell Biol 2003; 163: 777­
787.
Au HC, Seo BB, Matsuno-Yagi A, Yagi T, and 
Scheffler IE. The NDUFA1 gene product 
(MWFE protein) is essential for activity of 
complex I in mammalian mitochondria. Proc 
Natl Acad Sci U S A 1999; 96: 4354-4359.
Baker ME, Grundy WN, and Elkan CP. A com­
mon ancestor for a subunit in the mitochon­
drial proton-translocating NADH:ubiquinone 
oxidoreductase (complex I) and short-chain 
dehydrogenases/reductases. Cell Mol Life Sci 
1999; 55: 450-455.
Barghuti F, Elian K, Gomori JM, Shaag A, Ed- 
vardson S, Saada A, and Elpeleg O. The unique 
neuroradiology of complex I deficiency due 
to NDUFA12L defect. Mol Genet Metab 2008; 
94: 78-82.
Bender A, Krishnan KJ, Morris CM, Taylor GA, 
Reeve AK, Perry RH, Jaros E, Hersheson JS, 
Betts J, Klopstock T, Taylor RW, and Turnbull 
DM. High levels of mitochondrial DNA dele­
tions in substantia nigra neurons in aging 
and Parkinson disease. Nat Genet 2006; 38: 
515-517.
Benit P, Beugnot R, Chretien D, Giurgea I, de 
Lonlay-Debeney P, Issartel JP, Corral-Debrinski 
M, Kerscher S, Rustin P, Rotig A, and Munnich 
A. Mutant NDUFV2 subunit of mitochondrial 
complex I causes early onset hypertrophic 
cardiomyopathy and encephalopathy. Hum 
Mutat 2003a; 21: 582-586.
Benit P, Chretien D, Kadhom N, de Lonlay- 
Debeney P, Cormier-Daire V, Cabral A, Peu- 
denier S, Rustin P, Munnich A, and Rotig A. 
Large-scale deletion and point mutations 
of the nuclear NDUFV1 and NDUFS1 genes 
in mitochondrial complex I deficiency. Am J  
Hum Genet 2001; 68: 1344-1352.
Benit P, Slama A, Cartault F, Giurgea I, Chretien
D, Lebon S, Marsac C, Munnich A, Rotig A, and 
Rustin P. Mutant NDUFS3 subunit of mito­
chondrial complex I causes Leigh syndrome. 
J  Med Genet 2004; 41: 14-17.
108
References
Benit P, Steffann J, Lebon S, Chretien D, Kad- 
hom N, de LP, Goldenberg A, Dumez Y, Dom- 
mergues M, Rustin P, Munnich A, and Rotig 
A. Genotyping microsatellite DNA markers 
at putative disease loci in inbred/multiplex 
families with respiratory chain complex I de­
ficiency allows rapid identification of a novel 
nonsense mutation (IVSInt -1) in the NDUFS4 
gene in Leigh syndrome. Hum Genet 2003b; 
112: 563-566.
Berger I, Hershkovitz E, Shaag A, Edvardson 
S, Saada A, and Elpeleg O. Mitochondrial 
complex I deficiency caused by a deleteri­
ous NDUFA11 mutation. Ann Neurol 2008; 63: 
405-408.
Betarbet R, Sherer TB, MacKenzie G, Garcia- 
Osuna M, Panov AV, and Greenamyre JT. 
Chronic systemic pesticide exposure repro­
duces features of Parkinson's disease. Nat 
Neurosci 2000; 3: 1301-1306.
Blakely EL, Mitchell AL, Fisher N, Meunier B, 
Nijtmans LG, Schaefer AM, Jackson MJ, Turn­
bull DM, and Taylor RW. A mitochondrial cy­
tochrome b mutation causing severe respira­
tory chain enzyme deficiency in humans and 
yeast. FEBS J  2005; 272: 3583-3592.
Bradley JL, Blake JC, Chamberlain S, Thomas 
PK, Cooper JM, and Schapira AH. Clinical, bio­
chemical and molecular genetic correlations 
in Friedreich's ataxia. Hum Mol Genet 2000; 9: 
275-282.
BrandtU. Proton-translocation bymembrane- 
bound NADH:ubiquinone-oxidoreductase 
(complex I) through redox-gated ligand con­
duction. Biochim Biophys Acta 1997; 1318: 
79-91.
Brandt U. Energy converting NADH:quinone 
oxidoreductase (complex I). Annu Rev Bio- 
chem 2006; 75: 69-92.
Brandt U, Kerscher S, Drose S, Zwicker K, 
and Zickermann V. Proton pumping by 
NADH:ubiquinone oxidoreductase. A redox 
driven conformational change mechanism? 
FEBS Lett 2003; 545: 9-17.
Brockmann C, Diehl A, Rehbein K, Strauss H, 
Schmieder P, Korn B, Kuhne R, and Oschki- 
nat H. The oxidized subunit B8 from human 
complex I adopts a thioredoxin fold. Structure 
2004; 12: 1645-1654.
Brown MD, Starikovskaya E, Derbeneva O, 
Hosseini S, Allen JC, Mikhailovskaya IE, Suk- 
ernik RI, and Wallace DC. The role of mtDNA 
background in disease expression: a new pri­
mary LHON mutation associated with West­
ern Eurasian haplogroup J. Hum Genet 2002; 
110: 130-138.
Brown MD, Voljavec AS, Lott MT, Torroni A, 
Yang CC, and Wallace DC. Mitochondrial DNA 
complex I and III mutations associated with 
Leber's hereditary optic neuropathy. Genetics 
1992; 130: 163-173.
Budde SM, van den Heuvel LP, Janssen AJ, 
Smeets RJ, Buskens CA, DeMeirleir L, van 
Coster R, Baethmann M, Voit T, Trijbels JM, and 
Smeitink JA. Combined enzymatic complex I 
and III deficiency associated with mutations 
in the nuclear encoded NDUFS4 gene. Bio- 
chem Biophys Res Commun 2000; 275: 63-68.
Bych K, Kerscher S, Netz DJ, Pierik AJ, Zwicker 
K, Huynen MA, Lill R, Brandt U, and Balk J. The 
iron-sulphur protein Ind1 is required for ef­
fective complex I assembly. EMBO J  2008; 27: 
1736-1746.
Calvaruso MA, Smeitink J, and Nijtmans L. 
Electrophoresis techniques to investigate de­
fects in oxidative phosphorylation. Methods 
2008; 46: 281-287.
Calvo SE, Tucker EJ, Compton AG, Kirby DM, 
Crawford G, Burtt NP, Rivas M, Guiducci C, Bru­
no DL, Goldberger OA, Redman MC, Wiltshire 
E, Wilson CJ, Altshuler D, Gabriel SB, Daly MJ, 
Thorburn DR, and Mootha VK. High-through­
put, pooled sequencing identifies mutations 
in NUBPL and FOXRED1 in human complex I 
deficiency. Nat Genet 2010; 42: 851-858.
Carroll J, Fearnley IM, Shannon RJ, Hirst J, and 
Walker JE. Analysis of the subunit composition 
of complex I from bovine heart mitochondria. 
Mol Cell Proteomics 2003; 2: 117-126.
109
References
Carroll J, Fearnley IM, Skehel JM, Shannon RJ, 
Hirst J, and Walker JE. Bovine complex I is a 
complex of 45 different subunits. J  Biol Chem 
2006; 281: 32724-32727.
Cartegni L, Chew SL, and Krainer AR. Listen­
ing to silence and understanding nonsense: 
exonic mutations that affect splicing. Nat Rev 
Genet 2002; 3: 285-298.
Cejudo P, Bautista J, Montemayor T, Villago­
mez R, Jimenez L, Ortega F, Campos Y, San­
chez H, and Arenas J. Exercise training in 
mitochondrial myopathy: a randomized con­
trolled trial. Muscle Nerve 2005; 32: 342-350.
Chakrabarti P and Janin J. Dissecting protein­
protein recognition sites. Proteins 2002; 47: 
334-343.
Chen R, Fearnley IM, Peak-Chew SY, and Walk­
er JE. The phosphorylation of subunits of 
complex I from bovine heart mitochondria. J  
Biol Chem 2004; 279: 26036-26045.
Chen S and Guillory RJ. Identification of the 
NADH-NAD+ transhydrogenase peptide of 
the mitochondrial NADH-CoQ reductase 
(Complex I). A photodependent labeling 
study utilizing arylazido-beta-alanyl NAD+. J  
Biol Chem 1984; 259: 5124-5131.
Chinnery PF, Brown DT, Andrews RM, Singh- 
Kler R, Riordan-Eva P, Lindley J, Applegarth 
DA, Turnbull DM, and Howell N. The mito­
chondrial ND6 gene is a hot spot for muta­
tions that cause Leber's hereditary optic neu­
ropathy. Brain 2001; 124: 209-218.
De Rasmo D, Panelli D, Sardanelli AM, and 
Papa S. cAMP-dependent protein kinase reg­
ulates the mitochondrial import of the nucle­
ar encoded NDUFS4 subunit of complex I. Cell 
Signal 2008; 20: 989-997.
Diaz F, Fukui H, Garcia S, and Moraes CT. Cyto­
chrome c oxidase is required for the assem­
bly/stability of respiratory complex I in mouse 
fibroblasts. Mol Cell Biol 2006; 26: 4872-4881.
Dieteren CE, Willems PH, Vogel RO, Swarts HG, 
Fransen J, Roepman R, Crienen G, Smeitink
JA, Nijtmans LG, and Koopman WJ. Subunits 
of mitochondrial complex I exist as part of 
matrix- and membrane-associated subcom­
plexes in living cells. J  Biol Chem 2008; 283: 
34753-34761.
DiMauro S, Bonilla E, and De Vivo DC. Does 
the patient have a mitochondrial encepha- 
lomyopathy? J  Child Neurol 1999; 14 Suppl 1: 
S23-35.
Distelmaier F, Koopman WJ, Testa ER, de Jong 
AS, Swarts HG, Mayatepek E, Smeitink JA, and 
Willems PH. Life cell quantification of mito­
chondrial membrane potential at the single 
organelle level. Cytometry A 2008; 73: 129­
138.
Distelmaier F, Koopman WJ, van den Heuvel 
LP, Rodenburg RJ, Mayatepek E, Willems PH, 
and Smeitink JA. Mitochondrial complex I de­
ficiency: from organelle dysfunction to clini­
cal disease. Brain 2009a; 132: 833-842.
Distelmaier F, Visch HJ, Smeitink JA, Mayate­
pek E, Koopman WJ, and Willems PH. The anti­
oxidant Trolox restores mitochondrial mem­
brane potential and Ca2+ -stimulated ATP 
production in human complex I deficiency. J  
Mol Med 2009b; 87: 515-522.
Dudkina NV, Kouril R, Peters K, Braun HP, and 
Boekema EJ. Structure and function of mito­
chondrial supercomplexes. Biochim Biophys 
Acta 2010; 179: 664-670.
Dunning CJ, McKenzie M, Sugiana C, Lazarou 
M, Silke J, Connelly A, Fletcher JM, Kirby DM, 
Thorburn DR, and Ryan MT. Human CIA30 is 
involved in the early assembly of mitochon­
drial complex I and mutations in its gene 
cause disease. EMBO J 2007; 26: 3227-3237.
Edvardson S, Shaag A, Kolesnikova O, Go- 
mori JM, Tarassov I, Einbinder T, Saada A, and 
Elpeleg O. Deleterious mutation in the mi­
tochondrial arginyl-transfer RNA synthetase 
gene is associated with pontocerebellar hy­
poplasia. Am J  Hum Genet 2007; 81: 857-862.
Efremov RG, Baradaran R, and Sazanov LA. 
The architecture of respiratory complex I. Na­
110
References
ture 2010; 465: 441-445.
El Sheikh AA, van den Heuvel JJ, Koenderink 
JB, and Russel FG. Interaction of nonsteroidal 
anti-inflammatory drugs with multidrug re­
sistance protein (MRP) 2/ABCC2- and MRP4/ 
ABCC4-mediated methotrexate transport. J  
Pharmacol Exp Ther 2007; 320: 229-235.
Fassone E, Duncan AJ, Taanman JW, Pagna- 
menta AT, Sadowski MI, Holand T, Qasim W, 
Rutland P, Calvo SE, Mootha VK, Bitner-Glindz- 
icz M, and Rahman S. FOXRED1, encoding a 
FAD-dependent oxidoreductase complex-I 
specific molecular chaperone, is mutated in 
infantile-onset mitochondrial encephalopa­
thy. Hum Mol Genet 2010; 19: 4837-4847.
Fearnley IM, Carroll J, Shannon RJ, Runswick 
MJ, Walker JE, and Hirst J. GRIM-19, a cell 
death regulatory gene product, is a subunit 
of bovine mitochondrial NADH:ubiquinone 
oxidoreductase (complex I). J  Biol Chem 2001; 
276: 38345-38348.
Fearnley IM and Walker JE. Conservation 
of sequences of subunits of mitochondrial 
complex I and their relationships with other 
proteins. Biochim Biophys Acta 1992; 1140: 
105-134.
Fernandez-Moreira D, Ugalde C, Smeets R, 
Rodenburg RJ, Lopez-Laso E, Ruiz-Falco ML, 
Briones P, Martin MA, Smeitink JA, and Arenas 
J. X-linked NDUFA1 gene mutations associat­
ed with mitochondrial encephalomyopathy. 
Ann Neurol 2007; 61: 73-83.
Finel M. Organization and evolution of struc­
tural elements within complex I. Biochim Bio­
phys Acta 1998; 1364: 112-121.
FinelM,SkehelJM,AlbrachtSP,FearnleyIM,and 
Walker JE. Resolution of NADH:ubiquinone 
oxidoreductase from bovine heart mitochon­
dria into two subcomplexes, one of which 
contains the redox centers of the enzyme. 
Biochemistry 1992; 31: 11425-11434.
Finsterer J. Treatment of mitochondrial disor­
ders. Eur J  Paediatr Neurol 2010; 14: 29-44.
Fischer JC, Ruitenbeek W, Stadhouders AM, 
Trijbels JM, Sengers RC, Janssen AJ, and 
Veerkamp JH. Investigation of mitochondrial 
metabolism in small human skeletal muscle 
biopsy specimens. Improvement of prepara­
tion procedure. Clin Chim Acta 1985; 145: 89­
99.
Flinn L, Mortiboys H, Volkmann K, Koster RW, 
Ingham PW, and Bandmann O. Complex I de­
ficiency and dopaminergic neuronal cell loss 
in parkin-deficient zebrafish (Danio rerio). 
Brain 2009; 132: 1613-1623.
Friedrich T. Complex I: a chimaera of a redox 
and conformation-driven proton pump? J  
Bioenerg Biomembr 2001; 33: 169-177.
Friedrich T and Bottcher B. The gross structure 
of the respiratory complex I: a Lego System. 
Biochim Biophys Acta 2004; 1608: 1-9.
Gabaldon T, Rainey D, and Huynen MA. Trac­
ing the evolution of a large protein complex 
in the eukaryotes, NADH:ubiquinone oxi­
doreductase (Complex I). J  Mol Biol 2005; 348: 
857-870.
Gerards M, Sluiter W, van den Bosch BJ, de Wit 
E, Calis CM, Frentzen M, Akbari H, Schoonder- 
woerd K, Scholte HR, Jongbloed RJ, Hendrickx 
AT, de Coo IF, and Smeets HJ. Defective com­
plex I assembly due to C20orf7 mutations as 
a new cause of Leigh syndrome. J  Med Genet 
2010; 47: 507-512.
Gerards M, van den Bosch BJ, Danhauser K, 
Serre V, van Weeghel M, Wanders RJ, Nicolaes 
GA, Sluiter W, Schoonderwoerd K, Scholte HR, 
Prokisch H, Rotig A, de Coo IF, and Smeets HJ. 
Riboflavin-responsive oxidative phosphory­
lation complex I deficiency caused by defec­
tive ACAD9: new function for an old gene. 
Brain 2011; 134: 210-219.
Hayashi T, Ishimori C, Takahashi-Niki K, Taira T, 
Kim YC, Maita H, Maita C, Ariga H, and Iguchi- 
Ariga SM. DJ-1 binds to mitochondrial com­
plex I and maintains its activity. Biochem Bio­
phys Res Commun 2009; 390: 667-672.
He M, Rutledge SL, Kelly DR, Palmer CA, Mur-
111
References
doch G, Majumder N, Nicholls RD, Pei Z, Wat­
kins PA, and Vockley J. A new genetic disorder 
in mitochondrial fatty acid beta-oxidation: 
ACAD9 deficiency. Am J  Hum Genet 2007; 81: 
87-103.
Heidari MM, Houshmand M, Hosseinkhani S, 
Nafissi S, Scheiber-Mojdehkar B, and Khatami 
M. A novel mitochondrial heteroplasmic 
C13806A point mutation associated with 
Iranian Friedreich's ataxia. Cell Mol Neurobiol 
2009; 29: 225-233.
Herzer M, Koch J, Prokisch H, Rodenburg 
R, Rauscher C, Radauer W, Forstner R, Pilz P, 
Rolinski B, Freisinger P, Mayr JA, and Sperl W. 
Leigh disease with brainstem involvement in 
complex I deficiency due to assembly factor 
NDUFAF2 defect. Neuropediatrics 2010; 41: 
30-34.
Hinchliffe P and Sazanov LA. Organization of 
iron-sulfur clusters in respiratory complex I. 
Science 2005; 309: 771-774.
Hirst J, Carroll J, Fearnley IM, Shannon RJ, and 
Walker JE. The nuclear encoded subunits of 
complex I from bovine heart mitochondria. 
Biochim BiophysActa 2003; 1604: 135-150.
Hirst J, King MS, and Pryde KR. The production 
of reactive oxygen species by complex I. Bio- 
chem Soc Trans 2008; 36: 976-980.
Hoefs SJ, Dieteren CE, Distelmaier F, Janssen 
RJ, Epplen A, Swarts HG, Forkink M, Roden­
burg RJ, Nijtmans LG, Willems PH, Smeitink 
JA, and van den Heuvel LP. NDUFA2 complex 
I mutation leads to Leigh disease. Am J  Hum 
Genet 2008; 82: 1306-1315.
Hoefs SJ, Dieteren CE, Rodenburg RJ, Naess 
K, Bruhn H, Wibom R, Wagena E, Willems PH, 
Smeitink JA, Nijtmans LG, and van den Heu­
vel LP. Baculovirus complementation restores 
a novel NDUFAF2 mutation causing complex 
I deficiency. Hum Mutat 2009; 30: E728-E736.
Hoefs SJ, Skjeldal OH, Rodenburg RJ, Ne- 
dregaard B, van Kaauwen EP, Spiekerkotter 
U, Kleist-Retzow JC, Smeitink JA, Nijtmans 
LG, and van den Heuvel LP. Novel mutations
in the NDUFS1 gene cause low residual ac­
tivities in human complex I deficiencies. Mol 
GenetMetab 2010; 100: 251-256.
Hoefs SJ, van Spronsen FJ, Lenssen EW, Nijt­
mans LG, Rodenburg RJ, Smeitink JA, and van 
den Heuvel LP. NDUFA10 mutations cause 
complex I deficiency in a patient with Leigh 
disease. Eur J  Hum Genet 2011; 19: 270-274.
Hofhaus G, Weiss H, and Leonard K. Electron 
microscopic analysis of the peripheral and 
membrane parts of mitochondrial NADH de­
hydrogenase (complex I). J  Mol Biol 1991; 221: 
1027-1043.
Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo 
K, Lufei C, Zeng Q, and Cao X. GRIM-19, a cell 
death regulatory protein, is essential for as­
sembly and function of mitochondrial com­
plex I. Mol Cell Biol 2004; 24: 8447-8456.
Huynen M, Snel B, Lathe W  3rd, and Bork P. 
Predicting protein function by genomic con­
text: quantitative evaluation and qualitative 
inferences. Genome Res 2000; 10: 1204-1210.
Iuso A, Scacco S, Piccoli C, Bellomo F, Petruz­
zella V, Trentadue R, Minuto M, Ripoli M, Capi- 
tanio N, Zeviani M, and Papa S. Dysfunctions 
of cellular oxidative metabolism in patients 
with mutations in the NDUFS1 and NDUFS4 
genes of complex I. J  Biol Chem 2006; 281: 
10374-10380.
Janssen AJ, Smeitink JA, and van den Heuvel 
LP. Some practical aspects of providing a di­
agnostic service for respiratory chain defects. 
Ann Clin Biochem 2003; 40: 3-8.
Janssen AJ, Trijbels FJ, Sengers RC, Smeitink 
JA, van den Heuvel LP,Wintjes LT, Stoltenborg- 
Hogenkamp BJ, and Rodenburg RJ. Spectro- 
photometric assay for complex I of the respi­
ratory chain in tissue samples and cultured 
fibroblasts. Clin Chem 2007; 53: 729-734.
Janssen AJ, Trijbels FJ, Sengers RC, Wintjes LT, 
Ruitenbeek W, Smeitink JA, Morava E, van En­
gelen BG, van den Heuvel LP, and Rodenburg 
RJ. Measurement of the energy-generating 
capacity of human muscle mitochondria: di­
112
References
agnostic procedure and application to human 
pathology. Clin Chem 2006a; 52: 860-871.
Janssen RJ, Distelmaier F, Smeets R, Wijn­
hoven T, Ostergaard E, Jaspers NG, Raams A, 
Kemp S, Rodenburg RJ, Willems PH, van den 
Heuvel LP, Smeitink JA, and Nijtmans LG. Con­
tiguous gene deletion of ELOVL7, ERCC8 and 
NDUFAF2 in a patient with a fatal multisys­
tem disorder. Hum Mol Genet 2009; 18: 3365­
3374.
Janssen RJ, Nijtmans LG, van den Heuvel LP, 
and Smeitink JA. Mitochondrial complex I: 
structure, function and pathology. J  Inherit 
Metab Dis 2006b; 29: 499-515.
Jensen LJ, Kuhn M, Stark M, Chaffron S, 
Creevey C, Muller J, Doerks T, Julien P, Roth 
A, Simonovic M, Bork P, and von Mering C. 
STRING 8--a global view on proteins and their 
functional interactions in 630 organisms. Nu­
cleic Acids Res 2009; 37: D412-D416.
Jones S and Thornton JM. Principles of pro­
tein-protein interactions. Proc Natl Acad Sci U 
S A 1996; 93: 13-20.
Jun AS, Trounce IA, Brown MD, Shoffner JM, 
and Wallace DC. Use of transmitochondrial 
cybrids to assign a complex I defect to the 
mitochondrial DNA-encoded NADH dehy­
drogenase subunit 6 gene mutation at nucle­
otide pair 14459 that causes Leber hereditary 
optic neuropathy and dystonia. Mol Cell Biol 
1996; 16: 771-777.
Karry R, Klein E, and Ben Shachar D. Mitochon­
drial complex I subunits expression is altered 
in schizophrenia: a postmortem study. Biol 
Psychiatry 2004; 55: 676-684.
Keeney PM, Xie J, Capaldi RA, and Bennett JP 
Jr. Parkinson's disease brain mitochondrial 
complex I has oxidatively damaged subunits 
and is functionally impaired and misassem- 
bled. J  Neurosci 2006; 26: 5256-5264.
Kim SH, Vlkolinsky R, Cairns N, Fountoula- 
kis M, and Lubec G. The reduction of NADH 
ubiquinone oxidoreductase 24- and 75-kDa 
subunits in brains of patients with Down syn­
drome and Alzheimer's disease. Life Sci 2001; 
68: 2741-2750.
Kirby DM, Crawford M, Cleary MA, Dahl HH, 
Dennett X, and Thorburn DR. Respiratory 
chain complex I deficiency: an underdiag­
nosed energy generation disorder. Neurology 
1999; 52: 1255-1264.
Kirby DM, McFarland R, Ohtake A, Dunning C, 
Ryan MT, Wilson C, Ketteridge D, Turnbull DM, 
Thorburn DR, and Taylor RW. Mutations of the 
mitochondrial ND1 gene as a cause of MELAS. 
J  Med Genet 2004a; 41: 784-789.
Kirby DM, Salemi R, Sugiana C, Ohtake A, 
Parry L, Bell KM, Kirk EP, Boneh A, Taylor RW, 
Dahl HH, Ryan MT, and Thorburn DR. NDUFS6 
mutations are a novel cause of lethal neona­
tal mitochondrial complex I deficiency. J  Clin 
Invest 2004b; 114: 837-845.
Koene S and Smeitink J. Mitochondrial medi­
cine: entering the era of treatment. J  Intern 
Med 2009; 265: 193-209.
Koene S, Willems PH, Roestenberg P, Koop­
man WJ, and Smeitink JA. Mouse models for 
nuclear DNA-encoded mitochondrial com­
plex I deficiency. J  Inherit Metab Dis 2011; 
34:293-307.
Komen JC, Distelmaier F, Koopman WJ, Wan­
ders RJ, Smeitink J, and Willems PH. Phy­
tanic acid impairs mitochondrial respiration 
through protonophoric action. Cell Mol Life 
Sci 2007; 64: 3271-3281.
Koopman WJ, Nijtmans LG, Dieteren CE, 
Roestenberg P, Valsecchi F, Smeitink JA, and 
Willems PH. Mammalian Mitochondrial Com­
plex I: Biogenesis, Regulation and Reactive 
Oxygen Species Generation. Antioxid Redox 
Signal 2010; 12: 1431-1470.
Koopman WJ, Verkaart S, Visch HJ, van der 
Westhuizen FH, Murphy MP, van den Heuvel 
LW, Smeitink JA, and Willems PH. Inhibition 
of complex I of the electron transport chain 
causes O2-. -mediated mitochondrial out­
growth. Am J  Physiol Cell Physiol 2005; 288: 
C1440-C1450.
113
References
Krieger E, Darden T, Nabuurs SB, Finkelstein 
A, and Vriend G. Making optimal use of em­
pirical energy functions: force-field param­
eterization in crystal space. Proteins 2004; 57: 
678-683.
Kuffner R, Rohr A, Schmiede A, Krull C, and 
Schulte U. Involvement of two novel chap­
erones in the assembly of mitochondrial 
NADH:Ubiquinone oxidoreductase (complex 
I). J  Mol Biol 1998; 283: 409-417.
Kyriakouli DS, Boesch P, Taylor RW, and Ligh- 
towlers RN. Progress and prospects: gene 
therapy for mitochondrial DNA disease. Gene 
Ther 2008; 15: 1017-1023.
Langston JW, Ballard P, Tetrud JW, and Irwin 
I. Chronic Parkinsonism in humans due to a 
product of meperidine-analog synthesis. 
Science 1983; 219: 979-980.
Lazarou M, McKenzie M, Ohtake A, Thorburn 
DR, and Ryan MT. Analysis of the assembly 
profiles for mitochondrial- and nuclear-DNA- 
encoded subunits into complex I. Mol Cell Biol 
2007; 27: 4228-4237.
Lazarou M, Thorburn DR, Ryan MT, and Mc­
Kenzie M. Assembly of mitochondrial com­
plex I and defects in disease. Biochim Biophys 
Acta 2009; 1793: 78-88.
Lenaz G, Baracca A, Barbero G, Bergamini C, 
Dalmonte ME, Del Sole M, Faccioli M, Falasca 
A, Fato R, Genova ML, Sgarbi G, and Solaini
G. Mitochondrial respiratory chain super­
complex I-III in physiology and pathology. 
Biochim Biophys Acta 2010; 1797: 633-640.
Loeffen J, Elpeleg O, Smeitink J, Smeets R, 
Stockler-Ipsiroglu S, Mandel H, Sengers R, 
Trijbels F, and van den Heuvel L. Mutations in 
the complex I NDUFS2 gene of patients with 
cardiomyopathy and encephalomyopathy. 
Ann Neurol 2001; 49: 195-201.
Loeffen J, Smeitink J, Triepels R, Smeets R, 
Schuelke M, Sengers R, Trijbels F, Hamel B, 
Mullaart R, and van den Heuvel L. The first 
nuclear-encoded complex I mutation in a pa­
tient with Leigh syndrome. Am J  Hum Genet
1998; 63: 1598-1608.
Loeffen JL, Smeitink JA, Trijbels JM, Janssen 
AJ, Triepels RH, Sengers RC, and van den 
Heuvel LP. Isolated complex I deficiency in 
children: clinical, biochemical and genetic as­
pects. Hum Mutat 2000; 15: 123-134.
Maas MF, Sellem CH, Krause F, Dencher NA, 
and Sainsard-Chanet A. Molecular gene ther­
apy: overexpression of the alternative NADH 
dehydrogenase NDI1 restores overall physiol­
ogy in a fungal model of respiratory complex I 
deficiency. J  Mol Biol 2010; 399: 31-40.
Man PY, Griffiths PG, Brown DT, Howell N, 
Turnbull DM, and Chinnery PF. The epidemi­
ology of Leber hereditary optic neuropathy 
in the North East of England. Am J  Hum Genet 
2003; 72: 333-339.
Martin MA, Blazquez A, Gutierrez-Solana LG, 
Fernandez-Moreira D, Briones P, Andreu AL, 
Garesse R, Campos Y, and Arenas J. Leigh syn­
drome associated with mitochondrial com­
plex I deficiency due to a novel mutation in 
the NDUFS1 gene. Arch Neurol 2005; 62: 659­
661.
McBride HM, Neuspiel M, and Wasiak S. Mito­
chondria: more than just a powerhouse. Curr 
Biol 2006; 16: R551-R560.
McKenzie M, Lazarou M, Thorburn DR, and 
Ryan MT. Mitochondrial respiratory chain 
supercomplexes are destabilized in Barth 
Syndrome patients. J  Mol Biol 2006; 361: 462­
469.
McKenzie M and Ryan MT. Assembly factors 
of human mitochondrial complex I and their 
defects in disease. IUBMB Life 2010; 62: 497­
502.
Miller SA, Dykes DD, and Polesky HF. A simple 
salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res 
1988; 16: 1215.
Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzu­
ki K, Sato T, Oya H, Ozawa T, and Kagawa Y. De­
ficiencies in complex I subunits of the respi­
114
References
ratory chain in Parkinson's disease. Biochem 
Biophys Res Commun 1989; 163: 1450-1455.
Moran M, Rivera H, Sanchez-Arago M, 
Blazquez A, Merinero B, Ugalde C, Arenas J, 
Cuezva JM, and Martin MA. Mitochondrial 
bioenergetics and dynamics interplay in 
complex I-deficient fibroblasts. Biochim Bio­
phys Acta 2010; 1802: 443-453.
Morris AA, Leonard JV, Brown GK, Bidouki SK, 
Bindoff LA, Woodward CE, Harding AE, Lake 
BD, Harding BN, Farrell MA, Bell JE, Mirakhur 
M, and Turnbull DM. Deficiency of respiratory 
chain complex I is a common cause of Leigh 
disease. Ann Neurol 1996; 40: 25-30.
Munakata K, Tanaka M, Mori K, Washizuka 
S, Yoneda M, Tajima O, Akiyama T, Nanko S, 
Kunugi H, Tadokoro K, Ozaki N, Inada T, Saka­
moto K, Fukunaga T, Iijima Y, Iwata N, Tatsumi 
M, Yamada K, Yoshikawa T, and Kato T. Mito­
chondrial DNA 3644T-->C mutation associ­
ated with bipolar disorder. Genomics 2004; 
84: 1041-1050.
Murray J, Zhang B, Taylor SW, Oglesbee D, 
Fahy E, Marusich MF, Ghosh SS, and Capaldi 
RA. The subunit composition of the human 
NADH dehydrogenase obtained by rapid 
one-step immunopurification. J  Biol Chem 
2003; 278: 13619-13622.
NagashimaT, Mori M, Katayama K, Nunomura 
M, Nishihara H, Hiraga H, Tanaka S, Goto Y, and 
Nagashima K. Adult Leigh syndrome with mi­
tochondrial DNA mutation at 8993. Acta Neu- 
ropathol 1999; 97: 416-422.
Niers LE, Smeitink JA, Trijbels JM, Sengers 
RC, Janssen AJ, and van den Heuvel LP. Pre­
natal diagnosis of NADH:ubiquinone oxi- 
doreductase deficiency. Prenat Diagn 2001; 
21: 871-880.
Nijtmans LG, Henderson NS, and Holt IJ. Blue 
Native electrophoresis to study mitochon­
drial and other protein complexes. Methods 
2002; 26: 327-334.
Nouwen N and Driessen AJ. SecDFyajC forms 
a heterotetrameric complex with YidC. Mol
Microbiol 2002; 44: 1397-1405.
Nouws J, Nijtmans L, Houten SM, van den BM, 
Huynen M, Venselaar H, Hoefs S, Gloerich J, 
Kronick J, Hutchin T, Willems P, Rodenburg 
R, Wanders R, van den Heuvel L, Smeitink 
J, and Vogel RO. Acyl-CoA dehydrogenase 
9 is required for the biogenesis of oxidative 
phosphorylation complex I. Cell Metab 2010; 
12: 283-294.
Ogilvie I, Kennaway NG, and Shoubridge EA. 
A molecular chaperone for mitochondrial 
complex I assembly is mutated in a progres­
sive encephalopathy. J  Clin Invest 2005; 115: 
2784-2792.
Ohnishi T and Salerno JC. Conformation-driv­
en and semiquinone-gated proton-pump 
mechanism in the NADH-ubiquinone oxi- 
doreductase (complex I). FEBS Lett 2005; 579: 
4555-4561.
Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Va- 
fai SB, Ong SE,Walford GA, Sugiana C, Boneh A, 
Chen WK, Hill DE, Vidal M, Evans JG, Thorburn 
DR, Carr SA, and Mootha VK. A mitochondrial 
protein compendium elucidates complex I 
disease biology. Cell 2008; 134: 112-123.
Papa S, De Rasmo D, Scacco S, Signorile A, 
Technikova-Dobrova Z, Palmisano G, Sar- 
danelli AM, Papa F, Panelli D, Scaringi R, and 
Santeramo A. Mammalian complex I: a regu­
lable and vulnerable pacemaker in mitochon­
drial respiratory function. Biochim Biophys 
Acta 2008; 1777: 719-728.
Papa S, Scacco S, De Rasmo D, Signorile A, 
Papa F, Panelli D, Nicastro A, Scaringi R, San­
teramo A, Roca E, Trentadue R, and Larizza M. 
cAMP-dependent protein kinase regulates 
post-translational processing and expression 
of complex I subunits in mammalian cells. 
Biochim Biophys Acta 2010; 1797: 649-658.
Pellegrini M, Marcotte EM, Thompson MJ, 
Eisenberg D, and Yeates TO. Assigning protein 
functions by comparative genome analysis: 
protein phylogenetic profiles. Proc Natl Acad 
Sci U S A 1999; 96: 4285-4288.
115
References
Perales-Clemente E, Fernandez-Vizarra E, 
Acin-Perez R, Movilla N, Bayona-Bafaluy MP, 
Moreno-Loshuertos R, Perez-Martos A, Fer- 
nandez-Silva P, and Enriquez JA. Five entry 
points of the mitochondrially encoded sub­
units in mammalian complex I assembly. Mol 
Cell Biol 2010; 30: 3038-3047.
Pitkanen S, Feigenbaum A, Laframboise R, 
and Robinson BH. NADH-coenzyme Q re­
ductase (complex I) deficiency: heterogene­
ity in phenotype and biochemical findings. J  
Inherit Metab Dis 1996; 19: 675-686.
Rahman S, Blok RB, Dahl HH, Danks DM, Kirby 
DM, Chow CW, Christodoulou J, and Thorburn 
DR. Leigh syndrome: clinical features and bio­
chemical and DNA abnormalities. Ann Neurol 
1996; 39: 343-351.
Rappsilber J, Ishihama Y, and Mann M. Stop 
and go extraction tips for matrix-assisted la­
ser desorption/ionization, nanoelectrospray, 
and LC/MS sample pretreatment in proteom- 
ics. AnalChem 2003; 75: 663-670.
Rodenburg RJ. Biochemical diagnosis of 
mitochondrial disorders. J  Inherit Metab Dis 
2011; 34:283-292.
Rotig A. Genetic bases of mitochondrial respi­
ratory chain disorders. Diabetes Metab 2010; 
36: 97-107.
Rubio-Gozalbo ME, Dijkman KP, van den Heu­
vel LP, Sengers RC, Wendel U, and Smeitink 
JA. Clinical differences in patients with mito- 
chondriocytopathies due to nuclear versus 
mitochondrial DNA mutations. Hum Mutat 
2000; 15: 522-532.
Saada A, Bar-Meir M, Belaiche C, Miller C, and 
Elpeleg O. Evaluation of enzymatic assays 
and compounds affecting ATP production 
in mitochondrial respiratory chain complex I 
deficiency. AnalBiochem 2004; 335: 66-72.
Saada A, Edvardson S, Rapoport M, Shaag A, 
Amry K, Miller C, Lorberboum-Galski H, and 
Elpeleg O. C6ORF66 is an assembly factor of 
mitochondrial complex I. Am J  Hum Genet 
2008; 82: 32-38.
Saada A, Shaag A, and Elpeleg O. mtDNA de­
pletion myopathy: elucidation of the tissue 
specificity in the mitochondrial thymidine ki­
nase (TK2) deficiency. Mol Genet Metab 2003; 
79: 1-5.
Saada A,Vogel RO, Hoefs SJ, van den BrandMA, 
Wessels HJ, Willems PH, Venselaar H, Shaag A, 
Barghuti F, Reish O, Shohat M, Huynen MA, 
Smeitink JA, van den Heuvel LP, and Nijtmans 
LG. Mutations in NDUFAF3 (C3ORF60), encod­
ing an NDUFAF4 (C6ORF66)-interacting com­
plex I assembly protein, cause fatal neonatal 
mitochondrial disease. Am J  Hum Genet 2009; 
84: 718-727.
Santorelli FM, Tanji K, Kulikova R, Shanske S, 
Vilarinho L, Hays AP, and DiMauro S. Identifi­
cation of a novel mutation in the mtDNA ND5 
gene associated with MELAS. Biochem Bio- 
phys Res Commun 1997; 238: 326-328.
Saraste M. Oxidative phosphorylation at the 
fin de siecle. Science 1999; 283: 1488-1493.
Sazanov LA. Respiratory complex I: mecha­
nistic and structural insights provided by the 
crystal structure of the hydrophilic domain. 
Biochemistry 2007; 46: 2275-2288.
Sazanov LA and Hinchliffe P. Structure of the 
hydrophilic domain of respiratory complex I 
from Thermus thermophilus. Science 2006; 
311: 1430-1436.
Sazanov LA, Peak-Chew SY, Fearnley IM, and 
Walker JE. Resolution of the membrane do­
main of bovine complex I into subcomplexes: 
implications for the structural organization 
of the enzyme. Biochemistry 2000; 39: 7229­
7235.
Scacco S, Petruzzella V, Budde S, Vergari R, 
Tamborra R, Panelli D, van den Heuvel LP, 
Smeitink JA, and Papa S. Pathological muta­
tions of the human NDUFS4 gene of the 18- 
kDa (AQDQ) subunit of complex I affect the 
expression of the protein and the assembly 
and function of the complex. J  Biol Chem 
2003; 278: 44161-44167.
Schagger H. Respiratory chain supercom­
116
References
plexes of mitochondria and bacteria. Biochim 
Biophys Acta 2002; 1555: 154-159.
Schagger H, de Coo R, Bauer MF, Hofmann S, 
Godinot C, and Brandt U. Significance of res- 
pirasomes for the assembly/stability of hu­
man respiratory chain complex I. J  Biol Chem 
2004; 279: 36349-36353.
Schagger H and Pfeiffer K. Supercomplexes 
in the respiratory chains of yeast and mam­
malian mitochondria. EMBO J  2000; 19: 1777­
1783.
Schapira AH. Primary and secondary defects 
of the mitochondrial respiratory chain. J  In­
herit Metab Dis 2002; 25: 207-214.
Schapira AH, Cooper JM, Dexter D, Clark JB, 
Jenner P, and Marsden CD. Mitochondrial 
complex I deficiency in Parkinson's disease. J  
Neurochem 1990; 54: 823-827.
Schapira AH, Cooper JM, Dexter D, Jenner 
P, Clark JB, and Marsden CD. Mitochondrial 
complex I deficiency in Parkinson's disease. 
Lancet 1989; 1: 1269.
Scheffler IE, Yadava N, and Potluri P. Molecu­
lar genetics of complex I-deficient Chinese 
hamster cell lines. Biochim Biophys Acta 2004; 
1659: 160-171.
Schilling B, Aggeler R, Schulenberg B, Murray 
J, Row RH, Capaldi RA, and Gibson BW. Mass 
spectrometric identification of a novel phos­
phorylation site in subunit NDUFA10 of bo­
vine mitochondrial complex I. FEBS Lett 2005; 
579: 2485-2490.
Schuelke M, Smeitink J, Mariman E, Loeffen J, 
Plecko B, Trijbels F, Stockler-Ipsiroglu S, and 
van den Heuvel L. Mutant NDUFV1 subunit of 
mitochondrial complex I causes leukodystro­
phy and myoclonic epilepsy. Nat Genet 1999; 
2 1 : 260-261.
Schulenberg B, Aggeler R, Beechem JM, Ca­
paldi RA, and Patton WF. Analysis of steady- 
state protein phosphorylation in mitochon­
dria using a novel fluorescent phosphosensor 
dye. J  Biol Chem 2003; 278: 27251-27255.
Shanske S, Coku J, Lu J, Ganesh J, Krishna S, 
Tanji K, Bonilla E, Naini AB, Hirano M, and Di­
Mauro S. The G13513A mutation in the ND5 
gene of mitochondrial DNA as a common 
cause of MELAS or Leigh syndrome: evidence 
from 12 cases. Arch Neurol 2008; 65: 368-372.
Sherer TB, Kim JH, Betarbet R, and Gree- 
namyre JT. Subcutaneous rotenone exposure 
causes highly selective dopaminergic degen­
eration and alpha-synuclein aggregation. Exp 
Neurol 2003; 179: 9-16.
Sherer TB, Richardson JR, Testa CM, Seo BB, 
Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, 
and Greenamyre JT. Mechanism of toxicity of 
pesticides acting at complex I: relevance to 
environmental etiologies of Parkinson's dis­
ease. J  Neurochem 2007; 100: 1469-1479.
Shoffner JM. Maternal inheritance and the 
evaluation of oxidative phosphorylation dis­
eases. Lancet 1996; 348: 1283-1288.
Shoubridge EA. Nuclear genetic defects of 
oxidative phosphorylation. Hum Mol Genet 
2001; 10: 2277-2284.
Smeitink J, Sengers R, Trijbels F, and van den 
Heuvel L. Human NADH:ubiquinone oxi- 
doreductase. J  Bioenerg Biomembr 2001a; 33: 
259-266.
Smeitink J, van den Heuvel L, and DiMauro 
S. The genetics and pathology of oxidative 
phosphorylation. Nat Rev Genet 2001b; 2: 
342-352.
Smeitink JA, Loeffen JL, Triepels RH, Smeets 
RJ, Trijbels JM, and van den Heuvel LP Nuclear 
genes of human complex I of the mitochon­
drial electron transport chain: state of the art. 
Hum Mol Genet 1998; 7: 1573-1579.
Smeitink JA, Zeviani M, Turnbull DM, and Ja ­
cobs HT. Mitochondrial medicine: a metabol­
ic perspective on the pathology of oxidative 
phosphorylation disorders. Cell Metab 2006; 
3: 9-13.
Starkov AA. The role of mitochondria in reac­
tive oxygen species metabolism and signal­
117
References
ing. Ann N Y Acad Sci 2008; 1147:37-52.: 37-52. 
Starkov AA, Fiskum G, Chinopoulos C, Loren­
zo BJ, Browne SE, Patel MS, and Beal MF. Mi­
tochondrial alpha-ketoglutarate dehydro­
genase complex generates reactive oxygen 
species. J  Neurosci 2004; 24: 7779-7788.
Stroh A, Anderka O, Pfeiffer K, Yagi T, Finel M, 
Ludwig B, and Schagger H. Assembly of re­
spiratory complexes I, III, and IV into NADH 
oxidase supercomplex stabilizes complex I 
in Paracoccus denitrificans. J  Biol Chem 2004; 
279: 5000-5007.
Sugiana C, Pagliarini DJ, McKenzie M, Kirby 
DM, Salemi R, bu-Amero KK, Dahl HH, Hutchi­
son WM, Vascotto KA, Smith SM, Newbold RF, 
Christodoulou J, Calvo S, Mootha VK, Ryan 
MT, and Thorburn DR. Mutation of C20orf7 
disrupts complex I assembly and causes le­
thal neonatal mitochondrial disease. Am J  
Hum Genet 2008; 83: 468-478.
Sun X, Wang JF, Tseng M, and Young LT. 
Downregulation in components of the mi­
tochondrial electron transport chain in the 
postmortem frontal cortex of subjects with 
bipolar disorder. J  Psychiatry Neurosci 2006; 
31: 189-196.
Tachibana M, Sparman M, Sritanaudomchai
H, Ma H, Clepper L, Woodward J, Li Y, Ramsey 
C, Kolotushkina O, and Mitalipov S. Mitochon­
drial gene replacement in primate offspring 
and embryonic stem cells. Nature 2009; 461: 
367-372.
Taylor RW, Singh-Kler R, Hayes CM, Smith PE, 
and Turnbull DM. Progressive mitochondrial 
disease resulting from a novel missense mu­
tation in the mitochondrial DNA ND3 gene. 
Ann Neurol 2001; 50: 104-107.
Thorburn DR. Mitochondrial disorders: preva­
lence, myths and advances. J  Inherit Metab Dis 
2004; 27: 349-362.
Triepels RH, van den Heuvel LP, Loeffen JL, 
Buskens CA, Smeets RJ, Rubio Gozalbo ME, 
Budde SM, Mariman EC, Wijburg FA, Barth PG, 
Trijbels JM, and Smeitink JA. Leigh syndrome 
associated with a mutation in the NDUFS7
(PSST) nuclear encoded subunit of complex
I. Ann Neurol 1999; 45: 787-790.
Triepels RH, van den Heuvel LP, Trijbels JM, 
and Smeitink JA. Respiratory chain complex I 
deficiency. Am J  Med Genet 2001; 106: 37-45.
Tsuneoka M, Teye K, Arima N, Soejima M, 
Otera H, Ohashi K, Koga Y, Fujita H, Shirouzu 
K, Kimura H, and Koda Y. A novel Myc-target 
gene, mimitin, that is involved in cell prolif­
eration of esophageal squamous cell carci­
noma. J  Biol Chem 2005; 280: 19977-19985.
Ugalde C, Triepels RH, Coenen MJ, van den 
Heuvel LP, Smeets R, Uusimaa J, Briones P, 
Campistol J, Majamaa K, Smeitink JA, and 
Nijtmans LG. Impaired complex I assembly in 
a Leigh syndrome patient with a novel mis- 
sense mutation in the ND6 gene. Ann Neurol 
2003; 54: 665-669.
Ugalde C, Vogel R, Huijbens R, Van Den Heu­
vel B, Smeitink J, and Nijtmans L. Human mi­
tochondrial complex I assembles through 
the combination of evolutionary conserved 
modules: a framework to interpret complex 
I deficiencies. Hum Mol Genet 2004; 13: 2461­
2472.
Vahsen N, Cande C, Briere JJ, Benit P, Joza N, 
Larochette N, Mastroberardino PG, Pequi- 
gnot MO, Casares N, Lazar V, Feraud O, Debili 
N, Wissing S, Engelhardt S, Madeo F, Piacen­
tini M, Penninger JM, Schagger H, Rustin P, 
and Kroemer G. AIF deficiency compromises 
oxidative phosphorylation. EMBO J  2004; 23: 
4679-4689.
Valentino ML, Barboni P, Ghelli A, Bucchi L, 
Rengo C, Achilli A, Torroni A, Lugaresi A, Lodi 
R, Barbiroli B, Dotti M, Federico A, Baruzzi A, 
and Carelli V. The ND1 gene of complex I is a 
mutational hot spot for Leber's hereditary op­
tic neuropathy. Ann Neurol 2004; 56: 631-641.
Valko M, Leibfritz D, Moncol J, Cronin MT, Ma­
zur M, and Telser J. Free radicals and antioxi­
dants in normal physiological functions and 
human disease. Int J  Biochem Cell Biol 2007; 
39: 44-84.
118
References
Valsecchi F, Koopman WJ, Manjeri GR, Roden­
burg RJ, Smeitink JA, and Willems PH. Com­
plex I disorders: causes, mechanisms, and 
development of treatment strategies at the 
cellular level. Dev Disabil Res Rev 2010; 16: 
175-182.
van den Heuvel L, Ruitenbeek W, Smeets R, 
Gelman-Kohan Z, Elpeleg O, Loeffen J, Trij- 
bels F, Mariman E, de Bruijn D, and Smeitink 
J. Demonstration of a new pathogenic muta­
tion in human complex I deficiency: a 5-bp 
duplication in the nuclear gene encoding the 
18-kD (AQDQ) subunit. Am J  Hum Genet 1998; 
62: 262-268.
van der Knaap S and Valk J. Magnetic reso­
nance and myelination and myelin disorders. 
Springer 2005; third ed.
van Eijsden RG, Gerards M, Eijssen LM, Hen- 
drickx AT, Jongbloed RJ, Wokke JH, Hintzen 
RQ, Rubio-Gozalbo ME, De Coo IF, Briem E, 
Tiranti V, and Smeets HJ. Chip-based mtDNA 
mutation screening enables fast and reliable 
genetic diagnosis of OXPHOS patients. Genet 
Med 2006; 8 : 620-627.
Vasta V, Ng SB, Turner EH, Shendure J, and 
Hahn SH. Next generation sequence analy­
sis for mitochondrial disorders. Genome Med 
2009; 1: 100.
Verkaart S, Koopman WJ, Cheek J, van Emst- 
de Vries SE, van den Heuvel LW, Smeitink JA, 
and Willems PH. Mitochondrial and cytosolic 
thiol redox state are not detectably altered 
in isolated human NADH:ubiquinone oxi- 
doreductase deficiency. Biochim Biophys Acta 
2007a; 1772: 1041-1051.
Verkaart S, Koopman WJ, van Emst-de Vries 
SE, Nijtmans LG, van den Heuvel LW, Smeitink 
JA, and Willems PH. Superoxide production 
is inversely related to complex I activity in in­
herited complex I deficiency. Biochim Biophys 
Acta 2007b; 1772: 373-381.
Vogel RO, Dieteren CE, van den Heuvel LP, 
Willems PH, Smeitink JA, Koopman WJ, and 
Nijtmans LG. Identification of mitochondrial 
complex I assembly intermediates by trac­
ing tagged NDUFS3 demonstrates the entry 
point of mitochondrial subunits. J  Biol Chem 
2007a; 282: 7582-7590.
Vogel RO, Janssen RJ, Ugalde C, Grovenstein 
M, Huijbens RJ, Visch HJ, van den Heuvel LP, 
Willems PH, Zeviani M, Smeitink JA, and Nijt­
mans LG. Human mitochondrial complex I as­
sembly is mediated by NDUFAF1. FEBS J  2005; 
272: 5317-5326.
Vogel RO, Janssen RJ, van den Brand MA, Diet­
eren CE, Verkaart S, Koopman WJ, Willems PH, 
Pluk W, van den Heuvel LP, Smeitink JA, and 
Nijtmans LG. Cytosolic signaling protein Ecsit 
also localizes to mitochondria where it inter­
acts with chaperone NDUFAF1 and functions 
in complex I assembly. Genes Dev 2007b; 21: 
615-624.
Vogel RO, Smeitink JA, and Nijtmans LG. Hu­
man mitochondrial complex I assembly: a dy­
namic and versatile process. Biochim Biophys 
Acta 2007c; 1767: 1215-1227.
Vogel RO, van den Brand MA, Rodenburg RJ, 
van den Heuvel LP, Tsuneoka M, Smeitink JA, 
and Nijtmans LG. Investigation of the complex 
I assembly chaperones B17.2L and NDUF- 
AF1 in a cohort of CI deficient patients. Mol 
GenetMetab 2007d; 91: 176-182.
Walker JE. The NADH:ubiquinone oxi- 
doreductase (complex I) of respiratory chains. 
Q Rev Biophys 1992; 25: 253-324.
Washizuka S, Kakiuchi C, Mori K, Kunugi H, 
Tajima O, Akiyama T, Nanko S, and Kato T. As­
sociation of mitochondrial complex I subunit 
gene NDUFV2 at 18p11 with bipolar disorder. 
Am J  Med Genet B Neuropsychiatr Genet 2003; 
120B: 72-78.
Wikstrom M. Two protons are pumped from 
the mitochondrial matrix per electron trans­
ferred between NADH and ubiquinone. FEBS 
Lett 1984; 169: 300-304.
Yadava N, Houchens T, Potluri P, and Scheffler 
IE. Development and characterization of a 
conditional mitochondrial complex I assem­
bly system. J  Biol Chem 2004; 279: 12406-12413.
119
References
Yadava N, Potluri P, and Scheffler IE. Investiga­
tions of the potential effects of phosphoryla­
tion of the MWFE and ESSS subunits on com­
plex I activity and assembly. Int J  Biochem Cell 
Biol 2008; 40: 447-460.
Yadava N, Potluri P, Smith EN, Bisevac A, and 
Scheffler IE. Species-specific and mutant 
MWFE proteins. Their effect on the assem­
bly of a functional mammalian mitochon­
drial complex I. J  Biol Chem 2002; 277: 21221­
21230.
Yamaguchi M, Belogrudov GI, Matsuno-Yagi 
A, and Hatefi Y. The multiple nicotinamide 
nucleotide-binding subunits of bovine 
heart mitochondrial NADH:ubiquinone oxi- 
doreductase (complex I). Eur J  Biochem 2000; 
267: 329-336.
120
References
121
122
Dankwoord
123
Dankwoord
Dankwoord
Een proefschrift schrijven doe je nooit alleen. 
Daarom wil ik graag iedereen die een steentje, 
klein of groot, heeft bijgedragen aan het tot 
stand komen van dit proefschrift hiervoor 
hartelijk bedanken. Daarnaast wil ik enkele 
personen in het bijzonder bedanken.
Ten eerste wil ik mijn twee promotoren Bert 
van den Heuvel en Jan Smeitink bedanken. 
Beste Bert, bedankt dat je me de mogelijk­
heid hebt gegeven om bij jou op het lab te 
kunnen promoveren. Door je vele werkzaam­
heden was het soms moeilijk om je te kunnen 
spreken. Toch heb je er voor gezorgd dat dit 
proefschrift tot een goed einde is gebracht. 
Bedankt voor de begeleiding tijdens mijn 
promotietraject, waarin ik heel veel heb ge­
leerd, en voor je positieve instelling, bijvoor­
beeld over een mutatie die ik had gevonden, 
maar waarvan ik nog niet zeker was dat deze 
pathogeen zou kunnen zijn. Later bleek hier 
een mooie publicatie uit te volgen.
Beste Jan, bedankt voor je steun tijdens 
mijn promotietraject en voor de hulp bij het 
achterhalen en schrijven van de klinische 
achtergrond van de verschillende patiënten. 
Ik heb veel geleerd van jouw klinische achter­
grond en kritische vragen tijdens onze werk­
besprekingen. Tevens heb ik bewondering 
voor de manier waarop je het mitochondrieel 
onderzoek in de aandacht hebt gebracht 
en ervoor zorgt dat er nieuwe onderzoeks­
projecten gestart kunnen worden.
Vervolgens wil ik mijn copromotor Richard 
Rodenburg bedanken. Beste Richard, be­
dankt voor je verhelderende kijk op het 
onderzoek tijdens de wekelijkse werkbe­
sprekingen. Het was prettig datje bij deze be­
sprekingen aanwezig kon zijn om daar waar 
nodig meer uitleg over de biochemie en jouw 
visie over bepaalde experimenten te kunnen 
geven. Daarnaast heb je ervoor gezorgd dat 
ik de fibroblasten van de patiëntengroep 
heb kunnen kweken. Bedankt hiervoor!
Paulien, samen hebben we aan het MITO- 
CIRCLE project gewerkt. Ieder onze eigen 
patiëntengroep en genen om te screenen,
maar wel met hetzelfde doel. Uiteindelijk 
hebben we allebei genoeg artikelen kunnen 
schrijven voor onze proefschriften. Bedankt 
voor je hulp, adviezen en ideeën tijdens de 
wekelijkse werkbesprekingen en de back-up 
voor mijn cellen. Ik wens je heel veel succes 
met de verdediging van jouw proefschrift en 
je verdere carrière!
Toen ik met mijn promotietraject begon, 
had ik wel enige ervaring met DNA onder­
zoek en sequentie reacties uitvoeren, maar 
ik had nog nooit zelf met een sequentie ap­
paraat gewerkt. Ik wil graag de DNA-groep 
bedanken, omdat zij mij de kneepjes van het 
vak hebben geleerd. Als ik vragen had, kon ik 
altijd bij jullie voor uitleg terecht. Daarnaast 
hebben enkele van jullie ook mee geholpen 
met het screenen van een paar genen.
Er is veel werk verricht door die studenten 
die ik begeleid heb. Samen hebben jullie veel 
genen nagekeken op de aanwezigheid van 
mutaties. Sommige hebben inderdaad een 
pathogene mutatie gevonden die uiteinde­
lijk de basis vormde voor een van de artikelen 
die in dit proefschrift beschreven staan. Mar­
tin, Marleen, Esther, Inger, Ellen, Leah, Anne 
en Kim bedankt voor jullie inzet!
De mito-groep onder leiding van Leo Nijt­
mans wil ik graag bedanken voor de prak­
tische hulp en adviezen tijdens de 'eiwit- 
experimenten'. Zonder jullie uitleg was ik 
niet in staat geweest om de SDS-, BN-, en 2D 
BN/SDS-PAGE gelen te runnen. Beste Leo, 
bedankt voor je uitleg en hulp bij het inter­
preteren van de resultaten verkregen met de 
eiwit gelen en bedankt voor het kritisch lezen 
van mijn manuscripten.
Ook de spiergroep en de weefselkweek mag 
ik natuurlijk niet vergeten. De spiergroep wil 
ik bedanken voor alle metingen die soms 
op zeer korte termijn uitgevoerd moesten 
worden. De weefselkweek bedankt dat ik 
mijn cellen bij jullie kon kweken en voor de 
hulp daarbij.
Peter Willems, Werner Koopman en de rest 
van de Biochemie groep van het NCMLS be­
dankt voor het leveren van de baculovirus-
124
Dankwoord
sen, de ondersteuning en goede adviezen 
voor de experimenten met deze virussen. 
Ook bedankt voor de proeven waarbij de mi- 
tochondriële membraan potentiaal bepaald 
werd. Dit alles heeft enkele mooie figuren in 
dit proefschrift opgeleverd!
Martijn, ook ik ben er bijna! Jouw peptalks als 
ik het even niet meer zo zag zitten hebben 
hier zeker aan bijgedragen. Bedankt ook voor 
de gezellige etentjes. Veel succes met alles in 
de toekomst!
Cindy, allereerst bedankt dat je een van mijn 
paranimfen wil zijn. Je hebt een bijdrage 
geleverd aan twee van mijn artikelen en voor 
vragen of advies kon ik altijd bij je terecht. 
Ook was het fijn om de ups en downs van 
mijn promotietraject met jou te delen, zoals 
je zelf al noemde in "het hokje" waar we naast 
elkaar zaten te typen. Bedankt voor alles en 
veel succes met je verdere carrière!
Alle andere collega's van toen nog labora­
torium Kindergeneeskunde en Neurologie, 
zowel locatie P als Q wil ik bedanken voor 
de gezelligheid tijdens de koffiepauzes, lab- 
uitjes en etentjes. Iedereen bedankt voor de 
fijne tijd!
Niet alleen de collega's van het lab, maar zeker 
ook mijn familie en vrienden hebben ervoor 
gezorgd dat ik dit proefschrift kon afronden. 
Allemaal bedankt voor jullie interesse in mijn 
onderzoek. Enkele wil ik nog speciaal bedan­
ken.
Laura, al heel vaak hebben we samen gegeten 
en over onze promoties gesproken. Ook al is 
het onderwerp van jouw promotieonder­
zoek totaal anders, het was toch fijn om mijn 
ervaringen met jou te delen. Bedankt voor je 
gezelschap en heel veel succes met het afron­
den van jouw proefschrift!
Marieke, bedankt voor je interesse in mijn 
onderzoek en al de gesprekken over onze 
toekomst. En uiteindelijk komt het allemaal 
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voor alle gezellige etentjes bij iedereen thuis, 
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kon ik mijn hart luchten als het weer eens 
tegen zat, maar jullie hebben ook voor ont­
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voor de gezellige momenten samen.
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